Xenopus Laevis as a Model System for Evaluating the Function of Fanconi Anemia Proteins by Stone, S.N.
 1 
 1 
 2 
 3 
 4 
 5 
 6 
Xenopus Laevis as a Model System for Evaluating the Function 7 
of Fanconi Anemia Proteins 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
38 
 2 
 
Publication of this thesis was supported by the National Institute of Health, USA 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
Thesis Vrije Universiteit Amsterdam 41 
 42 
Copyright © S. Stone, Portland, Oregon, USA, 2008 43 
 3 
 
 1 
 2 
 3 
VRIJE UNIVERSITEIT 4 
 5 
 6 
 7 
 8 
Xenopus Laevis as a Model System for Evaluating the Function 9 
of Fanconi Anemia Proteins 10 
 11 
 12 
 13 
 14 
 15 
 16 
ACADEMISCH PROEFSCHRIFT 17 
 18 
ter verkrijging van de graad Doctor aan 19 
de Vrije Universiteit Amsterdam, 20 
op gezag van de rector magnificus 21 
prof.dr. L.M. Bouter, 22 
in het openbaar te verdedigen 23 
ten overstaan van de promotiecommissie 24 
van de faculteit der Geneeskunde 25 
op donderdag 24 april 2008 om 15.45 uur 26 
in de aula van de universiteit, 27 
De Boelelaan 1105 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
door 36 
 37 
Stacie Nicole Stone 38 
 39 
geboren te Springfield, Oregon, Verenigde Staten 40 
41 
 4 
 
 1 
promotor: prof.dr. H. Joenje 
copromotor: dr. M. Hoatlin 
 2 
 3 
 4 
5 
 5 
 
Table of Contents 1 
 2 
CHAPTER 1……………………………………………………………………………...6 3 
1.1 GENOMIC INSTABILITY SYNDROMES……………………………….……………... 6 4 
1.2 FANCONI ANEMIA…………………………………………….…………………… 9 5 
Clinical Features of FA....…………………………………………..….....……...... 9 6 
The Molecular Biology of the FA Pathway…………………………………...….. 12 7 
The FA Genes and Their Products……………………………..………………… 13 8 
Cellular Features……………………………………………...…………………. 23 9 
FA and Cancer……………………………………………….…………………... 25 10 
1.3 XENOPUS LAEVIS AS A MODEL SYSTEM…………………...…………………....... 27 11 
1.4 OUTLINE OF THE THESIS………………………………………………………..... 31 12 
CHAPTER 2 ......................................................................................................................... 33 13 
FANCONI ANEMIA PROTEINS ARE REQUIRED TO PREVENT ACCUMULATION OF REPLICATION- 14 
ASSOCIATED DNA DOUBLE-STRAND BREAKS 15 
Molecular and Cellular Biology, 2: 425-437, 2006 16 
CHAPTER 3 ......................................................................................................................... 64 17 
DNA STRUCTURE-INDUCED RECRUITMENT AND ACTIVATION OF THE FANCONI ANEMIA 18 
PATHWAY PROTEIN, FANCD2 19 
Molecular and Cellular Biology, 12: 4283-4292, 2007 20 
CHAPTER 4 ......................................................................................................................... 86 21 
IDENTIFICATION OF A NEW SMALL MOLECULE INHIBITOR OF THE FANCONI ANEMIA/BRCA 22 
PATHWAY USING A NOVEL CELL FREE ASSAY 23 
Submitted 2008 24 
CHAPTER 5 ....................................................................................................................... 103 25 
IDENTIFICATION, DEVELOPMENTAL EXPRESSION, AND REGULATION OF THE XENOPUS 26 
ORTHOLOG OF HUMAN FANCG/XRCC9 27 
Genes to Cells, 12: 841-851, 2007 28 
CHAPTER 6 ....................................................................................................................... 120 29 
DISCUSSION……………………………………………………...…….………….....120 30 
CHAPTER 7 ....................................................................................................................... 126 31 
SUMMARY………………………………………………….……....….……………..126 32 
SAMENVATTING……………………………………………………….………….….128 33 
LIST OF PUBLICATIONS ............................................................................................. 130 34 
REFERENCES................................................................................................................... 131 35 
ACKNOWLEDGEMENTS ............................................................................................. 145 36 
37 37 
 6 
Chapter 1 1 
1.1 Genomic Instability Syndromes 2 
 3 
 4 
Cells must guard their genomic integrity to avoid both the inheritance of mutations by 5 
daughter cells and the accumulation of mutations in genes that control cell 6 
proliferation. If this defense is compromised, malignant transformation is likely to 7 
follow. Although cells employ many safeguards to prevent genetic mutation, cellular 8 
DNA is constantly bombarded by mutagens from endogenous and exogenous sources. 9 
DNA replication, gene transcription, DNA repair, and cell-cycle checkpoints must all 10 
cooperate to promote cell survival following DNA damage to preserve the integrity of 11 
chromosomes. This requires a highly coordinated response, with the activation of 12 
appropriate repair pathways and the “buying” of time for repair to be completed 13 
through reversible arrest at cell-cycle checkpoints (176). 14 
 15 
Recently, the characterization of many proteins involved in sensing and responding to 16 
DNA damage has enhanced our understanding of malignant transformation. Biallelic 17 
mutations in the genes that encode DNA damage response proteins can result in a 18 
number of genomic instability syndromes, disorders that often result in a heightened 19 
predisposition to cancer (176). The phenotypes exhibited by genomic instability 20 
syndromes highlight the significance of proteins that sense, relay, or function in 21 
association with maintaining genomic integrity. Because these syndromes have an 22 
underlying combination of genomic instability with a predisposition to cancer, as a 23 
group they have been termed caretaker or stability genes. Mutations in stability genes 24 
do not lead directly to cancer, however a mutation in a stability gene increases the 25 
chance of a mutation in oncogenes and tumor suppressor genes. An oncogene is 26 
normally regulated, but when mutated can become constitutively active, directly 27 
initiating the growth of a tumor. A mutation in a tumor suppressor, disables a gene that 28 
otherwise would inhibit cell growth or promote normal cell death, resulting in 29 
uncontrolled tumor growth. Once tumor initiation has occurred due to a mutation in an 30 
oncogene or a tumor suppresor gene, the tumor is likely to progress further because of 31 
the increased mutation rate in other genes (92, 97, 149). 32 
 33 
Stability genes have a common function—maintaining genomic integrity—but do so 34 
by very different mechanisms. Some stability syndromes are defective in 35 
a specific DNA repair mechanism, for example xeroderma pigmentosum (XP) and 36 
Cockayne (CS), which are defective in nucleotide excision repair and 37 
transcription-coupled repair, respectively, resulting in genomic instability via point 38 
mutations. Ataxia telangiectasia (AT), caused by the protein encoded by the ATM 39 
gene, presents a defect in DNA damage sensing and cell cycle control rather than the 40 
actual physical repair of DNA. Other syndromes (including AT) such as Bloom 41 
syndrome (BS), Werner syndrome (WS), Rothmund-Thompson syndrome (RTS), 42 
 7 
 
Nijmegen breakage syndrome (NBS), and Fanconi anemia (FA) show widely 1 
divergent clinical symptoms (Table 1), but have genomic instability as a common 2 
denominator (81, 97). 3 
 4 
FA is arguably the most complex and certainly the least understood stability gene 5 
syndrome. The normal function of the FA network of proteins is to preserve genomic 6 
integrity, however the exact molecular mechanisms by which this occurs remains 7 
unknown (80, 178, 200). 8 
 9 
10 

 9 
1.2 Fanconi Anemia 1 
 2 
 3 
Eighty years ago, Dr. Guido Fanconi reported three siblings who exhibited both 4 
congenital defects and aplastic anemia (1). Since then, we have learned that Fanconi 5 
anemia (FA) is a rare disorder (a prevalence of 1-5 per million with a heterozygote 6 
carrier frequency of 1 in 300 (80)) that predisposes children and adults to life- 7 
threatening bone marrow failure, myelodysplasia (62), acute nonlymphocytic leukemia 8 
(AML), and certain epithelial malignancies (4, 104, 169). FA is remarkable in its 9 
genetic heterogeneity; it has been associated with mutations in any of at least 13 genes, 10 
suggesting that the FA gene products function in a common pathway (194). However, 11 
despite the identification of so many of the underlying Fanconi anemia genes, the 12 
essential understanding of how this pathway functions to preserve genome integrity 13 
remains elusive. A major hallmark of this disease is cytogenetic instability, which is 14 
exacerbated by exposure of FA cells to DNA crosslinking agents (3, 4). The main 15 
diagnostic test for FA, quantification of chromosomal breakage in response to DNA 16 
crosslinking agents, is based on this feature (reviewed in (80)). Classic clinical features 17 
such as slowed growth, small head size, abnormalities in skin pigmentation, and radial 18 
ray defects can be strong diagnostic clues, but FA can occur in patients without 19 
congenital defects and can remain undiagnosed until adulthood. In fact, some FA 20 
patients have minor hematopoietic abnormalities and have only been identified 21 
because they were tested after the diagnosis of a sibling (19).  22 
 23 
Clinical Features of FA 24 
 25 
Small stature and the presence of one or more congenital abnormalities (principally 26 
microcephaly (small head) and abnormalities of skin pigmentation) in the absence of 27 
aplastic anemia is how many FA patients present. They show slower growth both in 28 
utero and after birth which may be further complicated by the presence of hormonal 29 
deficiencies (88, 119). Two thirds of patients will also show multiple congenital 30 
abnormalities. These include upper limb abnormalities, especially absent radius and 31 
thumb anomalies, as well as renal abnormalities (e.g. horseshoe kidney). Less 32 
commonly there may be abnormalities of the urogenital and gastrointestinal systems, 33 
the lower limbs, cardiopulmonary defects, deafness and neurological abnormalities 34 
(16, 67). 35 
 36 
The major method for laboratory confirmation of the presence of FA has been to use 37 
blood samples to demonstrate the unusual chromosomal hypersensitivity of FA 38 
patients’ cells to DNA crosslinking agents such as mitomycin C (MMC) and 39 
diepoxybutane (DEB). Cells from all FA patients show an increase in spontaneous 40 
chromosome damage as well as sensitivity to DNA crosslinking agents, although the 41 
level of chromosome damage varies among patients (10).  42 
 10 
 
Due to the possibility of overlap in DNA crosslink sensitivity between FA and other 1 
disorders such as Nijmegen Breakage syndrome (NBS), other methods for diagnosing 2 
FA are typically used. One of these additional tests is the ability of the patient’s 3 
primary lymphocytes to monoubiquitylate the FANCD2 protein (79, 101, 115). Protein 4 
extracts of normal cells immunoblotted for FANCD2 contain two bands, with the 5 
larger form corresponding to monoubiquitylated FANCD2 (FANCD2-L). Cells from 6 
FA patients with mutations in an FA core complex protein (consisting of FANCA, -B, 7 
-C, -E, -F, -G, -L, and –M), or the FANCD2 binding partner FANCI, express only the 8 
non-ubiquitylated, smaller isoform of FANCD2 (FANCD2-S). The FA core complex, 9 
and FANCI are considered “upstream” of FANCD2 monoubiquitylation (192, 193, 10 
196, 201, 202) (reviewed in (174)). However, there are also FA patient groups that 11 
exhibit both forms of FANCD2, or function “downstream” of FANCD2 12 
monoubiquitylation. Among these are the complementation groups D1 (mutated in 13 
BRCA2), J (mutated in BRIP1), and N (mutated in PALB2) (192, 193, 196, 201, 202). 14 
However, most FA patients have a defect in an FA core complex protein, with FA-A 15 
being the most common complementation group accounting for 60-80% of all FA 16 
patients (80, 111).  17 
 18 
A Fanconi Anemia Mutation Database, is available on-line at 19 
(www.rockefeller.edu/fanconi/mutate). Currently, novel mutation analysis is done by 20 
denaturing high performance liquid chromatography (DHPLC) and sequencing of 21 
genomic DNA and cDNA. In addition to family studies, to confirm that a sequence 22 
variant represents a pathogenic mutation, complementation analysis (in which the wild 23 
type cDNA expressed in mutant cells corrects MMC/DEB sensitivity but the mutant 24 
cDNA does not) is commonly used (80). 25 
 26 
Prevalence of FA 27 
FA is a heterogeneous autosomal recessive disease (X-linked in the case of subtype 28 
FA-B), which seems to occur in all races and ethnic groups. However, in some isolated 29 
populations such as Ashkenazi Jews, South African Afrikaners, and Spanish gypsies, 30 
the carrier frequency is relatively high due to common founder mutations (18, 87, 31 
154). 32 
 33 
The median survival period for FA patients is ~24 years (111, 112). The International 34 
Fanconi Anemia Registry (IFAR) maintains case data on at least 3,000 patients, 35 
however the total number of FA patients worldwide is not documented. The clinical 36 
phenotypes of all FA patients, even those within the same patient group, vary. 37 
Identical twins have even been reported to have different clinical phenotypes (182). 38 
Variation in clinical phenotypes may be caused by genetic reversion of the disease trait 39 
in certain cell lineages, leading to somatic mosaicism, but unknown environmental 40 
factors may also influence the clinical severity of the disease. 41 
 42 
Recently studies on the molecular and cellular level have provided evidence linking 43 
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somatic inactivation of the FA-BRCA pathway by mutation or epigenetic silencing to 1 
sporadic cancers within the general population. This topic is discussed further in 2 
Chapter 1.2 (183). 3 
 4 
Hematological abnormalities  5 
Bone marrow failure is the most consistent clinical feature of young FA patients (146). 6 
In the original publication by Fanconi (1), aplastic anemia was the major finding in the 7 
report on three affected siblings. However a diagnosis of FA does not often coincide 8 
with the presence of aplastic anemia. The problem is that the pancytopenia is not 9 
usually present at birth but develops later, in most cases with a median age of onset at 10 
7 years (150). However, other features of FA, like the presence of congenital 11 
abnormalities, may be immediately apparent and diagnosis is frequently made before 12 
the onset of aplastic anemia. This can be an advantage, as early diagnosis will aid in 13 
better management of the impending anemia. However, it is worth noting that 14 
pancytopenia has been reported as early as neonatal life, at age 2 weeks in a FA-G 15 
patient without congenital abnormalities (130). 16 
 17 
The development of myelodysplastic syndrome (MDS) or acute myeloid leukemia 18 
(AML) is often preceded by bone marrow failure in FA patients. The cumulative 19 
incidence of any hematological finding in FA may be as high as 90%, and bone 20 
marrow failure requiring therapy at ~60%. The actual risk of developing any 21 
hematopoietic abnormality by age 40 is 98%; the risk of pancytopenia is 84% by the 22 
age of 20 years and the risk of either MDS or AML is about 50% by age 40 (20). The 23 
risk of bone marrow failure is highest in patients with abnormal radii and congenital 24 
abnormalities. Conversely the greatest risk for developing AML or a solid tumor 25 
occurs in older patients, those with the lowest risk of bone marrow failure (142). 26 
 27 
Leukemia  28 
An individual risk of MDS (formerly known as pre-leukemia) is 5%. When left 29 
untreated MDS can lead to AML in about 30% of diagnosed cases. There is a 5-10% 30 
individual risk of AML in patients with FA (104). 31 
 32 
Solid Tumors 33 
The risk of solid tumors increases with age and occurs in 5-10% of patients with a 34 
cumulative risk of ~30% by age 45 years (104), greater than the risk of AML. Young 35 
adults with FA show an increased risk of head and neck squamous cell carcinomas and 36 
tumors of epithelial tissues (specifically the esophagus, vulva and cervix) and 37 
neoplasms of the brain, kidney, and liver. Some patients may develop two or more 38 
tumors (111). The occurrence of liver tumors may be related to treatment with 39 
androgens for bone marrow failure (148).  40 
 41 
Infertility 42 
FA patients exhibit hypergonadotrophic hypogonadism with its associated 43 
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abnormalities of sexual development. Male FA patients have underdeveloped gonads 1 
and defective spermatogenesis, whereas female FA patients can have hypoplastic 2 
ovaries, infantile uteri, menstrual irregularities, secondary amenorrhea, and premature 3 
menopause (121). Consistent infertility phenotypes have also been reported for mice 4 
with targeted disruption in Fancc, Fanca, Fancl/Pog, Fancg, Fand2 and 5 
Fancd1/Brca2 (29, 34, 91, 96, 109, 144). The existence of infertility phenotypes (or 6 
meiotic errors), imply that the FA pathway plays a role in mammalian gametogenesis 7 
and meiotic success.  8 
 9 
Treatment 10 
Treatment of the hematological defect in FA is supportive with attempts to stimulate 11 
hematopoiesis with either androgens, or hematopoietic growth factor granulocyte- 12 
colony stimulating factor (G-CSF); both of these strategies are aimed at improving 13 
peripheral blood counts (12, 13, 33, 85). However, the long-term treatment of the 14 
hematological manifestation in FA patients is bone marrow (BM) or cord blood 15 
transplantation. Unfortunately BM transplantation using standard procedures is not 16 
possible with FA patients as they are hypersensitive to cyclophosphamide, an 17 
alkylating agent used to deplete the body of host BM and blood cells prior to 18 
transplantation.  However, a reduced regimen of cyclophosphamide has been shown to 19 
lower the risk of treatment failure in FA patients. A change that has led to a success 20 
rate of ~70% for BM transplantation with HLA-matched sibling donors but has not 21 
significantly changed the lower ~33% success rate with HLA-matched unrelated 22 
donors (25, 69). Recent protocols utilizing a fludarabine-containing conditioning 23 
regimen have substantially improved outcomes with unrelated donors, making the 24 
other alternative–gene therapy, less urgent (204). Gene therapy is, in theory, and 25 
attractive alternative for FA patients with no HLA-matched donor. This approach 26 
attempts to use stem cells in view of their self-renewal capacity, transduced with the 27 
wild type copy of the affected gene, to replenish the hematopoietic compartment and 28 
sustain long-term hematopoiesis (172). However, gene therapy is still in its infancy 29 
and many aspects such as the possibility of immune reactions against the vectors and 30 
transgenes, and random insertion of transgenes that can cause mutations leading to 31 
cancer, need to be resolved before it is widely used as a form of treatment for any 32 
disease.  33 
 34 
At present, no treatment is available to reduce the cancer risk in FA patients. Moreover 35 
cancer treatment in FA patients is complicated by the increased hypersensitivity of FA 36 
patient cells to many anti-tumor agents. 37 
 38 
The Molecular Biology of the FA Pathway 39 
 40 
There are 13 different patient groups for FA, A, B, C, D1, D2, E, F, G, I, J, L, M, and 41 
N; all of these groups are connected with distinct disease genes (reviewed in (198)). 42 
Some of the proteins encoded by the FA genes contain domains that may provide 43 
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insights into protein function. FANCG has been shown to have tetratricopeptide 1 
repeats (TPR) domains (125). FANCL has an E3 ubiquitin ligase domain (114). 2 
FANCM has homology to the archaeal protein Hef (Helicase-associated Endonuclease 3 
for Fork structured DNA), which contains both a DEAH-box helicase domain and an 4 
endonuclease domain (164). FANCJ (BRIP1) is a BRCA1-associated DNA helicase 5 
(161-163). FANCN (PALB2) contains an N-terminal prefoldin-like domain and two 6 
C-terminal WD40-like repeats (186).  7 
 8 
FANCD2 and FANCI are the only two FA proteins to date that share sequence 9 
similarity with each other, but not with other known proteins, suggesting the two 10 
proteins are paralogs (193, 194, 201, 202). However, the remaining FA genes and the 11 
proteins they encode have no strong homologies to one another or to other known 12 
proteins. 13 
 14 
The proteins encoded by FANCA, -B, -C, -E, -F, -G, -L, and -M, form a nuclear 15 
complex (termed the “FA core complex”) that may act as a ubiquitin ligase with 16 
FANCL (an E3 ubiquitin ligase) possibly acting as the catalytic subunit. The FA core 17 
complex is required for the damage-induced monoubiquitylation of the downstream 18 
FANCD2 and FANCI proteins, which together form a complex consisting of a dual 19 
ubiquitin-locking assembly that maintains the ubiquitin moiety on each protein, though 20 
monoubiquitylation is not required for FANCI/D2 complex formation (202). The 21 
monoubiquitylated FANCI and FANCD2 complex then colocalizes with BRCA1, 22 
BRCA2 (FANCD1), BRCA2 binding partner PALB2 (FANCN), Nbs1 and several 23 
other proteins implicated in DNA repair in nuclear foci as part of the response to DNA 24 
damage (74, 79, 103, 151, 158, 191, 202). FANCD2 can be monoubiquitylated in cells 25 
of the subtypes D1, J, and N, indicating that all three proteins act downstream of 26 
FANCD2/-I in the FA pathway (Fig 1). 27 
 28 
Recently, following immunoisolation of the FA core complex, Meetei and coworkers 29 
identified a new FA core complex protein they termed ‘Fanconi Anemia Associated 30 
Protein of 100 kilodaltons or FAAP100 (115, 196). Another FAAP protein was 31 
identified by Ciccia and coworkers, FAAP24, by its homology to the C-terminus of 32 
FANCM (192). No patients with a defect in FAAP100 or FAAP24 have been found 33 
though both are members of the FA core complex and are required for normal levels of 34 
FANCD2 monoubiquitylation following DNA damage. Depletion of either protein by 35 
siRNA results in cellular hypersensitivity to DNA-cross-linking agents and 36 
chromosomal instability, the classical phenotype resulting from defects in FA genes. 37 
Until patients with mutations in FAAP100 or 24 are identified they will remain 38 
classified as “FA associated” proteins. 39 
 40 
The FA Genes and Their Products  41 
 42 
FA Genes 43 
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Reviewed below are selected features of each FA gene and the proteins they encode. 1 
The chromosomal location (locus), exon number, cDNA size (in base pairs), the year 2 
and method of cloning, the known level of species conservation, the number of amino 3 
acids residues, molecular mass (in kilodaltons), and cellular location of the encoded 4 
proteins are listed in Table 2. 5 
 6 
FANCA 7 
The FANCA gene is responsible for the most prevalent of all FA patient 8 
complementation groups (30). There is significant diversity in the type and location of 9 
FANCA patient mutations, including deletions, insertions, missense, nonsense, splicing 10 
and frameshift mutations (39, 87, 117, 126). In addition numerous FANCA 11 
polymorphisms have been detected, complicating the verification of whether newly 12 
identified FANCA sequence variations are actually disease-associated mutations or 13 
polymorphisms.  14 
 15 
The FANCA protein contains two consensus bipartite nuclear localization signal 16 
(NLS) motifs, a leucine zipper motif, and is localized in the nucleus, though it can also 17 
be detected in the cytoplasm (37). The nuclear accumulation and function of FANCA 18 
requires the bipartite NLS motifs, as well as the C-terminal region (51, 58, 59) and has 19 
also been shown to depend on FANCB, -L, and -M (66, 114, 164, 184). Furthermore, 20 
FANCA contains nuclear export signals that seem to play a role in its nuclear 21 
accumulation (157). In addition, nuclear localization is required to correct the 22 
hypersensitivity of FANCA deficient cells to DNA crosslinking agents (50), likely via 23 
FANCA participation in the nuclear FA core complex. 24 
 25 
The N-terminus of FANCA binds directly to FANCG, while FANCC, FANCE, and 26 
FANCF bind FANCA indirectly or weakly (55, 61, 66, 68, 99, 108). FANCA-FANCG 27 
binding stabilizes these proteins, resulting in an increased half-life for both proteins 28 
(68). In addition, FANCF has been shown to further stabilize FANCA-FANCG 29 
binding (66). 30 
 31 
Little is known about how the cell regulates FANCA expression, protein-protein 32 
interaction, and nuclear localization, although phosphorylation may be important. 33 
Nuclear accumulation and function of FANCA seem to depend on phosphorylation by 34 
an unknown serine kinase (54, 89).  Phosphorylation of FANCA is absent in FA cells 35 
of complementation groups FA-B, C, E, F, and G but is present in D1 and D2 (54, 58). 36 
However, in a more recent study examining several FANCA mutant proteins, FANCA 37 
phosphorylation was reported to be independent of FANCA binding to FANCC and 38 
FANCG, supporting as yet undefined regulatory mechanisms affecting FANCA’s 39 
subcellular localization and function (90).  40 
 41 
FANCB 42 
FANCB was recently identified by coimmunoprecipitation in a multimeric protein  43 
44 
15 
The FA Pathway 
 
Fig 1. Model for the sequential assembly of the FA core complex proteins. In the nucleus, specific 
DNA lesions that are caused by either endogenous or exogenous DNA-damaging agents are encountered 
by the advancing replication fork during S phase. The FA nuclear core complex (consisting of: FANCA, -
B, -C, -E, -F, -G, -L, -M, FAAP24, and  FAAP100) responds to the DNA damage by becoming an active 
ubiquitin ligase (E3) and along with UBE2T (an E2 enzyme) are responsible for the monoubiquitylation of 
the FANCD2 and FANCI proteins. Following monoubiquitylation, the FANCD2/FANCI complex is 
targeted to chromatin where it interacts with BRCA2 (FANCD1) and its binding partner PALB2 
(FANCN) and possibly BRIP1 (FANCJ), to help coordinate the repair processes that resolve stalled 
replication forks. The deubiquitylating enzyme USP1 is a regulator of the FA pathway, involved in the 
removal of ubiquitin from FANCD2 and FANCI. 
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complex isolated from nuclear extracts by an antibody against FANCA. The protein 1 
was discovered by mass spectrometry analysis of a 95-kilodalton (kDa) protein that 2 
was found to be mutated in the FA patient complementation group B (135). The 3 
FANCB protein contains a putative bipartite nuclear localization signal at its C- 4 
terminus and is present in nuclear extracts of normal cells, but in mutant FA-A cells, 5 
FANCB is found, like FANCL, in the cytosol (184). FANCB has also been shown to 6 
be a direct binding partner of FANCL and FAAP100 (117, 104).FANCB is the first FA 7 
gene located on the X-chromosome where it is subject to X-chromosome inactivation 8 
in females. Because there is only a single active copy of FANCB, heterozygotes may 9 
show some characteristics of FA, although methylation studies of the gene showed that 10 
FANCB inactivation seems to be skewed toward the mutant allele. In the patient cases 11 
described, there are different mutations in this gene including insertional frameshifts in 12 
exon 3 and 8, a deletional frameshift in exon 8, and a large 5’ and promoter deletion 13 
(135). 14 
 15 
FANCC 16 
FANCC was the first FA gene to be cloned (15). Although there are a number of 17 
different patient mutations known in this gene, two mutations account for most of the 18 
known FA-C patients; the first in exon 1 (322delG) and the other in exon 4 19 
(c.711+4A>T) (22, 129).  20 
 21 
FANCC contains no recognizable nuclear localization sequences and early studies 22 
revealed predominantly cytoplasmic localization of the protein in several cell lines (23, 23 
24, 28). Additional refinement in more recent studies has demonstrated that 24 
approximately 10% of endogenous FANCC is reproducibly found in the nuclear 25 
fractions of lymphoblast cell lines (47). FANCC is a member of the FA core complex 26 
(56, 145, 165), and binds to FANCE, an interaction which facilitates nuclear 27 
accumulation of FANCC (177). At least one nuclear function of this protein is to 28 
facilitate the FANCD2/BRCA1 interaction in S-phase of the cell cycle and in cells 29 
exposed to DNA crosslinking agents (102, 108). A possible cytosolic function of 30 
FANCC might be to influence cell cycle control (G2 to M-phase transition), since wild 31 
type FANCC protein coimmunoprecipitates with cyclin-dependent kinase CDC2 (38). 32 
Other cytosolic partners include the stress response proteins and molecular chaperones 33 
GRP94 and Hsp70, proteins involved in oxygen radical metabolism and the signal 34 
transducer and activator of transcription, STAT1 (48, 49, 72, 77). In the nucleus, 35 
FANCC interacts with a member of the BTB/POZ family of transcriptional repressor 36 
proteins, Fanconi Anemia Zinc Finger (FAZF) (57). 37 
 38 
Studies of FANCC expression, subcellular localization, protein interactions and gain 39 
and loss of function have demonstrated roles for FANCC in a wide range of cellular 40 
activities including DNA crosslink repair, cell cycle control, protein transport, anti- 41 
apoptotic pathway, detoxification mechanism, and signal transduction (38, 40, 53, 70, 42 
83, 105, 106). 43 
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 1 
FANCD1 (BRCA2) 2 
The gene defective in FA complementation group D1 results from biallelic mutation of 3 
the Breast cancer associated gene 2 (BRCA2), a mutation of which is associated with 4 
predisposition to breast and other cancers (reviewed in (171)). The gene was found to 5 
be mutated in the FA group D1 based on a candidate gene approach, since BRCA1 and 6 
BRCA2 mutant cell lines are hypersensitive to DNA interstrand crosslinking agents 7 
(95). FANCD1/BRCA2 has known functions in homologous recombination (120) and 8 
is required for the stabilization of stalled DNA replication forks (113). It is also the 9 
first FA gene in which biallelic null mutations in mice are embryonic lethal. FA 10 
patients with a FANCD1 mutation have at least one hypomorphic allele resulting in 11 
expression of some truncated BRCA2 with partial activity (42).  12 
 13 
Importantly, the FANCD1/BRCA2 cells express the monoubiquitylated form of 14 
FANCD2, suggesting that FANCD1/BRCA2 functions downstream of the FA core 15 
complex proteins (79). Furthermore, monoubiquitylated FANCD2 seems to promote 16 
loading of FANCD1/BRCA2 into multimeric complexes on chromatin by binding to 17 
the C-terminus of FANCD1/BRCA2 (151). In addition, both the N and C-terminus of 18 
FANCD1/BRCA2 have been shown to interact with FANCG (110). 19 
 20 
 FANCD2 21 
After the designation of an FA-D reference cell line, microcell fusions using 22 
minichromosomes revealed that the FA-D locus was at 3p22-26 (27). Eventually, 23 
expressed sequence tags lead to the positional cloning of the FANCD gene.  However 24 
since mutations were only found in a subset of proposed FA-D cell lines, the 25 
nomenclature was changed to reflect this outcome, and the newly cloned gene was 26 
termed FANCD2, while the other unknown (at the time) FA-D group was designated 27 
FA-D1. The FANCD2 protein exists in two isoforms: FANCD2-S (short) ~155 kDa 28 
and FANCD2-L (long) ~163 kDa. The long form is generated by the attachment of a 29 
single ubiquitin molecule to lysine residue 561 of the FANCD2 protein (86). 30 
Monoubiquitylation of FANCD2 requires an intact FA core complex and the presence 31 
of its binding partner FANCI (115, 202). Recently, the deubiquitylating enzyme, USP1 32 
was found to regulate FANCD2 by removal of the FANCD2 ubiquitin moiety (167). 33 
FANCD2 has a nuclear localization signal and is localized to the nucleus.  During 34 
normal S-phase of the cell cycle or after DNA damage, monoubiquitylated FANCD2 35 
colocalizes in nuclear foci with many other proteins implicated in DNA repair such as 36 
BRCA1, FANCD1/BRCA2, RAD51, PCNA, ATM, ATR, BLM, and the MRN 37 
(MRE11/RAD50/NBS1) complex. However, the underlying molecular function of 38 
these nuclear foci is not clear (79, 98, 100, 102, 103, 115, 128, 140, 151). 39 
 40 
In normal cells, ATR (defective in Seckel syndrome) has been shown to mediate the 41 
phosphorylation of FANCD2 (140) and seems to be involved in the 42 
monoubiquitylation of FANCD2 (124). In response to ionizing radiation, FANCD2 is 43 
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phosphorylated on serine 222 by ATM (defective in ataxia telangiectasia) in 1 
cooperation with the MRN complex, which leads to an S-phase checkpoint response 2 
(98, 102).  3 
 4 
FANCE 5 
FA-E is a relatively rare complementation group (64). The protein it encodes is part of 6 
the FA core complex required for the monoubiquitylation of FANCD2 and assembly 7 
of FANCD2 foci. Moreover, FANCE interacts and colocalizes with FANCD2 (99). 8 
FANCE has a predicted bipartite nuclear localization signal (64). Mainly located in the 9 
cell nucleus, FANCE coimmunoprecipitates with FANCA, FANCC, and FANCG and 10 
it is not only necessary for FANCC nuclear accumulation, but also for optimal 11 
FANCC expression  (100, 177). 12 
 13 
Yeast 2-hybrid analysis of FANCE shows a direct interaction with FANCC or 14 
FANCD2 (108). Since FANCD2 was never coimmunopreciptiated with FANCC, it 15 
may be inferred that the interactions of FANCE/FANCC and FANCE/FANCD2 are 16 
independent.  17 
 18 
The crystal structure of the C-terminus of FANCE was recently published (199). This 19 
particular region of FANCE is of interest since it is required for the interaction of the 20 
FA core complex with FANCD2 (99). The structure of the C-terminus of FANCE 21 
revealed a non-globular, solenoidal conformation assembled by tandem repeats of a 22 
short helical motif. The study also predicted a more widespread adoption of this 23 
structural motif among FA proteins. 24 
 25 
FANCE has recently been shown to be directly phosphorylated by Chk1 on two 26 
conserved sites (threonine 346 and serine 374) (206). Following phosphorylation, 27 
FANCE assembles in nuclear foci and colocalizes with FANCD2. A 28 
nonphosphorylated mutant form of FANCE (FANCE-T346A/S374A), when expressed 29 
in a FANCE-deficient cell line, allows FANCD2 monoubiquitylation, FANCD2 foci 30 
assembly, and normal S-phase progression. However, the mutant FANCE protein fails 31 
to complement the MMC hypersensitivity of transfected cells, suggesting that Chk1- 32 
mediated phosphorylation of FANCE is required for a function independent of 33 
FANCD2 monoubiquitylation. 34 
 35 
FANCF 36 
Discovered by complementation cloning, De Winter and coworkers found that the 37 
FANCF gene contains no introns and encodes a peptide with homology to the N 38 
terminus (RNA binding domain) of the prokaryotic RNA binding protein ROM (65). 39 
FANCF is largely nuclear and is a member of the FA core complex. Patient mutations 40 
in FANCF described to date are mostly deletions.  41 
The protein encoded by this gene may function as a super-scaffold, organizing the 42 
formation the FA core complex. The C-terminus of FANCF interacts directly with 43 
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FANCG and may facilitate the assembly of other FA proteins into the core complex 1 
(132). The N-terminus of FANCF seems to stabilize the FANCA/FANCG interaction 2 
and is also required for binding of the FANCC/FANCE complex (132).  3 
 4 
The first x-ray crystal structure for an FA protein was recently published for the C- 5 
terminal domain of FANCF (195). The crystal structure revealed a helical repeat 6 
structure that has a slight similarity to the Cand1 regulator of the Cul1-Rbx1-Skp1- 7 
Fbox (Skp2) ubiquitin ligase complex.  8 
 9 
FANCG 10 
FANCG was cloned by the functional complementation of a FA-G cell line and 11 
confirmed by the identification of inactivating mutations in four other FA-G patient 12 
cell lines (45). The sequence appeared to be identical to the previously identified 13 
human gene XRCC9, which was able to complement the DNA damage 14 
hypersensitivity of the XRCC9 mutant cell line derived from the Chinese hamster 15 
ovarian cell line UV40 (41). The FANCG protein is located in both the nucleus and the 16 
cytoplasm and is phosphorylated at serines 7, 385, and 387 (78, 137).  17 
 18 
FANCG is a member of the FA core complex and binds directly to FANCA (137). 19 
FANCG has a putative leucine zipper motif at its N-terminus and seven 20 
tetratricopeptide repeat motifs (TPRs) (125). TPRs are degenerate 34 amino acid 21 
repeat motifs that form a scaffold structure for protein-protein interactions, which 22 
suggests that FANCG is essential in the assembly of the FA core complex. FANCG 23 
has also been linked to other biological pathways besides DNA damage. It was 24 
identified as a phosphoprotein, which can be induced, and phosphorylated in response 25 
to TNF-alpha treatment, a processes that appears to be NF-κB dependent (78). It has 26 
been shown to interact with cytochrome P450 2E1 (CYP2E1) a protein that is involved 27 
in production and activation of free radicals. CYP2E1 is highly expressed in cells not 28 
expressing FANCG, whereas its expression is undetectable in ectopically corrected 29 
FA-G cells and in normal lymphoblasts (94). FANCG has also been shown to interact 30 
physically with PRDX3 in mitochondria. Mitochondrial PRDX3 is a cellular 31 
antioxidant that regulates physiological levels of H2O2. In FA-G, C, and A, patient cells 32 
PRDX3 undergoes cleavage resulting in diminished mitochondrial peroxidase activity, 33 
The overexpression of PRDX3 can restore the resistance of FA cells to H2O2 exposure, 34 
suggesting that diminished mitochondrial peroxidase activity may be a key event 35 
resulting in the sensitivity of FA cells to oxidative stress (185). 36 
 37 
FANCH 38 
There is no FANCH gene. It was predicted from complementation group analysis and 39 
carried out on cells that were later shown to be FANCA mutants (71). As a result there 40 
are no patients assigned to group FA-H. In addition, there is no FA-K 41 
complementation group as the English pronunciation of FANCK is difficult to 42 
distinguish from that of FANCA. 43 
 21 
 
 1 
FANCI 2 
In 2004, Levitus and coworkers reported four cell lines that were excluded from the 3 
known FA subtypes on the basis of phenotypic complementation. These cell lines 4 
failed to complement each other in somatic cell hybrid studies and therefore 5 
represented a new FA complementation group termed FA-I. FA-I cell lines were 6 
capable of forming an FA core complex but failed to support the monoubiquitylation 7 
of FANCD2 (133). In 2007, Smogorzewska and coworkers identified a protein termed 8 
KIAA1794 by siRNA screening for ATR targets (202). The genetic locus of 9 
KIAA1794 turned out to be identical to FANCI which was identified at the same time 10 
by Dorsman and coworkers using positional cloning (193). Also at the same time, 11 
Sims and coworkers identified FANCI based on sequence-based homology searches 12 
for proteins similar to FANCD2 (201). Like FANCD2, the FANCI protein exists in 13 
two isoforms; FANCI-S (short) or nonubiquitylated, and FANCI-L (long) or 14 
monoubiquitylated, and is 20% similar to FANCD2 across the entire protein. 15 
Interestingly there is weak sequence similarity between the monoubiquitylation sites of 16 
FANCI (K523) and FANCD2 (K561). Both long and short forms of FANCI and 17 
FANCD2 exist in a complex that is important for the maintenance of ubiquitin on the 18 
other, forming a dual ubiquitin-locking system. Similar to FANCD2, 19 
monoubiquitylation of FANCI requires an intact FA core complex and is also 20 
deubiquitylated by the enzyme, USP1.  Like FANCD2, phosphorylation of FANCI can 21 
be induced by ionizing radiation. During normal S-phase of the cell cycle or after 22 
DNA damage the complex containing monoubiquitylated FANCI and FANCD2 23 
colocalizes in nuclear foci with many other proteins implicated in DNA repair such as 24 
BRCA1, FANCD1/BRCA2, RAD51, PCNA, ATM, ATR, BLM, and the MRN 25 
(MRE11/RAD50/NBS1) complex (79, 193, 194, 198, 201, 202).  26 
 27 
FANCJ/BRIP1 28 
Using positional cloning and genetic mapping, several groups revealed that BRIP1 29 
(BRCA1 Interacting Protein C-terminal Helicase) is the gene defective in the FA 30 
patient complementation group J (161-163). FANCJ is a member of the DEAH 31 
helicase family. The nuclear protein contains seven helicase-specific motifs that are 32 
conserved among members of the DEAH family; the helicase domain also includes a 33 
nuclear localization signal. BRIP1 is both a DNA-dependent ATPase and a 5’ to 3’ 34 
DNA helicase that unwinds DNA structures that result from DNA strand exchange 35 
during homologous recombination, or repair of stalled replication forks (141). The 36 
helicase is phosphorylated at serine 990 and binds the C-terminal domains of BRCA1 37 
during S phase of the cell cycle (123). However FANCJ has been shown to function in 38 
the FA pathway independent of BRCA1 since DNA crosslink sensitivity is corrected 39 
in homozygous knockout chicken DT40 cells by expression of human FANCJ lacking 40 
the BRCT-BRCA1 interaction domain (152). Because normal FANCD2 41 
monoubiquitylation is observed in FANCJ patient cells, FANCJ is believed to function 42 
downstream of this event in the FA pathway, however the exact role of this helicase in 43 
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the FA pathway remains unknown. 1 
 2 
FANCL 3 
FANCL was the first novel FA gene identified using an FA core complex 4 
immunoisolation approach. Meetei and coworkers identified several FA Associated 5 
Proteins termed FAAP43 (FANCL), FAAP95 (FANCB), FAAP100, and FAAP250 6 
(FANCM) (the numbers after FAAP represent the respective protein’s molecular 7 
weight) which coimmunoprecipitated with FANCA (114). FANCL is found in both the 8 
nucleus and the cytoplasm of the cell. The 43-kDa protein contains three WD40 9 
repeats and a linker region that have been shown to bind and stabilize the FA protein 10 
complex, and a PHD domain which is not required for FA protein complex assembly 11 
(175). FANCL has ubiquitin ligase (E3) activity and may play an important role in the 12 
monoubiquitylation of FANCD2 (136). Monoubiquitylation typically requires 13 
enzymes of three different functional types, E1 (ubiquitin-activating enzyme), E2 14 
(ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase) (84). In addition to FANCL, 15 
identified as the possible E3 moiety of the FA core complex, the ubiquitin-conjugating 16 
enzyme UBE2T (an E2) has also recently been shown play a role in the FA pathway 17 
(181). UBE2T has been shown to bind FANCL and is required for the 18 
monoubiquitylation of FANCD2 in vivo.  19 
 20 
FANCL was found to be defective in a single patient. The mutation was a deletion of 21 
exon 11 that removed part of the WD40 repeat and the entire conserved PHD finger. It 22 
arose by homozygous insertion of 177 bp at the intron 10/exon 11-splice junction. 23 
 24 
FANCM 25 
Using a biochemical approach to analyze components of a FANCA protein complex, 26 
Meetei and coworkers identified a novel protein similar to human ERCC4 or XPF that 27 
they termed FAAP250. The protein was homologous to an archaeal protein called Hef 28 
(Helicase-associated endonuclease for fork structured-DNA), and MPH1 in yeast. 29 
Immunoblot analysis for FAAP250 in several FA patient derived cell lines showed that 30 
the protein was absent in one cell line that had been excluded from known 31 
complementation groups. Sequencing analysis confirmed that FAAP250 was indeed 32 
the gene defective in this patient, establishing a new FA complementation group, FA- 33 
M (164). At the same time, another group found that the Hef ortholog is an important 34 
component of the FA pathway by using knockout approaches in chicken DT40 cells 35 
(166). 36 
 37 
FANCM contains a DEAH-box helicase domain and an endonuclease domain. The 38 
helicase domain has been shown to have translocase activity, which is stimulated by 39 
single- and double-strand DNA; however, the endonuclease domain seems inactive 40 
(164). The discovery of FANCM and its domains strengthens the link between FA and 41 
the DNA repair process, particularly in processes at replication fork-like structures. 42 
Like the other FA core complex proteins, FANCM is essential for the 43 
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monoubiquitylation of FANCD2. Furthermore FANCM is a phosphoprotein that 1 
becomes hyperphosphorylated in response to DNA damaging agents (164).  2 
 3 
FANCN/PALB2 4 
Recently, using mass spectrometry analysis to identify proteins that 5 
immunoprecipitated with FANCD1/BRCA2 from HeLa cell extracts, Xia and 6 
coworkers cloned PALB2 (Partner And Localizer of BRCA2). The predicted 1,186 7 
amino acid protein contains an N-terminal prefoldin-like domain and two C-terminal 8 
WD40-like repeats. PALB2 has been shown to colocalize with FANCD1/BRCA2 in 9 
nuclear foci, promote its localization and stability in nuclear structures, and to enable 10 
its recombinational repair and checkpoint functions (190). HeLa cells in which PALB2 11 
expression is reduced by siRNA, show an increased sensitivity to MMC, a hallmark of 12 
FA (190). Taken together, PALB2 proved an excellent candidate for a new FA 13 
complementation group. 14 
By mutation screening, two separate research groups identified mutations in PALB2 in 15 
unclassified individuals with FA who showed normal monoubiquitylation of FANCD2 16 
and did not have sequence alterations in BRCA2 or FANCJ. As no further FA subtypes 17 
were known to operate downstream of FANCD2 monoubiquitylation, they designated 18 
a new Fanconi anemia complementation group, subtype FA-N (186, 187, 190). FA 19 
patients with biallelic mutations in FANCN and FANCD1 have a risk to develop AML, 20 
Wilms tumor or medulloblastoma at a young age, while carriers of FANCN or FANCJ 21 
mutations have a a two-fold increased risk to develop breast cancer than the general 22 
population (205). In contrast to FANCN and FANCJ mutations, FANCD1 is a high 23 
penetrance breast cancer gene and carriers of a FANCD1 mutation have a much higher 24 
risk to develop breast cancer (>5 fold). 25 
Cellular Features 26 
 27 
Genomic Instability, DNA Crosslinker Hypersensitivity 28 
There is an increased level of spontaneous chromosomal aberrations including 29 
chromatid gaps, breaks, and interchanges in FA patient cells compared to normal cells 30 
(2). This phenomenon is likely to contribute to the increased cancer risk in FA patients 31 
and may also explain some of the growth abnormalities associated with FA, since 32 
DNA damage may result in cell cycle arrest and apoptosis. 33 
DNA crosslinking agents, such as MMC and DEB, increase the number of 34 
chromosomal aberrations observed in FA cells at relatively low concentrations that 35 
show no effect in normal cells (7, 31). It is generally thought that FA cells are 36 
defective in the repair of DNA-interstrand crosslink-induced DNA double strand 37 
breaks via homologous recombination (143). Whether or not ongoing replication is a 38 
factor is explored in Chapter 2 of this thesis. However, the nature of the exact DNA 39 
 24 
 
structures that recruit and activate the FA proteins, whether it is crosslinked DNA or 1 
another intermediate state of the DNA during crosslink repair is not known, in part 2 
because the FA proteins are functionally interdependent and not all the proteins in the 3 
FA pathway have been identified. In addition, interstrand crosslinks are difficult to 4 
detect and DNA crosslinking agents can produce (in addition to interstrand crosslinks) 5 
DNA-intrastrand crosslinks, and DNA-protein crosslinks, all DNA lesions that can 6 
block DNA and RNA polymerases leading to stalled replication or transcription and 7 
eventually G2 cell cycle arrest. The nature of the DNA structures that recruit and 8 
activate the FA proteins is presented in Chapter 3 of this thesis. 9 
 10 
Cell Cycle Control  11 
The G2/M transition in the cell cycle is prolonged in FA cells (6) and this effect is 12 
further increased when cells are exposed to DNA crosslinking agents or high oxygen 13 
concentrations (46). The G2/M checkpoint is associated with surveillance of the 14 
genome and repair of damage before progression to mitosis. This observation could be 15 
explained by the fact that FA cells fail to repair DNA damage efficiently and therefore 16 
are slow to transition from G2 to M-phase of the cell cycle.  17 
 18 
Oxygen Sensitivity 19 
Whether oxygen sensitivity observed in the primary cells of FA patients has any 20 
consequences for the clinical phenotype is currently unknown. However, cultured FA 21 
cells exhibit increased oxygen sensitivity and reduced chromosome aberrations in the 22 
presence of low oxygen concentrations (5, 11). Many DNA crosslinking agents 23 
produce reactive oxygen species (ROS) and it is possible that the sensitivity of FA 24 
cells to DNA crosslinking agents is the result of an impaired ability to counteract ROS. 25 
Clarke and coworkers studied apoptosis in FANCC cells and showed that they behave 26 
like normal cells when exposed to MMC at 5% oxygen concentration and were 27 
hypersensitive to MMC at 20% oxygen, implying that it is the ROS generated by 28 
MMC, rather than the DNA crosslink formation that causes toxicity in FA cells (36). 29 
However, FA fibroblasts transformed with SV40 large T-antigen lack hypersensitivity 30 
to oxygen but maintain hypersensitivity to MMC (17), suggesting that oxygen 31 
sensitivity is a secondary defect in human cells. 32 
Apoptosis  33 
Various studies have shown apoptosis to be abnormally regulated in FA cells although 34 
the exact nature of the abnormality remains disputed (52). In one study, treatment of 35 
four FA lymphoblast cell lines with MMC led to a higher level of apoptosis (31), but 36 
other studies have shown higher levels of spontaneous apoptosis, lower levels after 37 
gamma irradiation, and no difference after MMC (21, 26, 43). Increased apoptosis may 38 
be related to an inability of FA cells to repair damage or to defective FA protein 39 
interactions with other proteins in the apoptosis pathways (76, 82).  40 
 41 
 42 
 25 
 
Telomere Maintenance 1 
Accelerated telomere shortening has been detected in FA (76), but is also found in 2 
other forms of aplastic anemia (44) and in MDS (35). This could be explained by a 3 
hematopoietic stem cell undergoing a higher than normal number of cell divisions to 4 
generate mature end cells. However in addition to replicative shortening, there is also a 5 
higher rate of breakage at telomeric sequences in FA cells, suggesting there may be a 6 
defect in telomere maintenance (93). 7 
 8 
FA and Cancer 9 
 10 
FA patient phenotypes show that biallelic inactivation of one of the FA genes causes 11 
genomic instability, which in turn can lead to hematopoietic defects and cancer 12 
progression. However the precise role the FA proteins play in genomic instability is 13 
still unknown.  14 
 15 
Recently several studies have examined the role of somatic mutations in FA genes and 16 
sporadic cancers within the general population (180). In one study, several ovarian cell 17 
lines showed cisplatin sensitivity and a lack of monoubiquitylated FANCD2 but no 18 
underlying FA gene mutations. However, despite a genetic explanation, the phenotype 19 
was corrected by transfection with FANCF. The lack of FANCF expression in these 20 
cell lines was subsequently correlated with hypermethylation of the FANCF promoter 21 
(118). Promoter hypermethylation was also implicated in other studies of sporadic 22 
cancer such as head and neck squamous carcinomas, cervical carcinomas, non-small- 23 
cell lung cancer, and in sporadic AML (119, 134, 139). In another study, two 24 
pancreatic cancer cell lines were described to be MMC sensitive and defective in 25 
FANCD2 monoubiquitylation (147). One cell line had a homozygous deletion of 26 
FANCC and the other, a truncating mutation in FANCG. In a more recent study, 27 
FANCD2 expression was found to be absent in 10–20% of sporadic and BRCA1- 28 
related breast cancers, suggesting that somatic inactivating epigenetic events in 29 
FANCD2 may be important in both sporadic and hereditary breast cancer (203). 30 
 31 
The association of mutations or epigenetic silencing of FA genes with MMC 32 
sensitivity and lack of monoubiquitylated FANCD2 in cell lines from a subset of 33 
AML, ovarian, breast and pancreatic cancers, coupled with a functional rescue upon 34 
introduction of the correct FA gene, strongly suggests that inactivation of the FA 35 
pathway has a role in the development of these types of tumors.  36 
 37 
Therapeutics 38 
DNA interstrand crosslinking agents such as cisplatin and mephalan are commonly 39 
used as chemotherapeutics to treat cancers such as ovarian, testis, breast, bladder and 40 
head and neck (159, 170, 173). However tumor cells typically develop resistance to 41 
these particular crosslinking agents by multiple mechanisms during treatment, leading 42 
to eventual treatment failure. Re-sensitizing these resistant tumor cells is of utmost 43 
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importance for treating cancer. One approach for re-sensitization is to inhibit DNA 1 
damage response pathways involved in DNA interstrand crosslink repair. Since the FA 2 
pathway is proposed to be involved in the processing DNA interstrand crosslinks, 3 
there have been recent studies looking at the possibility of using the FA pathway as a 4 
re-sensitization target. In one study, transfection of a dominant-negative form of 5 
FANCA into a cancer cell line disrupted FANCD2 monoubiquitylation and produced 6 
cellular hypersensitivity to cisplatin (127). Another study of small interfering RNA 7 
(siRNA) knock down of FANCF in melphalan-resistant cells partially reversed their 8 
drug resistance (155). A study of BRCA2-deficient cells and tumors demonstrated a 9 
sensitivity to PARP (Poly ADP-Ribose Polymerase) inhibitors (153, 156). In addition, 10 
a cell-based screening strategy identified several small-molecule inhibitors of the FA 11 
pathway that may be used to sensitize cancer cells to DNA crosslinker-based therapy 12 
(173). 13 
 14 
An alternative screening strategy is presented in Chapter 4, which has several major 15 
advantages over the cell-based assays. It is technically simple, rapid, inexpensive, and 16 
well suited for adaptation to semi- or high-throughput methods to screen for small 17 
molecules that selectively inhibit the FA pathway by preventing the 18 
monoubiquitylation of FANCD2. Conversely, this assay also has the potential to 19 
screen for small molecules that may correct the inability of a defective FA core 20 
complex to monoubiquitylate FANCD2 and in that way could identify potential 21 
treatment modalities for patients with FA.  22 
23 
23 
23 
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1.3 Xenopus Laevis as a Model System  1 
 2 
 3 
Fanconi anemia is a complex disorder and understanding its underlying pathogenic 4 
mechanisms has been a major focus for FA researchers ever since the associated 5 
disease genes became identified. Genetic approaches have been essential for the 6 
identification of many proteins involved in the FA pathway. However, studies 7 
designed to unravel the pathway have been hampered by the general complexity of 8 
processes in the context of the intact living cell. Xenopus laevis egg extracts 9 
circumvent some of the problems, as they represent a special cytoplasmic extract 10 
enriched with a stockpile of the material required for the rapid divisions of the early 11 
embryo. The extract is amenable to manipulation of its constituents, including 12 
manipulation of cell cycle checkpoints (168, 189), and appears capable of 13 
recapitulating at least some of the subcellular events that take place in living cells. 14 
Studies on egg extracts have provided essential insights into many cellular processes, 15 
including DNA repair, DNA replication, chromatin assembly, transcription, and cell- 16 
cycle control, and have proven valuable even in the analysis of processes associated 17 
with mitosis, such as chromosome condensation, spindle formation, and chromosome 18 
segregation (179).  19 
 20 
We have firm evidence that the FA pathway is conserved in Xenopus; we have 21 
identified at least partial orthologs for all FA genes, demonstrated the conserved 22 
monoubiquitylation of FANCD2, and the formation of core complex. Therefore, the in 23 
vitro system should be useful to study the FA pathway at the molecular level. 24 
 25 
To provide an introduction for the remaining chapters of this thesis, in this section a 26 
brief description is given of the basic methodologies applicable to the use of Xenopus 27 
laevis egg extracts.  28 
 29 
Background 30 
The largest organ in Xenopus laevis is the ovary, which harbors several thousands of 31 
oocytes. Oocytes are cells that are blocked at the prophase stage of meiosis I. During a 32 
period lasting one to two years, they grow without dividing and accumulate a large 33 
stockpile of components destined to become active during the early developmental 34 
stages following fertilization. The maturation of the oocyte into an egg may be induced 35 
by injecting a female with the hormone gonadotropin, after which the unfertilized eggs 36 
are deposited outside the body of the animal. During this process—prior to 37 
fertilization—the oocyte’s nuclear envelope is degraded and the cell cycle becomes 38 
arrested at metaphase of meiosis II, due to the presence of an activity called cytostatic 39 
factor (CSF), which maintains high intra-cellular levels of Cdk1/Cyclin B (reviewed in 40 
(188)). This is the stage at which the eggs are used as a source of cell-free extracts. 41 
 28 
 
Different kinds of extracts can be obtained, depending on the mechanism to be 1 
analyzed or the question to be addressed. Figures 1, 2, and 3 summarize some of the 2 
different types of extracts and their specific uses. 3 
 4 
Preparation of egg extracts 5 
Freshly laid unfertilized eggs are collected and crushed by centrifugation to remove 6 
meiotic chromosomes, mitochondria, yolk, pigments, and lipids (Fig 1). Sperm entry 7 
triggers a calcium spike, which induces the destruction of CSF and Cyclin B and 8 
subsequent exit from metaphase. Extracts prepared in the presence of the calcium 9 
chelator EGTA, are able to maintain metaphase arrest and are called CSF extracts. 10 
Importantly, these extracts can be cycled through interphase by adding calcium and 11 
can then be driven back into metaphase with the addition of fresh CSF extract (fresh 12 
CSF extract provides the Cyclin B necessary to progress the cell cycle). 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
Cell free DNA Replication 29 
Interphase egg extracts are highly efficient in replicating DNA from sperm nuclei. 30 
When sperm nuclei are added to these extracts, the DNA decondenses (~0-30 minutes) 31 
and a nuclear membrane forms (~30-60 minutes), followed by one round of semi- 32 
conservative chromosomal replication (~90 minutes) (Fig 2). If fresh CSF extract is 33 
added (restoring Cyclin B levels), then the extract will enter metaphase; without the 34 
addition of exogenous Cyclin B the extract will remain arrested at the end of 35 
interphase. After the addition of sperm chromatin, nuclei and chromatin fractions can 36 
be collected at different time points throughout replication and assayed for the 37 
presence of a protein of interest (14). Another useful feature of this in vitro system is 38 
its biochemical accessibility. Inhibitory reagents like geminin, a protein which binds 39 
Cdt1 (a protein that promotes the loading of the pre- replication complex onto 40 
chromatin to initiate DNA replication), preventing the loading of replication- 41 
Fig 1. Xenopus Egg Extract Preparation. Schematic diagram showing the preparation of Xenopus egg 
extracts from eggs into CSF and interphase extracts. 
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associated proteins at replication origins, may be added to allow the analysis of 1 
proteins in the absence of replication (73). In addition, cell cycle checkpoints may be 2 
altered by the addition of reagents such as caffeine, which inactivates both the ATM 3 
and ATR checkpoint kinases, allowing replication without cell cycle checkpoint 4 
activation (60). Furthermore, reagents that cause a specific type of DNA damage, such 5 
as aphidicolin (which inhibits replicative DNA polymerases, and results in long 6 
stretches of single strand DNA by the uncoupling from helicase activity) may be added 7 
and specific proteins may be monitored for their changed chromatin binding behavior 8 
that results from specific types of DNA damage (9).  9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
Analysis of Target Proteins  22 
To reveal a target protein’s contribution to replication or to establish the order 23 
of chromatin recruitment, a protein of interest can be removed from the extract 24 
by immunodepletion (Fig 3). This technique provides a powerful approach for 25 
the study of protein function, as it is similar to a genetic null mutant. However, 26 
depletion has an advantage over a genetic null mutant in that a protein, which is 27 
essential for development, such as ATR or BRCA2, can be depleted and the 28 
consequences of depletion can be studied at the molecular level. An example of 29 
an assay for protein function during replication is the terminal 30 
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) 31 
assay, which is used to determine the accumulation of DNA breaks which are 32 
known to arise during the course of normal replication (75). Importantly, 33 
recombinant proteins can be added back to depleted extracts to “rescue” the 34 
phenotype. Also co-depleted factors can be identified by mass spectrometry 35 
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Fig 2. Cell-Free DNA Replication. Schematic diagram of one round of semi-conservative  
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analysis or immunoblotting. Further examples of the use of these and other 1 
techniques to investigate the function of FA proteins are presented in Chapters 2 
2-5 of this thesis.  3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
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1.4 Outline of the Thesis 1 
 2 
 3 
Previous investigations have established that error-free replication of DNA in 4 
vertebrate animals critically depends on an intact FA pathway. The precise way in 5 
which the FA proteins ensure the stability of the genome is still unknown, however. In 6 
order to define the individual molecular events that make up the FA pathway, it would 7 
be desirable to study the pathway in a cell-free system, in which the presence of 8 
(modified) FA proteins as well as the nature of the DNA substrates could be 9 
experimentally manipulated. A system that seemed to meet such requirements is that 10 
provided by cell-free extracts of unfertilized eggs from the South-African clawed frog, 11 
Xenopus laevis. This system, which has been developed over the past 30 years, is 12 
suitable to study the replication of exogenous DNA, since all the proteins that are 13 
needed to carry out DNA replication are present at high concentrations and “ready to 14 
go.”  15 
 16 
The purpose of this thesis is to describe the utility of Xenopus laevis cell-free extracts 17 
to obtain and exploit novel knowledge about the molecular functions of FA proteins. 18 
 19 
After a general introduction to genomic instability syndromes (Chapter 1.1), and 20 
Fanconi anemia (Chapter 1.2), the Xenopus-derived cell-free DNA replication system 21 
is introduced in Chapter 1.3. 22 
 23 
In Chapter 2, we exploit one of the advantages of the in vitro system, i.e. the 24 
possibility to study the consequences of immunodepletion of FA proteins. Based on 25 
these studies, we provide the first evidence that FA proteins, at least FANCA and 26 
FANCD2, are required for the prevention of DNA breaks that arise during the course 27 
of unperturbed replication, independent of the cell-cycle checkpoints that regulate the 28 
FA response to exogenous DNA damage. 29 
 30 
Is there a specific DNA lesion that serves as a catalyst for the activity of FA proteins 31 
during replication? This question is addressed in Chapter 3. By mimicking various 32 
DNA structures that may arise during replication, it was possible to define the 33 
preferred DNA structures that are preferential binding targets for FA proteins. These 34 
recruiting structures as well as other FA pathway “activating” structures are presented 35 
in this Chapter.  36 
 37 
The FA pathway, as well as other DNA repair pathways, may be used as possible 38 
targets for the re-sensitization of chemotherapy-resistant tumor cells in cancer patients. 39 
In Chapter 4, we present a novel cell-free assay utilizing Xenopus extracts to find 40 
 32 
 
small molecule inhibitors of the FA and MRE11 DNA repair pathways. We also 1 
present a novel inhibitor of FANCD2 monoubiquitylation.  2 
 3 
In addition to the function of FA proteins in DNA repair, the developmental 4 
abnormalities observed in FA patients suggest that the FA proteins play a role in 5 
vertebrate morphogenesis. In Chapter 5, we examine the expression of the FA proteins 6 
during the earliest stages of embryonic development using Xenopus embryos. We 7 
describe a zygotically-regulated variant of Xenopus FANCG that may have a 8 
functional role during development. This Chapter also introduces the advantages of 9 
using Xenopus as a developmental model for FA. 10 
 11 
Finally, in a general discussion (Chapter 6), a hypothesis and a simplified model for 12 
the role of the FA proteins during DNA replication is proposed. 13 
 33 
Chapter 2 1 
 2 
Fanconi Anemia Proteins are Required to Prevent Accumulation of 3 
Replication-Associated DNA Double-Strand Breaks 4 
 5 
 6 
 7 
 8 
 9 
Published in a slightly modified form,  10 
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Fanconi Anemia Proteins are Required to Prevent Accumulation of 
Replication-Associated DNA Double Strand Breaks 
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Fanconi anemia (FA) is a multigene cancer susceptibility disorder characterized 
by cellular hypersensitivity to DNA interstrand cross-linking agents such as 
mitomycin C (MMC). FA proteins are suspected to function at the interface 
between cell cycle checkpoints, DNA repair, and DNA replication. Using 
replicating extracts from Xenopus eggs, we developed cell-free assays for FA 
proteins (xFA). Recruitment of the xFA core complex and xFANCD2 to 
chromatin is strictly dependent on replication initiation, even in the presence of 
MMC indicating specific recruitment to DNA lesions encountered by the 
replication machinery. The increase in xFA chromatin binding following 
treatment with MMC is part of a caffeine-sensitive S-phase checkpoint that is 
controlled by xATR. Recruitment of xFANCD2, but not xFANCA, is dependent 
on the xATR-xATR-interacting protein (xATRIP) complex. Immunodepletion of 
either xFANCA or xFANCD2 from egg extracts results in accumulation of 
chromosomal DNA breaks during replicative synthesis. Our results suggest 
coordinated chromatin recruitment of xFA proteins in response to replication-
associated DNA lesions and indicate that xFA proteins function to prevent the 
accumulation of DNA breaks that arise during unperturbed replication. 
 
INTRODUCTION 
The hereditary syndrome Fanconi anemia (FA) belongs to a group of caretaker gene 
diseases characterized by genomic instability and increased susceptibility to cancer. A 
hallmark of FA is cellular hypersensitivity to DNA interstrand cross-links (ICLs), 
suggesting a defect in the DNA damage response (18, 19, 48). Twelve FA 
complementation groups have been identified, and the majority of the corresponding 
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genes have been cloned (FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, 
FANCF, FANCG, FANCJ, FANCL, and FANCM) (22, 23, 25, 43, 55, 59, 60, 66, 87, 
93). Although the function of the FA proteins is unknown, identification of BRCA2 
(breast cancer-associated gene 2) as FANCD1 and of FANCJ as the BRCA1-associated 
helicase gene Brip1/BACH1, suggests convergence of the FA/BRCA pathway with a 
larger network of proteins involved in DNA repair (7, 51-53, 95). This is underscored 
by the discovery that FANCM is related to archaeal Hef, a protein that binds and 
processes irregular arrangements of DNA in branched structures resembling replication 
forks (50, 71, 72). 
 
According to current models, the FA pathway consists of an upstream nuclear core 
complex, including FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, 
and FANCM, required for the activation of its target, FANCD2 (24, 34-36, 59, 60, 66). 
FANCD2 is monoubiquitinated during S phase and in response to various types of 
DNA damage, including DNA ICLs, DNA double-strand breaks (DSBs), and 
replication fork stalling (36, 89). DNA damage-induced monoubiquitination of 
FANCD2 is also reduced in cells from Seckel syndrome patients with a defect in the 
ataxia telangiectasia- and RAD3-related gene, ATR (1), suggesting that the FA pathway 
is under at least partial control of the ATR kinase. Monoubiquitination of FANCD2 is 
required for its association with chromatin and localization into nuclear foci containing 
BRCA1, RAD51, MRE11-RAD50-NBS1, replication protein A (RPA), PCNA, and 
BRCA2 (37, 42, 44, 65, 68, 89). FANCD2 is also phosphorylated in response to 
different types of DNA damage (68, 78, 90), and it is suspected that FANCD2 
phosphorylation is part of two separate pathways that are controlled by one of the two 
checkpoint kinases, ATR or ATM (ataxia telangiectasia mutated) (68, 78, 90). 
 
Several findings support the idea that FA proteins function during the S phase of the 
cell cycle. ICLs, the major genotoxic challenge for FA cells, are processed through 
generation of DNA DSB intermediates, which are generated specifically during S 
phase (5, 21, 28, 82) and repaired by the process of homologous recombination (HR) 
(83). The hypothesis that FA proteins are likely to function in ICL removal via HR 
repair during S phase is supported by evidence that FANCD1/BRCA2 is a central 
component of the HR repair mechanism (47, 79) and interacts with both RAD51 
recombinase and FANCD2 (10, 20, 44, 98). Additional evidence supports a role for 
FANCA, FANCC, FANCG, and FANCD2 in HR (69, 70, 100, 101). New evidence 
from the DT40 model strongly implicates the FA downstream protein BRIP1/BACH1 
helicase in DNA interstrand cross-link repair (7). Furthermore, the FA core complex 
proteins are part of BRAFT, a larger complex containing the Blm helicase, 
topoisomerase III, and RPA (61), which supports the hypothesis of a function for FA 
proteins in replication-associated repair mechanisms. 
To elucidate FA protein function(s) in the DNA damage response during replication, 
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we established cell-free assays using Xenopus egg extracts that have been used to 
understand the role of other DNA repair proteins such as Mre11, Blm, ATR, and ATM 
during replication (12-17, 38, 39, 49, 54, 56, 85, 102). We have cloned the Xenopus 
laevis homologs of several of the FA proteins (generally termed xFA) and show that 
these proteins are recruited to chromatin in response to DNA lesions encountered by 
the replication machinery. Our findings suggest that the xFA proteins are required to 
prevent accumulation of DNA breaks that arise not only in response to exogenous 
DNA damage, but also during unperturbed replication. 
RESULTS 
Conservation of the FA pathway in Xenopus laevis 
We identified Xenopus homologs of several human FA genes (see Fig. S1 in the 
supplemental material). A downstream effector of the FA pathway, xFANCD2, has an 
overall homology of 70% compared with that of human FANCD2; both known 
modification target sites, i.e., K561 for monoubiquitination (K563 in Xenopus) and 
S222 for phosphorylation (S224 in Xenopus) are conserved (Fig. 1) (36, 90). 
Furthermore, interactions between FA core complex members and the DNA damage-
induced appearance of FANCD2-L (36) occur in Xenopus cells and egg extracts (see 
Fig. S3 in the supplemental material). We infer from these data that the critical 
components and the activation of the FA pathway are conserved in Xenopus. 
 
xFA proteins associate with chromatin in a replication initiation-dependent manner 
To analyze localization and chromatin binding behavior of xFA proteins, we used 
extracts prepared from Xenopus eggs. These extracts are arrested at the end of meiosis 
(M-phase extract) and contain only negligible amounts of DNA. Upon chemical 
activation, the extracts are released into S phase in tight synchrony. When sperm 
chromatin is added to S-phase extracts, the DNA decondenses and a nuclear membrane 
forms (20 min), followed by one round of semiconservative chromosomal replication. 
Following addition of sperm chromatin, we reisolated nuclei and chromatin fractions at 
time points before, during, and after replication and assayed for the presence of 
xFANCA, xFANCF, and xFANCD2. These proteins accumulated in the newly formed 
nuclei and associated with chromatin during replication (Fig. 2A), which typically 
occurred between 30 to 60 min (Fig. 2B) (67). A slow-mobility form of xFANCD2 was 
predominant in whole nuclei (Fig. 2A, lanes 1 to 4), as well as in the nuclear chromatin 
fractions (Fig. 2A, lanes 5 to 7), at the indicated time points. Since the extracts were 
precisely synchronized throughout S phase and replication of added sperm chromatin 
started shortly after nuclear membrane formation, it is likely that xFANCD2-S was 
converted to its modified form (FANCD2-L) immediately upon nuclear import and 
then recruited to replicating chromatin. Only the small isoform of xFANCD2 was 
detected in M-phase and S-phase extracts (Fig. 2C), where only negligible amounts of 
DNA were present. This observation implies that modification of xFANCD2 during S 
phase is dependent on the presence of chromatin, consistent with previous evidence 
that chromatin binding is associated with monoubiquitination of FANCD2 (65, 98).  
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Figure 1. Homology between Xenopus and  human FANCD2. Full length Xenopus FANCD2 
(xFANCD2) was aligned with full length human FANCD2 (hFANCD2) using MacVector 7.1.1. Amino 
acid identity is indicated by dark shading; similar amino acids are indicated by light shading.  The two 
known critical residues, S222 and K561, (denoted by arrows) are conserved between human and Xenopus 
FANCD2. 
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Chromatin-bound FA proteins are labeled with the suffix "-chr" in the text to provide a 
frame of reference because egg extracts and nuclear chromatin reisolated from egg 
extracts typically contain only a single isoform of xFANCD2. Egg extracts have a 
form comparable to FANCD2-S in cellular extracts, while chromatin replicated in egg 
extracts contained FANCD2-chr, comparable to FANCD2-L on chromatin isolated 
from cells. The mobility changes for FANCD2-chr and FANCA-chr compared with 
chromatin-bound counterparts in cell extracts (Fig. 2A, compare lanes 7 and 8) are 
likely due to large amounts of chromatin and protein in the egg extract samples. 
 
Unlike other DNA replication proteins such as xRPA70 or xPCNA, the xFA proteins 
remained associated with chromatin once the bulk of replication was completed (Fig. 
2D, lane 90). On the other hand, the chromatin binding pattern of the checkpoint 
signaling kinase xATM, which monitors origin firing during normal replication (85), 
closely resembled the temporal binding pattern of both xFANCA and xFANCD2. To 
further investigate the observed chromatin association pattern of xFA proteins, we 
used egg extracts prepared in the absence of cycloheximide. In classically prepared 
Xenopus egg extracts, cycloheximide blocks accumulation of cyclin B, which is 
required for the transition from S to M phase. Thus, in the presence of cycloheximide, 
extracts were halted in a G2-like state after DNA replication (Fig. 2D), whereas 
absence of cycloheximide allows the extracts to exit S phase (63, 67). Interestingly, in 
cycloheximide-free extracts, xFA proteins dissociated from chromatin once replication 
was over (Fig. 2E). Thus, the release of xFA proteins from chromatin was not triggered 
by the completion of replicative DNA synthesis alone but occurred only when extracts 
were allowed to exit S phase (compare Fig. 2D and E). 
 
Accumulating evidence suggests that FA proteins function in the repair of specific 
DNA lesions that are encountered during transit through S phase (40, 70, 82, 89, 92). 
To determine if xFA proteins bound to chromatin in a replication-dependent manner, 
we blocked replication initiation by adding geminin to S-phase egg extracts. Geminin 
prevents assembly of prereplication complexes and thus inhibits replication initiation 
but does not affect chromosome decondensation or nuclear membrane formation (88). 
As shown in Fig. 3A, top left, accumulation of xFA core complex proteins and 
xFANCD2 on chromatin (compare lanes 1 and 2) was drastically inhibited in the 
presence of geminin, demonstrating that recruitment of FA proteins to chromatin 
occurs in a strictly replication initiation-dependent manner. 
 
Recruitment of FA proteins to chromatin during disrupted replication. 
The hallmark of Fanconi cells is their hypersensitivity to DNA interstrand cross-
linking agents such as MMC. As shown in Fig. 3A, top left, chromatin binding of 
xFANCA, xFANCF, and xFANCD2 increased in the presence of MMC (compare 
lanes 1 and 3), consistent with fractionation and immunofluorescence data for FA by 
one of the caffeine-sensitive kinases ATM or ATR (Fig. 3A, top left, compare lanes 1 
and 5). Importantly, even in the presence of MMC, extracts failed to support chromatin 
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Figure 2. xFA proteins accumulate in nuclei and associate with chromatin in a replication-
dependent manner. (A) Nuclear accumulation and chromatin-binding of FA proteins during replication. 
Sperm chromatin was added to S-phase egg extracts and re-isolated at indicated time points during 
replication. Nuclear or chromatin fractions were analyzed by SDS-PAGE and immunoblot. Xenopus 
XTC-2 cell lysates (see also suppl. data) were used as control for xFANCD2-S, L and xFANCA; a Flag-
tagged xFANCF was used as positive control. (B) Replication assay. Throughout the experimental 
procedure described in (A), semi-conservative replication was monitored by pulsing replicating extract 
aliquots with α-32P-GTP at time windows 0-30, 30-60, and 60-90 min. (C) Isoforms of FANCD2 
detectable in M- and S- phase, and in chromatin fractions from replicating nuclei. An isoform of 
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xFANCD2 with relatively slower mobility associates with chromatin during replication. Electrophoretic 
mobility was compared among xFANCD2 isolated from XTC-2 cell lysates, DNA-free mitotic egg 
extracts (M-phase), DNA-free S-phase egg extracts (S-phase), and from nuclear sperm chromatin 
replicating in S-phase egg extracts (chromatin). (D) Comparison of chromatin binding patterns between 
xFA proteins and other DNA replication-associated proteins. Sperm chromatin was added to 
cycloheximide-containing S-phase egg extracts, chromatin fractions were re-isolated at the times shown 
and analyzed for the indicated proteins by immunoblotting. (E) xFA proteins dissociate from chromatin in 
non-arrested extracts following replication. Sperm chromatin was added to S-phase egg extracts in the 
absence of cycloheximide. Chromatin fractions were re-isolated at the indicated time points and analyzed 
for xFANCA, xFANCD2, and xFANCF by immunoblotting. 
 
 
recruitment of xFA proteins when replication initiation was blocked with geminin (Fig. 
3A, top left, compare lanes 3 and 4). Replication in these extracts was monitored in 
matched aliquots by measuring incorporation of radiolabeled nucleotides into the 
nascent DNA strand. The replication assay shown in Fig. 3A, top right, demonstrated 
that replication occurred (lane 1), was reduced by exposure to MMC (lane 3), and 
was rescued by addition of caffeine (lane 2). As expected, no incorporation was 
detected in the presence of geminin (lane 4). Taken together, these data suggest 
that chromatin binding of xFA proteins is specifically triggered by DNA lesions 
that are encountered during DNA replication. 
 
The finding that caffeine restored wild-type-like incorporation of nucleotides 
during replication in MMC-treated extracts suggests that replication inhibition 
induced by MMC is due to activation of an S-phase checkpoint, a response that 
allows cells to repair damage before they proceed to the next cell division, thus 
preventing the transmission of mutations (4, 9, 73, 75). To further explore the 
effect of MMC on replication, we determined whether the reduction of replication 
products occurred in an MMC dose-dependent manner. As shown in Fig. 3A, 
bottom, DNA replication was significantly blocked at high concentrations of MMC 
(150 µM) (lane 3) and could not be rescued by caffeine (lane 6). In contrast, at 
lower MMC concentrations, replication was less inhibited (50 µM, lane 4; 5 µM, 
lane 5) and could be rescued in the presence of caffeine (lane 7). 
 
To determine if the MMC-induced replication block was under control of the 
major replication checkpoint kinase, ATR, we added a neutralizing anti-xATR 
antibody (Fig. 3A, bottom, lanes 8 and 9) to egg extracts to specifically block the 
xATR kinase function, thereby preventing phosphorylation of the Chk1 protein 
that is required for activation of the S-phase checkpoint (57). Comparable to the 
effect observed in the presence of caffeine, inhibition of xATR did not rescue the 
very strong replication block in high MMC concentrations (lane 7); however, at 
lower MMC concentrations, reduction of replication products was restored back to 
wild-type levels when xATR was blocked. Thus, at lower doses the MMC-induced 
reduction in incorporation of nucleotides during replication is due to activation of 
an S-phase checkpoint that depends on xATR and results in an increase in xFA-
chromatin binding. 
 
To determine the influence of fork stalling during DNA replication on recruitment 
of FA proteins to chromatin, we added aphidicolin to replicating extracts.  
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Figure 3: Chromatin recruitment of xFA proteins in response to replication fork stalling and 
checkpoint activation. (A) Mitomycin C induces recruitment of xFA proteins to chromatin in a 
replication-and S-phase checkpoint-dependent manner. S-phase extracts were treated as indicated and 
supplemented with sperm chromatin. Following replication (60 min), chromatin was re-isolated and 
assayed for the presence of xFA proteins by immunoblot.  
 
Aphidicolin treatment blocks replicative polymerases, while helicases continue to 
unwind the DNA helix, thereby generating long single-stranded DNA (ssDNA) 
stretches (74, 85, 97). As shown in Fig. 3B, addition of aphidicolin to replicating 
extracts resulted in increased chromatin association of xFA proteins, as well as the 
ssDNA binding protein xRPA. Interestingly, whereas chromatin binding of xRPA 
ncreased significantly when aphidicolin was added before or during ongoing 
replication, recruitment of xFA proteins to chromatin increased only when 
aphidicolin was added during ongoing replication at 45 min (midreplication) and 
60 min (late replication) (compare lane 1 with lanes 4 and 5). In contrast, when 
aphidicolin was added to extracts before the onset of replication (0 min or 30 min; 
compare lane 1 with lanes 2 and 3) or after replication was finished (90 min, compare 
lane 1 with lane 6), chromatin binding of xFA proteins did not increase. It is also 
important to note that under our experimental conditions, aphidicolin does not result in 
detectable DNA DSBs (54). These results suggest that the xFA proteins are recruited 
when the moving replication fork encounters sites of DNA damage. 
 
 
% incorporation of  
α32P-labeled dGTPs 
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Figure 3. (B) Stalling of replication forks induces recruitment of xFA proteins to chromatin. Sperm 
chromatin added to untreated (-) or aphidicolin-treated (+) S-phase egg extracts was re-isolated at the 
indicated time points: 5 min, pre-nuclear membrane formation; 40 min, mid-replication; 60 min, late 
replication; 90 min, post-replication. Chromatin fractions were isolated and analyzed by SDS-PAGE and 
immunoblot. (C) MMC-treated extracts activate a caffeine-sensitive S-phase checkpoint. Replication 
assay to monitor incorporation of α-32P-GTP during one round of replication in extracts treated as 
indicated. Total amounts of replication products at 60 min following addition of sperm chromatin to 
untreated or treated extracts were analyzed by agarose gel electrophoresis. 
 
The xATRIP/xATR complex controls chromatin binding of xFANCD2 
independently of xFANCA. 
ATR plays a critical role in coordinating the response to DNA damage. Its activation is 
usually linked to ongoing DNA replication (39, 57, 86, 91). The current model 
suggests that the ATR complex consisting of the ATR kinase and its binding partner, 
ATRIP, control S-phase progression in response to DNA damage and replication fork  
stalling. ATR and ATRIP are mutually dependent partners in the cellular S-phase 
checkpoint and DNA damage response (2, 3, 6, 11, 30, 45, 46, 94, 103). Generation 
of RPA-coated ssDNA is the critical signal that triggers recruitment of the tightly  
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Figure 4. Replication-associated chromatin binding of xFANCD2 requires the presence of xFANCA. 
(A) S-phase egg extracts were incubated either with bead-coupled anti-xFANCA antibody (xA) or with 
bead-coupled pre-immune serum (Pre) and assayed for presence of xFANCA by immunoblot. Right lane: 
xFANCA binds to anti-xFANCA-beads during the depletion process. (B) Sperm chromatin was added to 
xA- or Pre-depleted extracts, re-isolated following replication and assayed for the presence of xFANCD2-
chr by immunoblot. (C, D) Replication-associated chromatin binding of xFANCA does not require the 
presence of xFANCD2. (C) S-phase egg extracts were incubated either with bead-coupled anti-xFANCD2 
antibody (xD2) or with bead-coupled pre-immune serum (Pre), and assayed for presence of xFANCD2 by 
immunoblot. Right lane: xFANCD2 binds to anti-xFANCD2-beads during the depletion process. (D) 
Sperm chromatin was added to xD2- or Pre-depleted extracts, re-isolated following replication and 
assayed for the presence of xFANCA-chr by immunoblot. 
 
associated ATRIP-ATR complex. Our results demonstrated that MMC-induced 
increase in xFA-chromatin binding was reversed by the ATR-ATM inhibitor 
caffeine (Fig. 3A, top left, and data not shown). Thus, we asked whether depletion 
of the xATRIP subunit of the xATR kinase affected recruitment of the xFA 
proteins to chromatin. As shown in Fig. 3C, recruitment of xFANCD2 to chromatin 
was negligible in replicating extracts depleted of xATRIP, regardless of whether 
replicating extracts were unchallenged or treated with aphidicolin. In contrast, the 
xATRIP-depleted extracts still fully supported recruitment of xFANCA to 
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chromatin in the presence or absence of aphidicolin. Similar results were 
obtainedwhen extracts contained the neutralizing xATR antibody that blocked 
xATR phosphatidylinositol 3-kinase function (data not shown). To further 
investigate the influence of ATRIP on the FA pathway, we quantitatively depleted 
xFANCA from replicating extracts and tested for chromatin binding of xATRIP. Since 
levels of chromatin-associated xATRIP during unperturbed replication were barely 
detectable by Western blotting (Fig. 3C and D), we added aphidicolin to induce 
chromatin recruitment of xATRIP. As shown in Fig. 3D, immunodepletion of 
xFANCA did not affect the aphidicolin-inducedchromatin recruitment of xATRIP. 
Thus, the xATRIP-xATR complex regulates recruitment of xFANCD2 to chromatin 
independently of the regulation that xFANCA and other core complex proteins exert in 
unperturbed replication, as well as in response to replication fork stalling. 
 
Chromatin association of xFANCD2 depends on xFANCA 
A functional FA core complex is believed to act upstream of FANCD2 by mediating 
its monoubiquitination (36, 89). The core complex protein xFANCA was 
quantitatively depleted from egg extracts to determine its influence on recruitment of 
xFANCD2 to chromatin (Fig. 4A). Sperm chromatin was added to the xFANCA-
depleted extracts, followed by reisolation of replicated chromatin after 90 min. As 
shown in Fig. 4B, replication-associated binding of xFANCD2 to chromatin was 
abrogated in the absence of xFANCA. In contrast, immunodepletion of xFANCD2 
from egg extracts (Fig. 4C) did not affect chromatin binding of xFANCA (Fig. 4D). 
Our results indicate that the xFANCA core complex is required for recruitment or 
stabilization of xFANCD2 at chromatin in response to DNA damage encountered 
during the replication process. 
 
xFANCA and xFANCD2 are required to prevent accumulation of DNA DSBs 
during replication. 
Accumulating evidence points to a role for the FA pathway in repair of DNA DSBs 
(26, 27, 69, 82, 100, 101). Our results implied that xFA proteins are specifically 
recruited to chromatin during unperturbed replication and when exogenous DNA 
damage is encountered during replication. Thus, we first asked whether the absence of 
xFANCA (as a representative core complex member) or xFANCD2 (as an effector of 
the FA core complex) affects the overall kinetics of DNA replication. 
 
Following immunodepletion of xFANCA or xFANCD2 from egg extracts, we 
monitored timing and levels of nucleotide incorporation during chromosomal 
replication. No gross difference in replication kinetics was observed between mock- 
and xFANCA-depleted extracts (Fig. 5A and C) or between mock- and xFANCD2- 
depleted extracts (Fig. 5B and D). Thus, neither xFANCA nor xFANCD2 was required 
for initiation or elongation in the replication process itself. We then used a TUNEL   
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Figure 5. xFA proteins are required to prevent accumulation of DNA breaks during unperturbed 
replication (A, B) xFANCA and xFANCD2 are not essential for DNA replication. Genomic DNA 
replication was monitored by 30 min pulses of α-32P-GTP. (A) Nucleotide incorporation into replicating 
chromatin in extracts incubated with protein A beads bound to preimmune serum (xA pre-immune 
depleted extracts) or extract incubated with protein A beads bound to anti-xFANCA antibodies (xA 
depleted extracts). (B) Incorporation into replicating chromatin in extracts incubated with protein A beads 
bound to preimmune serum (xD2 pre-immune depleted extracts) or extract incubated with protein A beads 
bound to anti-xFANCD2 antibodies (xD2 depleted extracts). (C, D) Depletion of xFANCA or xFANCD2 
causes DNA breaks during normal replication. (C) Egg extracts were treated with beads coupled to xA-
preimmune serum (lane 1) or beads coupled to anti-xFANCA (lane 2). (D) Likewise, extracts were treated 
with either beads coupled to xD2-preimmune serum (lane 1) or beads coupled to anti-xFANCD2 (lane 2). 
Sperm chromatin was added to treated extracts and after 2 h, TUNEL assays were performed. Samples 
were subjected to agarose gel electrophoresis and phosphorimaging.  
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assay to investigate whether the xFA proteins might be necessary to prevent the 
accumulation of DNA DSBs that are known to arise during the course of normal 
replication (15, 54). Chromosomal DNA was added to preimmune serum-, xFANCA-, 
or xFANCD2-depleted extracts, followed by one round of replication and isolation of 
replication products. Putative DNA DSBs in the postreplicative chromatin were 
labeled using terminal transferase and radioactive deoxynucleotides. We detected 
strong signals for incorporation of [32P]dGTP in replication products from extracts 
depleted of either xFANCA (Fig. 5E) or xFANCD2 (Fig. 5F) compared to mock-
depleted extracts. Thus, absence of xFANCA or xFANCD2 from egg extracts results 
in accumulation of DNA breaks during unperturbed DNA replication. 
 
DISCUSSION 
We established cell-free assays for functional evaluation of the FA network proteins, 
which play critical but largely unknown roles in mechanisms that preserve genomic 
stability. 
 
Analysis of the Xenopus homologs of FANCD2, FANCA, FANCF, and FANCL 
revealed regions of strong homology compared to their human counterparts, suggesting 
that they might contain some as-yet-unrecognized domains. Importantly, the known 
FA pathway characteristics are conserved in Xenopus including (i) conservation of the 
functional modification target sites of FANCD2, K561 (monoubiquitination), and S222 
(phosphorylation); (ii) interactions between core complex members xFANCA and 
xFANCF (24, 34, 59, 61); and (iii) induction of an xFANCD2-L isoform following 
DNA damage. Thus, Xenopus egg extracts provide a cell-free system for functional 
analysis of the FA proteins during DNA replication and repair. 
 
The downstream target of the FA pathway, FANCD2, is monoubiquitinated during S 
phase (FANCD2-L form), and this FANCD2-L isoform associates with S-phase 
chromatin (65, 89). Taking advantage of the fact that proteins can be analyzed in the 
highly synchronized Xenopus egg extracts in M and S phases even in the absence of 
DNA, we found that entry of the egg extract into S phase alone does not induce the 
xFANCD2-L form. In contrast, xFANCD2 is very quickly modified upon its import 
into nuclei that form once sperm chromatin is added to S-phase extracts, suggesting 
that formation of FANCD2-L is a DNA-dependent process. Following import of 
xFANCD2, xFANCA, and xFANCF into sperm nuclei, the proteins are recruited to 
chromatin during unperturbed replication. Chromatin binding of all three xFA proteins 
increases further in the presence of MMC, consistent with previous work showing that 
FANCD2-L and FA core complex proteins are chromatin bound during S phase and in 
response to DNA damage (36, 62, 64, 80, 89). Interestingly, when untreated egg 
extracts are prohibited from exiting S phase following DNA replication (i.e., they halt 
in a G2-like state), the xFA proteins stay bound to chromatin, unlike other replication-
associated proteins such as xRPA70 or xPCNA. This observation supports a model in 
which the FA proteins participate in specific DNA repair events that occur during late 
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replication and after the bulk of replication is completed (28, 70, 92, 100). The fact that 
xFA proteins dissociate from chromatin following replication when extracts are 
capable of exiting S phase suggests that the release from chromatin requires signaling 
associated with the G2-M transition of the cell cycle. 
 
Previous reports show S-phase- and DNA damage-dependent chromatin association of 
several FA proteins (36, 62, 64, 80, 89). However, whether chromatin assembly of the 
FA proteins is directly associated with the replication process has not been evaluated. 
We found that in extracts containing the replication initiation inhibitor geminin, xFA 
proteins did not associate with chromatin even in the presence of MMC. Thus, 
chromatin association of the xFA proteins is strictly replication dependent. A 
remaining question is why DNA replication is required for recruitment of FA proteins. 
Our finding implies that the xFA proteins are selectively recruited to DNA lesions that 
either arise during normal replication or are recognized in a replication context 
following exogenous DNA damage. 
 
In agreement with this idea, treatment of extracts with an inhibitor of replicative DNA 
polymerases, aphidicolin, also resulted in increased recruitment of xFA proteins to 
chromatin. Aphidicolin treatment leads to the generation of ssDNA regions due to 
uncoupling of the replicative helicase from the DNA polymerase. These ssDNA 
regions are generated regardless of whether aphidicolin is added to the egg extract 
before or during ongoing replication (as monitored by comparing chromatin-bound 
levels of the ssDNA binding protein xRPA). Interestingly, increased binding of xFA 
proteins to chromatin is only triggered when aphidicolin is added during the ongoing 
replication process, suggesting that the generation of ssDNA alone might not be 
sufficient for recruitment of the xFA proteins. In this regard, Cimprich and coworkers 
recently showed that functional uncoupling of MCM helicase and DNA polymerase 
occurs in response to several forms of DNA damage and that the subsequent 
accumulation of ssDNA is required but not sufficient to trigger the ATR-controlled 
checkpoint response (8). Further studies will be required to determine if the stalled 
replication fork itself or subsequently generated DNA intermediates and possibly 
additional factors trigger recruitment of the xFA proteins. 
 
Analysis of MMC-treated extracts revealed that the MMC-induced increase in xFA-
chromatin binding coincided with a reduction in replicative products. We demonstrated 
that this is due to activation of an intra-S-phase checkpoint that is controlled by the 
caffeine-sensitive checkpoint kinase ATR. In extracts containing MMC at 
concentrations between 5 and 50 µM, caffeine restored replication products back to 
wild-type levels and blocked the MMC-induced increase of xFA-chromatin 
association. Similarly, neutralization of the xATR kinase domain with a specific 
antibody inhibited checkpoint activation and subsequent reduction of replication 
products. In contrast, at higher MMC concentrations (150 µM), the replication block 
could not be overcome by caffeine or xATR neutralization. It is possible that at such 
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high MMC concentrations the DNA lesions typically induced by this agent (intra- and 
interstrand cross-links) reach a level at which each replicon contains a cross-link. This 
could cause quantitative inhibition of replication by physical impairment of the DNA 
polymerase-helicase to get through the cross-links, despite the caffeine-xATR-induced 
block of checkpoint activation. We conclude from these findings that the additional 
recruitment of xFA proteins to chromatin in response to exogenous DNA damage 
occurs as part of an intra-S-phase checkpoint controlled by ATR. In agreement with 
this, Andreassen et al. recently showed that the MMC-induced increase in FANCD2 
monoubiquitination, a step required for its targeting to chromatin, is dependent on ATR 
(1). 
 
Moreover, we could demonstrate that chromatin recruitment of xFANCD2 is abrogated 
in extracts that either contained the ATR-neutralizing antibody or were depleted of 
xATRIP, a functional subunit of the xATR kinase. Strikingly, depletion of xATRIP 
had no effect on chromatin binding of xFANCA, raising the question of whether 
xATRIP was positioned between xFANCA (and perhaps the entire core complex) and 
the downstream target, xFANCD2, or whether xATRIP controlled chromatin 
recruitment of xFANCD2 independently of xFANCA. Testing chromatin binding of 
xATRIP in xFANCA-depleted extracts demonstrated that it is recruited to chromatin 
independently of xFANCA. In addition, xATRIP-chromatin binding was unaffected in 
extracts depleted of xFANCD2. These data support a model where recruitment of 
xFANCD2 to DNA lesions encountered by the replication machinery is under control 
of two entities: the xFA core complex and the xATR/xATRIP complex. The fact that 
absence of xATRIP blocked xFANCD2-chromatin binding even in the absence of 
exogenous DNA damage suggests that the xATR-xATRIP complex regulates 
FANCD2 not only during checkpoint activation but also as part of the DNA repair 
response that deals with basal levels of DNA damage during normal replication. 
 
The current FA model suggests that modification and chromatin recruitment of 
FANCD2 are dependent on a functional FA core complex (1, 24, 36, 59, 62, 98). In 
support of this model, we found that the replication-associated chromatin binding of 
xFANCD2 is completely abrogated in egg extracts depleted of xFANCA. In contrast, 
depletion of xFANCD2 from S-phase extracts did not affect association of xFANCA 
with replicating chromatin. We conclude that the xFA proteins associate with 
chromatin in a coordinated manner. One possibility is that the xFA core complex binds 
to chromatin to recruit and activate xFANCD2 at specific types of DNA lesions 
encountered by the replication machinery. 
 
Since our results demonstrated that accumulation of xFA proteins on chromatin is 
dependent on replication origin unwinding, we also investigated a potential 
requirement of xFA proteins in the replication process itself. As predicted by the 
absence of gross defects in genomic duplication in cells from FA patients, the rate and 
timing of replicative DNA synthesis were not affected in the absence of either 
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xFANCA or xFANCD2. However, we found strikingly increased levels of DNA 
breaks in replication products from xFANCA- or xFANCD2-depleted extracts. 
 
These results provide first proof that even in the absence of exogenous DNA damage, 
the xFA proteins are required to prevent accumulation of DNA DSBs that are known 
to arise during unperturbed replication. A similar function has been described for the 
xBlm and xMre11 proteins (15, 54), both of which are functionally dependent on the 
FA core complex (76, 78). Blm and the FA core complex proteins are part of a larger 
complex (named BRAFT), hinting at interrelated functions for the Blm and FA 
pathways (61). Rescue of the observed accumulation of replication-associated DNA 
DSBs will require adding back the respective recombinant wild-type xFA protein to 
the depleted egg extracts. However, rescue experiments are hampered by the lack of in 
vitro assays to assess the function of recombinant FANCD2 or any of the FA core 
complex proteins. In addition, rescue may not be possible with a single recombinant 
monomeric protein because the FA core complex contains at least eight proteins that 
act as an entity to mediate FANCD2 monoubiquitination (24, 34, 36, 58). On the other 
hand, the finding that depletion of xFANCA or xFANCD2 results in the same 
phenotype, i.e., accumulation of DSBs during replication, and the observation that 
xBlm or xMre11 protein levels are not reduced in extracts depleted of either xFA 
protein (data not shown) strongly suggest that the observed phenotype results from a 
defect in the FA pathway rather than from codepletion of other non-FA proteins such 
as xMre11 or the BRAFT complex components. 
 
Since Mre11 and Blm have both been implicated in resolution and restart of stalled 
replication forks (29, 31-33, 77, 78, 99), our results support a model where concerted 
function among FA, Blm, and Mre11 pathways is required to prevent accumulation of 
DNA DSBs as a result of replication fork stalling. 
 
In summary, we show new evidence that association of FA proteins with chromatin 
occurs specifically when replication forks encounter certain DNA lesions and that they 
are crucial to prevent chromosomal DNA breaks during normal replication. To our 
knowledge, this is the first report of a cell-free assay for FA protein function that 
introduces a powerful system for dissecting the function of the FA proteins in context 
with replication and within the network of proteins collaborating to ensure genomic 
stability in vertebrates. 
 
MATERIALS AND METHODS 
Production of xFA antibodies 
Generation of anti-human FANCD2 rabbit polyclonal antisera (#3686) was described 
previously (33). Anti-xFANCD2 (#4368) polyclonal rabbit antibodies were raised against an 
equal mix of three KLH bound xFANCD2 peptides (Global peptides) corresponding to amino 
acids 1-18, 890-908, and 1425-1443. The antisera were affinity purified against the three non-
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KLH bound peptides immobilized on an AminoLink Plus column (Pierce) according to 
manufacturer’s instructions. Anti-xFANCA (#1771) and anti-xFANCF (#1398) polyclonal 
rabbit antibodies were raised against a chimeric protein containing an N-terminal GST tag 
(GST/pDEST 15) with a C-terminal region of xFANCA (amino acids 1205-1383) or full-length 
xFANCF (amino acids 1-340) and purified from bacteria as previously described (75).  Affinity 
purification columns were made with a chimeric HIS-xFANCA1205-1383, and HIS-xFANCF1-340 
(HIS/pDEST 17), purified as described in the QIAexperessionist protocol (Qiagen) and 
immobilized on an AminoLink Plus column. For antibody characterization see supplemental 
data, Fig 2. 
Preparation of Xenopus egg extracts 
Extracts were prepared from Xenopus eggs according to (Murray et al., 1991). In brief, eggs 
were de-jellied in 2% cysteine, pH 7.8, washed three times in XB buffer (10 mM KCl, 1 mM 
MgCl2, 100 nM CaCl2, 10 mM HEPES, 5 mM EGTA, 1.75% w/v sucrose, pH 7.8) and three 
times in CSF-XB buffer (XB buffer containing 5mM EGTA, 2mM MgCl2). Eggs were crushed 
by low speed centrifugation (10,000 g, 10 min) and the cytoplasmic fraction was cleared by 
centrifugation (16,000 g, 20 min) after the addition of energy mix (15 mM creatine phosphate, 
2 mM ATP, 2 mM MgCl2), cytochalasin B (10 µg/ml), cycloheximide (100 µg/ml), and 
Pefabloc (100 µg/ml). To release extracts from M to S phase, CaCl2 was added to a final 
concentration of 0.4 mM and the extracts were incubated for 20 min at 23°C. Mitomycin C 
(100 µM), aphidicolin (50 ng/µl), and caffeine (4 mM), were added to S-phase extracts 
immediately prior to the addition of sperm chromatin and incubated for the time indicated. For 
inhibition of replication initiation, recombinant Xenopus geminin (11) was added to S-phase 
extracts and incubated at 23°C for 15 minutes prior to addition of sperm chromatin. 
Preparation of nuclei and chromatin fractions 
At given time points, identical aliquots (50-100µl) of egg extract containing 1000 pronuclei 
(sperm heads)/µl were each diluted in nuclear isolation buffer (40 mM HEPES, 100 mM KCl, 
20 mM MgCl2) or chromatin isolation buffer (40 mM HEPES, 100 mM KCl, 20 mM MgCl2, 
0.2% Triton X-100) and purified through a 30% (w/v) sucrose cushion. Samples were 
centrifuged for 20 min at 6000 g and the nuclear and chromatin pellets, respectively, were 
analyzed by SDS-Page and immunoblot. 
DNA Replication Assay 
Replication of sperm chromatin in S-phase egg extracts was monitored as described previously 
(9). Briefly, sperm chromatin was added to S-phase extracts at 1000 pronuclei/µl. Reaction 
aliquots were pulse labeled with α- 32P-dGTP (Amersham) at time windows of 0-30 min, 30-60 
min, 60-90 min, and 90-120 min at 23°C. Reactions were stopped with 1% SDS, 40 mM EDTA 
(pH 7.8) and digested with proteinase K (1 mg/ml) at 37 °C for 1h. DNA was extracted with 
phenol/chloroform and electrophoresed on a 1% agarose gel. 
Immunodepletion 
To immunodeplete from S phase extracts, 200 µl of pre-swelled and washed (50% slurry in 
PBS) sepharose 4B beads (Amersham) were rotated overnight at 4ºC with 500 µl of PBS and 
100 µl of xFANCD2 (rabbit #68), xFANCA (rabbit #71) affinity purified antisera, or the 
corresponding pre-immune sera. The beads were pelleted from solution by centrifugation at 
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2500 rpm for 10 minutes at 4ºC and washed three times in XB buffer. 100 µl of extract was 
added to the beads. The extract/bead mix was rotated for two rounds at 4ºC for 40 minutes.  
TUNEL Assay 
50 µl of xFANCA, xFANCD2 or pre-immune depleted S-phase egg extracts were incubated 
with 10,000 pronuclei/µl for 120 minutes at 23ºC. The TUNEL assay was performed as 
previously described (9). 
Immunoblotting   
Protein samples were separated on 3-8% Tris-acetate gels or 4-12% NuPAGE Bis-Tris gels 
(Invitrogen) and transferred to Immobilon P membranes (Millipore). 
After blocking in 5% milk for 1h, membranes were incubated with the following primary 
antibodies: anti-hFANCD2 (1:300), xFANCA (1:300), or xFANCF (1:300), xATM (63) 
(1:1000), xTOP3α (1:1000), hORC2 (1:1500), hRPA70 (1: 3000), and hPCNA (Santa Cruz, 
1:1000). Horseradish peroxidase (HRP)-conjugated rabbit or mouse secondary (Jackson labs) 
was used (1:10,000). Protein bands were visualized using an ECL plus system (Amersham). 
Antibodies against xTOP3α, ORC2, and RPA70 were a kind gift from W. Dunphy. 
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SUPPLEMENTAL MATERIAL 
Xenopus FA (xFA) homologs contain domains conserved in vertebrates 
We searched for Xenopus laevis DNA sequences homologous to human FA genes. 
Partial gene sequences of xFANCA, and xFANCD2 were identified in sequence 
databases for Xenopus laevis and Xenopus tropicalis. Full-length sequences for 
xFANCA, and xFANCD2 were obtained by RT- and RACE-PCR. An image clone 
containing xFANCL was found at NCBI Genbank (BJ095024).  The sequence for 
xFANCB, xFANCC, xFANCE, xFANCG, and xBRCA2/FANCD1 are also present in 
Xenopus laevis and will be described elsewhere. Comparison of the amino acid 
sequences of xFANCA, xFANCD2 and xFANCL with their human counterparts 
revealed regions of high homology (Fig 1).  
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Figure 1.  Regional homologies between Xenopus and human FA proteins. (A) Blocks represent 
regions of the xFA protein with more than 50% sequence identity to the human protein sequence. 
Predicted sizes for xFA and hFA homologs are listed to the right of the schematic along with the overall 
amino acid identity. 
 
xFANCA has an overall homology of 53% compared to human FANCA (Fig 1). A 
highly homologous region (amino acids 321 – 616), contains the consensus sequence 
for four SRC-homology-module binding motifs (SH2 and SH3), proposed to be 
protein-protein interaction domains that could be important for the phosphorylation 
and subcellular localization of FANCA (Pawson, 1995; van de Vrugt et al., 2000; 
Yamashita et al., 1998). In addition, the reported phosphorylation target site in the 
human sequence at Ser 1149 is conserved in xFANCA (Otsuki et al., 2002). 
 
xFANCL is very highly conserved (79%) and contains the characteristic WD40 
domains as well as the PHD finger domain, which is thought to be the catalytic site of 
the E3 ubiquitin ligase for the FA core complex (Meetei et al., 2003; Meetei et al., 
2004).  The xFANCF sequence has been reported previously (Leveille 2004) (Fig 1). 
 
Characterization of antibodies specific for xFA proteins for subsequent use in 
functional assays with Xenopus egg extracts.  
We generated antibodies against xFA proteins for use in western blot, 
immunoprecipitation, and immunodepletion. Rabbit polyclonal antibodies were 
generated against: (1) xFANCF using a GST-xFANCF (aa 1-340) fusion protein, 
xFANCA using a GST-xFANCA (aa #1205-1383) fusion protein. The resulting 
polyclonal anti-xFANCF, and -xFANCA antibodies specifically recognize the 
corresponding Flag-tagged antigens in western blotting (Fig 2 A). As shown in Fig 2 
B, these xFA antibodies also immunoprecipitate their corresponding antigens. 
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Figure 2. Characterization of antibodies that recognize Xenopus laevis FA proteins. (A) Anti-
xFANCA, and -xFANCF antibodies recognize the corresponding Flag-tagged xFA protein by immunoblot 
when expressed in transfected 293 EBNA cells (Flag-xFA) but not in mock-transfected Flag-pCEP (-
).The same blots were stripped and reprobed with anti-Flag (right panel). (B) Immunoprecipitates (IPs) of 
293 EBNA cells transfected with Flag-xFANCA or Flag-xFANCF were analyzed by SDS-PAGE and 
immunoblotted as indicated with the corresponding anti-xFANCA (xA) or xFANCF (xF) antibody (lane 
2). An IP with anti-Flag serves as a positive control (lane 3), and an IP with normal rabbit sera is a 
negative control (lane 4). A Flag-xFANCA, and Flag-FANCF lysate is a positive control for each (lane 1). 
(C) An antibody against hFANCD2 recognizes xFANCD2 on an immunoblot of XTC-2 cell lysate. FA 
patient fibroblast cells that expresses only short form (EUFA868, FANCL patient cell line) or lack both 
forms (EUFA 1289, FANCD2 patient cell line) of hFANCD2 were used as controls. 
 
An antibody generated against the N-terminus of human FANCD2 (Holzel et al., 
2003) detected two isoforms of xFANCD2 in lysates from a Xenopus tadpole cell line, 
XTC-2 (Pudney et al., 1973). The isoforms co-migrate with the human FANCD2 short 
form (hFANCD2-S) and long form (hFANCD2-L), indicated as xFANCD2-S and 
xFANCD2-L, respectively (Fig 2 C). 
 
Conservation of the FA pathway in Xenopus 
DNA damage-induced monoubiquitination of hFANCD2 at residue K561 is a key step 
in the FA pathway and depends on a functional FA core complex (Garcia-Higuera et 
al., 2001). We tested if DNA damage-dependent modification of FANCD2 also occurs 
in Xenopus. As shown in Fig 3 A, SDS-PAGE and immunoblot analysis of lysates 
from XTC-2 cells detected proteins co-migrating with both isoforms of human  
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Figure 3.  The central steps of the FA pathway are conserved in Xenopus. (A) Activation of the long 
form of xFANCD2 (xFANCD2-L) following exogenous DNA damage.  Human HeLa cells and Xenopus 
XTC-2 cells exposed to mitomycin C (MMC, 150 nM) or hydroxyurea (HU; 2mM) from 0 to 72 hours 
show a comparable time course for induction of FANCD2-S to FANCD2-L. (B) Chromatid interchange 
formation (quadriradial indicated by arrow) in metaphase chromosomes from Xenopus XTC-2 cells 
treated with a DNA crosslinking agent mitomycin C (MMC; 150 nM) and caffeine for 48 hours. (C) 
Interactions between CCPs xFANCA and xFANCF, in Xenopus egg extracts. Specific antibodies for 
xFANCA and xFANCF proteins (as indicated) or normal rabbit anti-sera (indicated as N) were added to 
equal amounts (2 mg/ml) of egg extract. Resulting immunoprecipitates were analyzed by SDS-PAGE 
followed by immunoblot as indicated (left). Positive controls: Flag-xFANCA (top), Flag-xFANCF 
(bottom). 
 
FANCD2, the shorter non-ubiquitinated form (FANCD2-S) and the larger 
monoubiquitinated form (FANCD2-L).  
 
xFANCD2-L was induced in XTC-2 cells treated with DNA damaging agents MMC 
or hydroxyurea (HU), following a time course comparable to that observed for 
FANCD2 in human cells (Fig 3 A). In addition, we found that XTC-2 cells (like 
human cells) show increased formation of chromatid interchanges following MMC-
treatment (Table I. and Fig 3 B). Co-immunoprecipitation using specific xFA 
antibodies revealed that interactions among the FA core complex proteins (CCPs) are 
conserved in egg extracts synchronized in S-phase (Fig 3 C and data not shown), while 
xFANCD2, like its human counterpart, does not associate with the FA core complex 
(data not shown). We infer from these data thatinteractions among the CCPs and the 
response of FANCD2 to DNA damage, are conserved in Xenopus. 
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Table I. Cytogenetic analysis of Xenopus metaphase chromosomes. XTC-2 cells were untreated, 
treated with caffeine, mitomycin C (MMC) + caffeine or hydroxyurea (HU) + caffeine and metaphase 
chromosomes were analyzed for chromosomal aberrations. 
    
MATERIALS AND METHODS 
Isolation of Xenopus laevis FA gene homologs 
Tblastn-based searches were performed at NCBI/JGI as previously described (Blom et al., 
2002). Several short homologous protein fragments were identified using a tblastn search with 
full-length human FANCD2 in a Xenopus tropicalis database (JGI).  Primers designed from 
these sequences were used in an RT-PCR to amplify a central region of FANCD2 from a 
Xenopus laevis testis mRNA. The amplified fragment was sequenced and primers were 
designed for 3’ and 5’ RACE PCRs.  Full-length Xenopus laevis FANCD2 (xFANCD2) was 
amplified using primers; 5’-ATGGTGGCCAAAAGAAAGCTG and 5’-
TTAATCTGAATCTTCATCCTCATT.  
 
To isolate Xenopus laevis FANCA, a tblastn search was performed with full-length human 
FANCA in the Xenopus laevis EST database (NCBI). Four image clones were found and 
specific primers were designed to PCR-amplify a partial 3’ sequence of FANCA from Xenopus 
laevis testis tissue. An additional tblastn search of the Sanger Xenopus tropicalis database 
identifed a Xenopus tropicalis sequence homologous to the 3’ end of human FANCA. Primers 
were designed from these sequences and a PCR was performed to obtain the 5’ region of 
Xenopus laevis FANCA (xFANCA). Subsequently, full-length xFANCA was amplified by RT-
PCR using primers; 5’-ATGTCCGCTGTGTCAGGGT and 5’-
TTAAAAGACAGGCTCAAAGAAC. 
 
A Xenopus laevis image clone containing a highly similar sequence to full length human 
FANCL (including extra 5’ and 3’ flanking sequences) was found at NCBI Genbank 
(BJ095024). The clone was obtained and full length xFANCL was sequenced and submitted to 
NCBI with accession number AY633666.  The xFANCF image clone has been previously 
reported (Leveille et al., 2004) 
 
The full length nucleotide sequence for xFANCA, and xFANCD2, were submitted to the NCBI 
Genbank with accession numbers; AY633664, and AY633665, respectively.  
 
 56 
 
Cloning and sequencing of Xenopus cDNAs 
For cloning of xFA cDNAs, a Flag-tagged destination vector (pDEST-Flag/pCEP) was created 
using the conversion kit for Gateway (Invitrogen) according to the manufacturer’s instructions. 
PCRs were performed with the primers for full-length xFANCA, xFANCD2, xFANCF, and 
xFANCL using “Elongase” DNA polymerase (Invitrogen). PCR products were  ligated (via BP 
reaction) into the pDONR201 vector of the Gateway Cloning System (Invitrogen) according to 
the manufacturer’s instructions. Subsequently, an LR reaction was performed to create three 
destination vectors; GST (pDEST 15), HIS (pDEST 17), and Flag (pDEST-Flag/pCEP) each 
for xFANCA, xFANCD2, xFANCF, and xFANCL. 
Cell Culture 
The Xenopus tadpole cell line XTC-2 (Pudney et al., 1973) was cultured at room temperature 
without CO2 in Leibovitz’s L-15 media containing 10% fetal bovine serum.  The human 293 
EBNA cell line was cultured in Dulbecco’s modified eagle medium with 10% fetal bovine 
serum and transfected with lipofectamine (Invitrogen) according to manufacturer’s 
specifications. 
Immunoprecipitation  
To immunoprecipitate FA proteins, 2 mg of egg extract was added to 1 ml of lysis buffer (10 
mM Tris pH 7.4, 150 mM NaCl, 1% NP40, 0.5% Deoxycholate, 1mM EDTA, 0.5 mg/ml 
Pefabloc, 1mM DTT). 10 µl of rabbit polyclonal antibody against xFANCA, or xFANCF, were 
added and samples were mixed by rotating overnight at 4ºC. Then 100 µl of pre-swelled and 
washed (50% slurry in PBS) sepharose 4B beads (Amersham) were added and rotated for 30 
minutes at 4 °C. The beads were pelleted from solution by centrifugation at 2500 rpm for 10 
minutes at 4ºC and washed three times with lysis buffer. Beads were mixed with 50 µl 4X 
SDS-page sample buffer and boiled. 10 µl of each sample was analyzed by SDS-PAGE and 
immunoblot. 
Cytogenetic analysis   
Xenopus XTC-2 cells were cultured to approx. 70 % confluence and then incubated for 24 
hours in untreated media or media containing either 4mM caffeine (to override MMC-induced 
S-phase arrest), 4 mM caffeine + 150 nM Mitomycin C (MMC), or 4 mM caffeine + 2 mM 
hydroxyurea (HU). Next, the cells were exposed to colcemid (10 µg/ml) for 2 hours, collected 
by trypsinization and exposed to 75 mM KCl for 20 minutes. Cells were washed 3 times and 
finally fixed onto glass slides in methanol: acetic acid (3:1). Slides were stained with Wright’s 
stain and up to 50 metaphases were evaluated for chromosomal aberrations as previously 
described (Joenje et al., 1981). 
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The Fanconi Anemia (FA) pathway proteins are thought to be involved in the 
repair of irregular DNA structures including those encountered by the moving 
replication fork. However the nature of the DNA structures that recruit and 
activate the FA proteins is not known. Because FA proteins function within an 
extended network of proteins, some of which are still unknown, we recently 
established cell-free assays in Xenopus egg extracts to deconstruct the FA 
pathway in a fully replication-competent context.  Here we show that the central 
FA pathway protein, xFANCD2, is monoubiquitinated (xFANCD2-L) rapidly in 
the presence of linear and branched double stranded  (ds) DNA structures, but 
not single stranded or Y-shaped DNA. xFANCD2-L associates with dsDNA 
structures in an FA core complex-dependent manner but independently of 
xATRIP, the regulatory subunit of xATR. Formation of xFANCD2-L is also 
triggered in response to circular dsDNA, suggesting that dsDNA ends are not 
required to trigger monoubiquitination of FANCD2. The induction of xFANCD2-
L in response to circular dsDNA is replication-and checkpoint-independent. Our 
results provide new evidence that the FA pathway discriminates among DNA 
structures and demonstrate that triggering the FA pathway can be uncoupled 
from DNA replication and ATRIP-dependent activation. 
 
INTRODUCTION 
Fanconi anemia (FA) belongs to the group of chromosomal instability syndromes 
including Ataxia telangiectasia (AT), Bloom syndrome (BLM) and hereditary breast 
cancer. FA cells are hypersensitive towards DNA interstrand crosslink (ICL)-inducing 
agents and have highly elevated spontaneous chromosomal breakage rates, suggesting 
a role for FA proteins in the DNA damage response. The FA pathway consists of an 
upstream FA “core complex” containing at least eight proteins (FANCA, -B, -C, -E, -
F, -G, -L, and –M) that is required for the DNA damage-induced activation 
(monoubiquitination) of its downstream target, FANCD2 (9, 12, 13, 18, 27, 37). 
Accumulating evidence supports a role for the FA pathway in DNA double strand 
break (DNA DSB) repair via homologous recombination (HR). Indeed, FA cells are 
defective in the repair of ICL-induced DNA DSBs mediated by HR (44). Activated 
FANCD2 interacts with major components of HR repair, such as BRCA1 (breast 
cancer associated protein 1), Rad51, and the downstream FA protein, 
BRCA2/FANCD1 (8, 12, 17, 22, 47, 49), moreover, the BRCA2-interactor PALB2 
was recently identified as a Fanconi protein, FANCN (42, 43, 50). In addition, 
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involvement of the FA proteins in DNA DSB repair via single-strand annealing (SSA) 
and non-homologous end-joining (NHEJ) has been suggested (10, 11, 26, 36). The 
recently identified FANCM and FANCJ proteins indicate a direct involvement of FA 
proteins at sites of DNA repair: FANCM is an FA core complex member (30, 31, 34) 
homologous to the archeal protein Hef (helicase-associated endonuclease for fork-
structured DNA), which resolves stalled replication forks (20). FANCJ/BRIP1, which 
is thought to play a role downstream in the FA pathway (23, 24, 39) is a 5'-to-3' DNA 
helicase with substrate specificity towards splayed DNA duplexes (Y-shaped DNA) 
(14).  In support of a role for FA proteins in the processing of DNA structures, a recent 
study demonstrated that recombinant FANCD2 has direct DNA binding activity in 
vitro (38). Moreover, Ciccia et al. reported that recombinant FANCM is directed to 
branched DNA structures by a novel FA core complex member, FAAP24 (4). 
Accumulating evidence suggests that the FA proteins act specifically during the 
replication stage of the cell cycle. Rothfuss et al. (2004) showed that ICL-induced 
formation of DNA DSBs is a replication-associated event and that repair of such 
breaks is defective in FA cells (44). Our laboratory recently established cell-free 
assays in Xenopus laevis egg extracts to show that FA proteins are recruited to 
chromatin in a replication-dependent, DNA damage-stimulated manner, where they 
function to prevent accumulation of chromosomal breaks during each round of 
replicative DNA synthesis (46). Thus, the current model suggests that FA proteins are 
recruited to DNA lesions generated from replication fork stalling at sites of damaged 
DNA.  However, which types of DNA lesions trigger the recruitment and activation of 
the FA proteins has not yet been investigated, in part because the FA proteins are 
functionally interdependent and not all the proteins in the FA pathway have been 
identified.  We developed a new strategy that allows us to bypass the requirement for 
ongoing replication to activate the FA pathway by mimicking irregular DNA 
structures and specific replication intermediates in cell-free assays. Using this strategy 
we investigated which types of DNA structures induce monoubiquitination and 
recruitment of FANCD2 in the presence of a fully functional FA pathway.  
 
RESULTS 
 
DNA substrates stimulate monoubiquitination of xFANCD2 
Although little is known about how the FA proteins are activated and recruited to 
DNA, the mobility shift of FANCD2 (FANCD2-L) during S phase and following 
DNA damage is widely used as a measure for FA pathway activation. To test whether 
FANCD2-L can be directly induced in Xenopus egg extracts in response to DNA 
substrates, we generated double stranded DNA (dsDNA) fragments by restriction 
digest of a dsDNA plasmid. A similar strategy was used by Costanzo et al., who 
demonstrated that the ends of these dsDNA fragments mimic DNA double strand 
breaks (DNA DSBs) that activate the DNA DSB repair enzyme xMre11 by 
hyperphosphorylation in egg extracts (6).  Addition of the dsDNA fragments to egg 
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extracts resulted in appearance of a slower mobility form of xFANCD2 (xFANCD2-L) 
(Fig. 1A, panel 2). As expected, the dsDNA fragments also induced 
hyperphosphorylation of xMre11 (xMre11-PPP, Fig. 1A, panel 1). In contrast, the FA 
core complex protein, xFANCA, did not undergo a detectable size change in the DNA-
containing extract (Fig. 1A, panel 3). Taken together, dsDNA fragments stimulated the 
activation of xFANCD2 and Mre11.  
 
The mobility shift of human FANCD2 following DNA damage has been shown to be 
due to monoubiquitination (12).  To test if the dsDNA fragment-induced mobility shift 
of xFANCD2 in egg extracts (Fig. 1A, panel 2) is due to monoubiquitination, we 
added His-tagged ubiquitin (His-Ub) to DNA-free or dsDNA fragment-containing 
extracts, followed by re-isolation of His-Ub-tagged proteins using nickel beads. As 
shown in Fig. 1B, His-Ub-xFANCD2 was highly enriched in extracts containing 
dsDNA fragments compared to DNA-free extracts, demonstrating that the dsDNA 
fragment-induced xFANCD2-L represents ubiquitinated xFANCD2.  
 
Linear and branched dsDNA substrates trigger activation of xFANCD2-L 
To further map the structural characteristics of DNA capable of triggering formation of 
xFANCD2-L, we compared four DNA substrates mimicking DNA structures known to 
arise during replication: single stranded linear DNA (ssDNA70; length: 70 nucleotides), 
double stranded linear DNA (dsDNA70; length: 70 base pairs (bp)), Y-shaped DNA 
(Y-DNA70; length: 70 bp) and forked dsDNA (fork-DNA70; length: 70 bp) (25) (table 
1). These DNA structures were recently used to stimulate the interaction between 
topoisomerase IIIα and the BLM helicase in Xenopus egg extracts (25). Following 
addition of the DNA substrates, extracts were analyzed for the presence of xFANCD2-
L and xMre11-PPP. The dsDNA70 substrate induced both xFANCD2-L and xMre11-
PPP (Fig. 1 C, lanes 4 + 5), similar to what we observed in response to plasmid-
derived dsDNA fragments (Fig 1A). In addition, fork-DNA70 (Fig. 1 C, lanes 8 + 9), 
but not ssDNA70 (Fig.1 C, lanes 2 + 3) or Y-DNA70 (Fig. 1 C, lanes 6 + 7) induced 
xFANCD2-L. Interestingly, fork-DNA70 did not induce xMre11-PPP (Figure 1 C, 
lanes 8 + 9) despite the presence of three dsDNA ends in this structure. The FA core 
complex protein xFANCA did not show a detectable mobility shift in response to any 
of the four DNA structures tested (data not shown). Taken together, xFANCD2-L 
induction was triggered by linear and forked dsDNA but not ssDNA or Y-shaped 
DNA. 
 
xFANCD2-L associates with linear and branched dsDNA substrates 
Following monoubiquitination, human FANCD2 is thought to associate with sites of 
DNA damage (12, 33, 47, 49). Thus, we hypothesized that xFANCD2-L associated 
with those DNA structures that triggered its formation in egg extracts. To test this, we 
coupled ssDNA70 and fork-DNA70 to magnetic beads prior to incubation in egg 
extracts. After incubation, the bead-DNA structures were pelleted from the extract and  
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Figure 1. Monoubiquitination of xFANCD2 in response to dsDNA structures. (A) Presence of 
dsDNA fragments triggers formation of xFANCD-L. dsDNA fragments were incubated in egg extracts for 
30 min. 1 µl of egg extract containing no DNA (∅) or 150 ng/µl dsDNA fragments was analyzed for 
xMre11, xFANCD2, and xFANCA by immunoblot. Mobility shift of xMre11 was used as positive control 
(6) Egg extracts contained the phosphatase inhibitor tautomycin to stabilize phosphorylated isoforms of 
xMre11. (B) xFAND2-L induced by dsDNA fragments represents monoubiquitinated xFANCD2. DNA-
free extracts (lanes 1, 3, 5, and 7) or extracts containing 160 ng/µl dsDNA fragments (lanes 2, 4, 6, and 8) 
were supplemented with either His-tagged human ubiquitin (His-Ub) (lanes 3 and 4; 7 and 8) or an equal 
volume of H2O (lanes 1 and 2; 5 and 6). Following incubation for 30 min, 1 µl of extract was directly 
analyzed for xFANCD2-L (lanes 1 - 4). His-tagged, ubiquitinated proteins were re-isolated from DNA-
containing or DNA-free extracts using Ni-beads and analyzed for presence of xFANCD2 by immunoblot 
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(lanes 7 and 8). Ni-beads re-isolated from DNA-free or DNA-containing extracts that did not contain His-
Ub (lanes 5 and 6) were used as negative control for direct binding of xFANCD2-S or –L to Ni-beads. (C) 
xFANCD2-L is induced by linear and forked dsDNA structures. DNA structures ssDNA70 (lanes 2 and 3), 
dsDNA70 (lanes 4 and 5), Y-DNA70 (lanes 6 and 7), and forkDNA70 (lanes 8 and 9) were incubated in egg 
extracts for 30 min and 1 µl of extract was analyzed for induction of xFANCD2-L or xMre11-PPP by 
immunoblot. Symbols for each DNA substrate are explained in table 1. For stabilization of xMre11-PPP, 
the phosphatase inhibitor tautomycin (T) was added to egg extracts where indicated (lanes 3, 5, 7, and 9). 
 
 
 
Figure 2. xFANCD2-L associates with linear and branched dsDNA structures. (A) xFANCD2-L is 
recruited to DNA structures that trigger its activation. Bead-coupled ssDNA70 and forkDNA70 structures 
were incubated in egg extracts for 30 min and 1 µl of extract was directly analyzed for induction of 
xFANCD2-L (lanes 1 – 3). Bead-DNA substrates were separated from the extract followed by analysis of 
bead-DNA (lanes 7 – 9) and extract supernatant (lanes 4 – 6) for xFANCD2 and xFANCA by 
immunoblot. Empty beads were used as negative control (lanes 1, 4, and 7). (B) xFANCD2-L associates 
with linear and branched dsDNA structures. Bead-coupled ssDNA70, dsDNA70, Y-DNA70, and forkDNA70 
were incubated in egg extracts for 30 min, re-isolated, and analyzed for bound xFANCD2 and xFANCA 
by immunoblot. (C) xFANCD2-L associates with a Holliday junction structure. Bead-coupled HJ-DNA68 
or dsDNA68 were incubated in egg extract for 30 min, re-isolated, and analyzed for xFANCA and 
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xFANCD2 by immunoblot. DNA substrate concentrations: HJ-DNA68 was incubated at 10 pmol/10 µl 
extract (lane 1); dsDNA68 was incubated at 10 pmol/10 µl extract (lane 2), 20 pmol/10 µl extract (lane 3), 
or 30 pmol/10 µl extract (lane 4). The three different molar ratios between HJ-DNA68 and dsDNA68 are 1: 
1 (compare lanes 1 and 2), 1: 2 (compare lanes 1 and 3), and 1: 3 (compare lanes 1 and 4), respectively. 1 
µl of DNA-free extract was used as size control for xFANCD2-S (lane 5). 
 
the pellet and soluble fractions were analyzed separately. As shown in Fig. 2 A, 
xFANCD2-L was induced in the presence of bead-fork-DNA70 but not in the presence  
of bead-ssDNA70 (compare lanes 2 and 3). Re-isolation of the bead-DNA structures 
from the extract revealed that xFANCD2-L was associated with the fork-DNA70 (Fig. 
2 A, lane 9), whereas no free xFANCD2-L was detected in the post-incubation extract 
(Fig. 2 A, lane 6). We also observed that xFANCA was enriched on the bead-DNA 
structures (Fig. 2 A, lanes 8 and 9), consistent with previous results suggesting close 
DNA association of the FA core complex proteins (32, 41). Next, we directly 
compared xFANCD2-L recruitment to bead-bound ssDNA70, dsDNA70, Y-shaped-
DNA70, and fork-DNA70. As shown in Fig. 2 B, xFANCD2-L associated with 
dsDNA70 (lane 2) and fork-DNA70 (lane 4), but not with ssDNA70 (lane 1) or Y-DNA70 
(lane 3), consistent with the results described for the soluble DNA structures. 
Interestingly, a portion of the non-ubiquitinated form of xFANCD2, xFANCD2-S, was 
associated with all four bead-DNA substrates (Fig. 2 A, lanes 8 and 9; Fig. 2 B, lanes 1 
- 4). xFANCA associated with all tested bead-DNA structures but did not exhibit any 
detectable mobility changes (Fig. 2 B, lanes 1 - 4). Together, these results show that 
non-modified xFANCD2 associated with DNA substrates irrespective of their 
composition, whereas monoubiquitinated xFANCD2-L was found associated 
selectively with linear and forked dsDNA. We also tested whether xFANCD2-L 
formation was triggered by a Holliday junction, a cruciform structure generated as a 
major intermediate during HR. We compared the cruciform structure HJ-DNA68 to a 
linear dsDNA68 structure of similar length and sequence (table 1). For the comparison, 
we took into account that the bead-bound HJ-DNA68 structure contains twice the 
number of base pairs and three times the number of free dsDNA ends compared to the 
bead-bound dsDNA68 structure.  Following coupling to beads, the DNA structures 
were each incubated separately in 10 µl egg extract at the following concentrations: 10 
pmol HJ-DNA68, 10 pmol dsDNA68, 20 pmol dsDNA68, and 30 pmol dsDNA68. This 
strategy allowed us to test three different molar ratios of HJ-DNA68: dsDNA68 (Fig. 2 
C); 1: 1 (equal number of DNA molecules), 1: 2 (equal number of total DNA base 
pairs) and 1: 3 (equal number of free dsDNA ends). We found that similar amounts of 
xFANCD2-L bound to the HJ-DNA68 compared to dsDNA68 at a molar ratio of 1: 1 
between the two structures (Fig. 2 C, compare lanes 1 and 2). In addition, xFANCD2-
L recruitment did not occur proportionally to the total number of DNA base pairs 
present in the DNA structures (Fig. 2 C, compare lanes 1 and 3) or in proportion to the 
number of DNA ends presented by the DNA structures (Fig 2 C, compare lanes 1 and 
4). The marked increase in dsDNA68-bound xFANCD2-L between extracts containing 
10 pmol dsDNA68 (lane 2) and 20 pmol dsDNA68  (lane 3) is a phenomenon we 
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consistently observe, indicating that above a critical DNA concentration in the egg 
extracts, binding of xFANCD2-L to activating DNA structures increases in a non-
linear manner. In summary, xFANCD2-L was induced by - and recruited to – a 
Holliday junction but did not show a preference towards this structure compared to a 
linear dsDNA structure. 
 
DNA structure-bound xFANCD2-L is controlled by the FA core complex 
During DNA replication and after DNA damage, monoubiquitination of FANCD2 
depends on the FA core complex proteins (12, 28-30, 46, 47).  Thus we tested if 
monoubiquitination of xFANCD2 in response to the DNA structures in egg extracts 
depended on the FA core complex. We depleted the core complex protein xFANCA 
from extracts followed by incubation with plasmid-derived dsDNA fragments. As 
shown in Fig. 3 A, xFANCD2-L was not induced in xFANCA-depleted extracts 
compared to mock-depleted extracts (panel 2, compare lanes 2 and 3). Interestingly, 
levels of activated xMre11-PPP were reduced in xFANCA-depleted extracts compared 
to the control extracts (panel 3, compare lanes 2 and 3), whereas depletion of 
xFANCD2 did not inhibit activation of xMre11-PPP or vice versa (Fig. 3 A). Thus, the 
FA core complex regulates formation of xFANCD2-L and – at least partially - 
xMre11-PPP in response to dsDNA fragments, but the two events occur 
independently. Next we tested whether association of xFANCD2 (-S or -L) with DNA 
structures was FA core complex-dependent. We incubated bead-coupled ssDNA70 and 
fork-DNA70 in xFANCA-depleted or mock-depleted extracts. We found that 
association of xFANCD2-L with fork-DNA70 was abrogated in xFANCA-depleted 
extracts (Fig. 3 B, panel 1, compare lanes 3 and 4). In contrast, binding of xFANCD2-
S to ssDNA70 or forkDNA70 was not affected in the absence of xFANCA (Fig. 3 B, 
panel 1, compare lanes 1 and 2; 3 and 4). Thus, formation and DNA binding of 
xFANCD2-L was strictly core complex-dependent, whereas xFANCD2-S bound the 
DNA structures independently of the FA core complex. We also tested whether 
absence of xMre11 might affect xFANCD2-L binding to the forked DNA substrate. As 
expected from the results shown in Fig. 3 A, depletion of xMre11 did not affect 
induction or binding of xFANCD2-L to forkDNA70 (data not shown). 
 
DNA structure-associated xFANCD2-L is xATRIP-independent  
Apart from the FA core complex, ATR and its regulatory subunit, ATRIP, are also 
suspected to control FANCD2 function. Recently, we showed that the replication-
associated, chromatin-bound form of xFANCD2 (xFANCD2-L) is absent in xATRIP-
depleted extracts (46). Moreover, in human cells with ATR deficiency, 
monoubiquitination of FANCD2 is inhibited (1). We tested whether association of 
xFANCD2 with bead-bound ssDNA70 or forkDNA70 in egg extracts required the 
presence of xATRIP. Interestingly, neither binding of xFANCD2-S to either DNA 
substrate, nor association of xFANCD2-L with the forkDNA70 was affected in  
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Figure 3. DNA-induced formation and recruitment of xFANCD2-L is dependent on FANCA, but 
not on xMre11 or the ATR/ATRIP complex. (A) Formation of xFANCD2-L and xMre11-PPP in 
response to dsDNA fragments is FANCA-controlled. (A) Egg extracts were depleted of xFANCA (lane 
3), xFANCD2 (lane 4), xMre11 (lane 1) or mock-depleted (lane 2), and incubated with dsDNA fragments 
for 30 min. 1 µl of extract was subsequently analyzed for xFANCA, xFANCD2, or xMre11 by 
immunoblot. The inset in Figure 3 A (upper right corner) shows that xFANCD2 and xMre11 protein 
levels are not affected in an xFANCA-depleted extract (lane 2) compared to a mock-depleted extract (lane 
1). (B) Recruitment of xFANCD2-L to fork DNA is dependent on xFANCA but not xATRIP. Egg 
extracts were depleted of xFANCA (upper panel, lanes 2 and 4) or xATRIP (lower panel, lanes 2 and 4). 
Mock-depleted extract was used as control in all depletion experiments (lanes 1 and 3). Depleted extracts 
were incubated with bead-coupled ssDNA70 (lanes 1 and 2) or bead-coupled forkDNA70 (lanes 3 and 4) 
for 30 min and analyzed for the indicated proteins. 1 µl of DNA-free egg extract was used as a control for 
protein size (lane 5). 
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xATRIP-depleted extracts (Fig. 3 B, lower panel, compare lanes 1 and 2; 3 and 4). 
Thus, xATRIP appears to be dispensable for the induction and recruitment of 
monoubiquitinated xFANCD2 in response to the DNA structures tested in this assay. 
Induction of xFANCD2-L does not require the presence of dsDNA ends  
We demonstrated above that xFANCD2 is activated by linear and branched dsDNA 
substrates – however, it was not evident from these studies whether the DNA 
structures per se or their respective dsDNA ends triggered xFANCD2 activation. To 
determine whether dsDNA ends are required to activate xFANCD2, we compared 
induction of xFANCD2-L in extracts containing equal amounts of (I) circular plasmid 
DNA (no dsDNA ends),  (II) linearized plasmid DNA (two dsDNA ends per plasmid 
molecule), and (III) HaeIII-fragmented plasmid DNA (28 dsDNA ends per plasmid 
molecule). Interestingly, xFANCD2-L was induced in response to all three DNA 
substrates (Fig. 4 A, panel 1, lanes 1 – 3). In all three cases, induction of xFANCD2-L 
was abrogated in xFANCA- depleted extracts, showing that these responses are part of 
the FA pathway (data not shown). In contrast, xMre11- known to be stimulated by 
dsDNA ends - was activated in proportion to the number of DNA ends present in the 
extract (HaeIII-fragmented plasmid >> linearized plasmid; Fig. 4 A, panel 2, lanes 2 
and 3) with no Mre11-PPP being induced by circular plasmid DNA (lane 1). We 
further compared the timing and DNA dose-dependency of xFANCD2-L and xMre11-
PPP formation in response to linearized and fragmented plasmid dsDNA. As shown in 
Fig. 4 B, xFANCD2-L was detected as early as 15 min following addition of linearized 
plasmid DNA (at 50 and 25 ng/µl, upper panel 1, lanes 5 and 6, respectively), whereas 
only a very weak induction of xMre11-PPP was detectable at a later time point (25 
min, 50 and 25 ng/µl, upper panel 2, lanes 8 and 9). In contrast, in the presence of 
fragmented plasmid dsDNA, xMre11-PPP was detectable at 15 min at all three DNA 
concentrations (50, 25, and 10 ng/µl, lower panel 2, lanes 5 - 7).  xFANCD2-L was 
detected later and only at the highest DNA concentration (25 min, 50 ng/µl, lower 
panel 1, lane 8). In summary, activation of xFANCD2 occurred in response to dsDNA 
but  - in contrast to xMre11 - did not require the presence of dsDNA ends, moreover, 
longer dsDNA molecules appeared to be a better stimulus for formation of xFANCD2-
L than shorter ones. 
 
Robust induction of xMre11-PPP was not observed at the low concentrations of 
circular plasmid DNA that stimulated FANCD2-L, but Mre11-PPP was observed at 
high concentrations of DNA (160 ng/µl) (Fig. 4 C, panel 2). There are at least two 
possible explanations for this observation. First, the presence of circular dsDNA alone 
might induce xMre11-PPP, although much less efficiently than dsDNA ends. 
Alternatively, the circular DNA preparation could contain an undetectable minor 
amount of nicked or linearized plasmid sufficient to activate xMre11. No nicked or  
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Figure 4. Double stranded DNA ends are not a major trigger for xFANC2-L formation. (A) 
Induction of xFANCD2-L occurs independently of dsDNA ends. Egg extracts were incubated for 30 min 
with 45 ng/µl of circular plasmid dsDNA (lane 1), fragmented plasmid dsDNA (lane 2), or linearized 
plasmid dsDNA (lane 3). DNA-free extract served as a negative control (lane 4). Following incubation, 1 
µl of extract was analyzed for xFANCD2 and xMre11 by immunoblot. (B) Linearized plasmid dsDNA 
induces xFANCD2-L earlier and at lower DNA concentrations than fragmented plasmid dsDNA. Egg 
extracts were incubated with three different concentrations of linearized or fragmented plasmid dsDNA 
(50 ng/µl, lanes 2, 5, 8; 25 ng/µl, lanes 3, 6, 9; 10 ng/µl, lanes 4, 7). Aliquots were taken at 5 min, 15 min, 
and 25 min and 1 µl of extract was analyzed for xFANCD2 and xMre11 by immunoblot. 1 µl of DNA-
free extract was used as negative control (lane 1). (C) High concentrations of circular plasmid dsDNA 
induce both xFANCD2-L and xMre11-PPP. Egg extracts were incubated for 30 min with increasing 
concentrations of circular plasmid dsDNA as indicated. Following incubation, 1 µl of extract was 
analyzed for xFANCD2 and xMre11 by immunoblot. DNA-free extract incubated for 30 min served as a 
negative control (lane 5). (D) Low concentrations of nicked plasmid DNA induce xFANCD2-L and 
xMre11-PPP. Egg extracts were incubated for 30 min with 30 ng/µl (lanes 2 – 4) or 60 ng/µl (lanes 5 – 7) 
of linearized plasmid dsDNA (lanes 2 and 5), nicked plasmid dsDNA (lanes 3 and 6), or circular plasmid 
dsDNA (lanes 4 and 7). DNA-free extract served as a negative control (lane 1). Following incubation, 1 µl 
of extract was analyzed for xFANCD2 and xMre11 by immunoblot. Fig. 4 D inset: For quality control of 
circular plasmid dsDNA (lanes 2 and 3), linear plasmid dsDNA (lanes 4 and 5) and nicked plasmid 
dsDNA (lanes 6 and 7), DNA samples (2.5 µg/lane) were analyzed by agarose gel electrophoresis. M: 
dsDNA size marker. (E) xFANCD2-L is induced by  circular ssDNA. Egg extracts were incubated for 30 
min with 160 ng/µl of circular plasmid dsDNA (lane 2) or circular plasmid ssDNA (lane 3). DNA-free 
extract served as a negative control (lane 1). Following incubation, 1 µl of extract was analyzed for 
xFANCD2 and xMre11 by immunoblot. 
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linearized plasmid DNA was detected by agarose gel electrophoresis in the circular 
plasmid DNA preparation used in the experiment (Fig. 4 D, inset, lanes 2 and 3).  As 
shown in Fig. 4 D, low concentrations (30 - 60 ng/µl) of nicked and linearized, but not 
circular plasmid DNA induced xMre11-PPP, whereas xFANCD2 was activated by all 
three DNA substrates (Fig. 4 D). Taken together, minor amounts of nicked and/or 
linearized plasmid DNA contained in circular plasmid preparations might be 
responsible for the induction of xMre11-PPP when higher concentrations of the 
circular plasmid DNA are incubated in egg extracts (as seen in Fig. 4 C).  
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Figure 5. Formation of xFANCD2-L in response to circular dsDNA is replication- and checkpoint-
independent. (A, B) Circular dsDNA induces xFANCD2-L in a checkpoint-independent manner. (A) Egg 
extracts were incubated with 160 ng/µl circular plasmid dsDNA for 30 min in the absence (lanes 2 and 3) 
or presence of caffeine (lanes 4 and 5). Where indicated, extracts were supplemented with the phosphatase 
inhibitor, tautomycin, to stabilize xMre11-PPP. Following incubation, 1 µl of extract was analyzed for 
xFANCD2 and xMre11 by immunoblot. DNA-free extract was used as a negative control (lane 1).  (B) 
Egg extracts depleted of xATRIP (lanes 2 and 4) or mock-depleted extracts (lanes 1 and 3) were incubated 
with 160 ng/µl circular plasmid dsDNA. Aliquots were taken at 20 min (lanes 1 and 2) and 60 min (lanes 
3 and 4) and assayed for xFANCD2 by immunoblot. DNA-free extract was used as a size control for 
xFANCD2 (lane 5). (C, D) Circular dsDNA induces xFANCD2-L in a replication-independent manner. 
(C) Egg extracts were incubated with 160 ng/µl of circular plasmid dsDNA for 30 min in the absence 
(lane 2) or presence (lane 3) of geminin and assayed for xFANCD2 and xMre11 by immunoblot. DNA-
free extract was used as a size control for xFANCD2 and xMre11 (lane 1). The efficiency of replication 
inhibition was measured in a parallel replication assay using an aliquot of the geminin-treated extract 
supplemented with Xenopus sperm chromatin (smaller panel in Fig. 5 C). (D) Non-activated, M-phase 
egg extracts or CaCl2-activated, S-phase egg extracts were incubated with 160 ng/µl circular plasmid 
dsDNA. Extract aliquots were taken at the indicated time points and analyzed for xFANCD2 and xMre11. 
 
Our analysis of small DNA structures incubated in egg extracts showed that an ssDNA 
substrate (70 nt) did not activate xFANCD2. However, recent work by Zhu et al. 
demonstrated that FANCD2 localizes to ssDNA regions that are generated during  
illegitimate chromosomal re-replication in the cell (53, 54). To test whether longer 
stretches of ssDNA might be able to activate xFANCD2, we incubated a circular 
ssDNA plasmid (M13 phage ssDNA, 7249 nt) in egg extracts and assayed for 
induction of xFANCD2-L. As shown in Fig. 4 E, the ssDNA plasmid induced 
activation of xFANCD2 but not xMre11 (lane 3), even at the high DNA concentration 
D 
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used in this experiment (160 ng/µl). This result suggests that longer ssDNA regions 
can stimulate xFANCD2-L formation. However, since single-stranded DNA molecules 
are known to fold back on themselves to form irregular double-helical hairpin 
structures (15), such “pseudo”-dsDNA regions on the M13 ssDNA plasmid might 
contribute to the stimulation of xFANCD2-L formation. 
 
Circular plasmid-induced activation of the FA pathway is checkpoint- and 
replication independent 
One possible mechanism for the circular plasmid induction of FANCD2-L is that 
plasmid DNA activates a checkpoint in the egg extract, which in turn might induce 
xFANCD2-L (1, 5, 16). To examine this possibility, we added the checkpoint kinase 
inhibitor caffeine to extracts containing circular plasmid dsDNA (160 ng/µl). As 
shown in Fig. 5 A, activation of xFANCD2-L was not affected in the presence of 
caffeine (panel 1, compare lanes 2 and 4; 3 and 5). In contrast, induction of xMre11-
PPP was inhibited (panel 2, compare lanes 2 and 4; 3 and 5), consistent with a 
previous study showing that caffeine blocks the induction of xMre11-PPP in response 
to dsDNA fragments (6). In addition, depletion of xATRIP, which functionally blocks 
the checkpoint mediator xATR (19), had no effect on xFANCD2-L formation (Fig. 5 
B, compare lanes 1 and 2; 3 and 4). Thus, activation of xFANCD2-L by circular 
plasmid DNA is unlikely to be part of a checkpoint response. 
 
Next, we asked whether replicative DNA synthesis on the circular plasmid template 
was responsible for inducing xFANCD2-L. When directly added to an S-phase extract, 
plasmid DNA can be remodeled into a functional nucleus and replicated, although 
replication efficiency is very low under these conditions (2, 3, 52). We added the 
replication inhibitor geminin to egg extracts containing circular plasmid DNA (160 
ng/µl). As shown in Fig. 5 C, geminin did not affect formation of xFANCD2-L or 
xMre11-PPP in the presence of plasmid DNA. Moreover, plasmid-induced formation 
of xFANCD2-L and xMre11-PPP was comparable between a replication-competent S-
phase extract and an extract unable to support replication (M-phase extract) (Fig. 5 D, 
compare lanes 3 and 5; 4 and 6), further supporting the idea that formation of 
xFANCD2-L and xMre11-PPP was not induced by replication of the plasmid DNA. 
 
DISCUSSION 
In this study, we showed that the FA pathway is directly triggered in Xenopus egg 
extracts by DNA structures that mimic DNA intermediates occurring in replicating 
chromatin. We measured FA pathway activation by monitoring the modified form of 
xFANCD2, xFANCD2-L, which we determined to be monoubiquitinated xFANCD2. 
We did not detect a mobility change of xFANCA in response to the DNA structures 
tested, whereas Thomashevski et al. reported a phosphorylation-induced mobility shift 
of chromatin-bound human FANCA in cells treated with a DNA interstrand 
crosslinker (48). However, the authors describe that detection of phosphorylated 
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FANCA required several purification steps of cellular chromatin extracts (including 
chromatography), suggesting that phosphorylated FANCA might not be readily 
detectable in egg extracts.                  
 
We showed that plasmid-derived dsDNA fragments trigger monoubiquitination of 
xFANCD2 Further analysis revealed that linear or forked dsDNA substrates, both 
structures with high dsDNA content, induced formation of xFANCD2-L. In contrast, 
only the linear but not the forked dsDNA substrate induced formation of xMre11-PPP. 
Since xMre11-PPP is known to be induced by the presence of dsDNA ends (6), the 
three ends presented by the forked DNA structure were apparently not recognized by 
xMre11, possibly because the fork arms are too short to mimic dsDNA breaks 
recognizable by this repair enzyme. The fact that the forked DNA triggered 
xFANCD2-L but not xMre11-PPP suggests that the forked or the double stranded 
nature of this substrate, but not its DNA ends, activated xFANCD2. The finding that 
ssDNA and a Y-shaped DNA substrate, structures with no or little dsDNA content, 
failed to activate xFANCD2-L, further supports the idea that the presence of linear or 
branched dsDNA regions is sufficient to trigger the FA pathway.  
 
The fact that newly formed xFANCD2-L associated with its activating dsDNA 
structures is an important finding because it provides us with a simple strategy to 
isolate xFANCD2 in its monoubiquitinated, DNA-associated form from egg extracts. 
In addition, this new cell-free assay can be adapted to a small molecule screen for 
inhibitors or activators of the FA pathway.  
 
Whether xFANCD2-L binds DNA directly is uncertain, however the fact that 
recombinant non-ubiquitinated human FANCD2 binds DNA in vitro (38) suggests 
direct DNA binding for the activated FANCD2-L form as well. The forked dsDNA 
substrate, mimicking a stalled replication fork, reproducibly recruited xFANCD2-L 
more efficiently than the linear dsDNA substrate (see Fig. 2 B), suggesting that forked 
DNA structures might be a preferred target for the FA proteins. Another candidate 
structure for FA pathway activation was the Holliday junction, a key repair 
intermediate in HR-mediated repair. The fact that Hef, the archaeal homolog of human 
FANCM can unwind and cleave Holliday junctions (20, 21), suggested an 
involvement of the FA pathway in HJ-processing. Indeed, xFANCD2-L was induced 
by - and recruited to - the HJ structure, however, it did not show a preference towards 
this substrate compared to linear dsDNA hinting that this HJ structure might not be a 
specific target for xFANCD2-L. 
 
As expected, induction of xFANCD2-L and its subsequent association with the linear 
and branched dsDNA structures was strictly FA core complex dependent. Surprisingly, 
the non-modified xFANCD2-S form associated with all DNA structures we tested, 
even the ones that did not trigger FANCD2-L formation. This is unexpected since 
current evidence, including results from our laboratory, suggests that only FANCD2-L 
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is recruited to sites of damaged DNA in chromatin (12, 33, 46, 47, 49). One possible 
explanation is that xFANCD2-S can associate with small, naked DNA structures 
incubated in egg extracts whereas its interaction with DNA is more tightly controlled 
at the chromatin level. The fact that xFANCD2-S associates with DNA structures even 
in the absence of a functional FA core complex suggests that xFANCD2-S has low 
affinity to DNA but becomes specifically activated by monoubiquitination via the FA 
core complex at dsDNA structures.  Somewhat in contrast with our data, Park et al. 
reported that human recombinant FANCD2-S showed specificity towards certain DNA 
structures, e.g. a Holliday junction, in vitro. However, observational differences are 
likely due to the fact that Park et al. studied direct DNA binding of non-modified 
recombinant hFANCD2 whereas the Xenopus extract assay monitors DNA association 
of monoubiquitinated endogenous xFANCD2 in a core complex-controlled context.  
We found that the levels of xMre11-PPP were reduced, though not abrogated, in the 
absence of a functional FA core complex, indicating that either the stability of 
phosphorylated xMre11 or the efficiency of its phosphorylation are partly controlled 
by the FA core complex. Interestingly, in human cells the localization of Mre11 into 
DNA-damage induced chromatin foci is also inhibited when there is a deficient FA 
core complex (40). A surprising finding was that induction and recruitment of 
xFANCD2-L to DNA structures was not affected in an xATRIP-depleted extract. This 
is unexpected because FANCD2-L formation is inhibited in ATR-deficient human 
cells (1), moreover, we recently demonstrated that chromatin-bound xFANCD2-L is 
absent in xATRIP-depleted egg extracts. One possible explanation is that xATRIP 
controls chromatin binding of xFANCD2-L but not its formation and association with 
the DNA structures used in this study.  
 
Several studies suggest a role for FA proteins in the repair of DNA DSBs. However, 
our findings do not indicate simple DNA DSBs as the major trigger of the FA 
pathway: (A) forked dsDNA activated xFANCD2 but not the DNA DSB-binding 
protein xMre11 (see above). (B) Equal amounts of xFANCD2-L were recruited to an 
HJ structure compared to a linear dsDNA structure despite the presence of three free 
DNA ends in the bead-bound HJ structure versus one free end in the bead-bound linear 
dsDNA substrate. For further investigation, we compared the xFANCD2-L response to 
linear dsDNA substrates of different lengths where the relative number of dsDNA ends 
was indirectly measurable by the degree of xMre11 hyperphosphorylation. Comparing 
circular, nicked, linearized, and restriction-fragmented plasmid DNA revealed that 
xFANCD2-L was activated independently of the number of dsDNA ends. In fact, the 
linearized plasmid DNA was a stronger trigger for FANCD2-L formation than the 
shorter plasmid DNA fragments, whereas the opposite was the case for triggering 
xMre11-PPP formation. Thus, the length of the linear dsDNA substrate rather than its 
ends influenced the degree of xFANCD2-L induction. Interestingly, low 
concentrations of nicked and linearized – but not intact circular - plasmid DNA 
activated xMre11, hinting that nicks in dsDNA can also trigger xMre11-PPP 
formation.   
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To determine how the circular plasmid triggered activation of xFANCD2-L, we tested 
two hypotheses: induction of FANCD2-L could be (1) part of a plasmid-induced 
checkpoint in the extract, or (2) due to replication of the plasmid DNA in the extract. 
The induction of xFANCD2-L was unaffected by caffeine or absence of the 
xATR/xATRIP checkpoint kinase complex, suggesting that plasmid-induced FA 
pathway activation was checkpoint-independent. Likewise, geminin treatment or use 
of replication-incompetent M-phase extracts had no inhibitory effect on xFANCD2-L, 
ruling out a replicating plasmid-mediated induction of xFANCD2-L. We are currently 
investigating if processing or remodeling of the plasmid in the extracts is involved in 
triggering the ubiquitination of FANCD2. 
 
Interestingly, a circular ssDNA plasmid was also able to trigger activation of 
xFANCD2, but not xMre11. Like the dsDNA plasmid, the ssDNA plasmid induced 
xFANCD2-L independently of replication or checkpoint activation (data not shown). 
Since ssDNA plasmids are known to fold into dsDNA-like hairpin structures, it is at 
this point not possible to determine whether the long ssDNA stretches of the M13 
ssDNA plasmid or its double-stranded hairpin regions are responsible for xFANCD2 
activation. However, the fact that FANCD2 localizes specifically to ssDNA regions 
generated by re-replication in human cells suggests that longer ssDNA regions are in 
fact a trigger for xFANCD2-L induction (54). 
 
In summary, we showed that the FA pathway is inducible in a replication-free 
environment in the presence of defined DNA structures. Monoubiquitinated 
xFANCD2 associates with dsDNA structures in an xFA core complex-dependent, but 
xATRIP-independent manner. The DNA substrate specificity of xFANCD2-L suggests 
that a rather broad spectrum of single- and double- stranded linear or branched DNA 
lesions– but not simple DNA DSBs - activate the FA pathway.  Taken together, our 
results suggest a model where FANCD2 activation occurs during DNA replication 
when dsDNA is exposed at the replication fork either because of stalling or damage. 
 
MATERIALS AND METHODS 
Production of xFA antibodies 
Generation of antibodies against xFANCD2 and xFANCA was described previously (46). 
Antibodies against xMre11 were a kind gift of J. Gautier and antibodies against xATRIP were a 
kind gift from K. Cimprich.  
Preparation of Xenopus egg extracts 
Extracts were prepared from Xenopus eggs according to Murray et al. (1991) (35). Tautomycin 
(3 µM), caffeine (4 mM), and recombinant Xenopus geminin (5 ng/µl) (7) were added as 
indicated.  
DNA Replication Assay 
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Replication of sperm chromatin in S-phase egg extracts was monitored as described previously 
(46).  
Preparation of DNA substrates 
Plasmid-derived DNA substrates: Circular plasmid DNA (pBSKS) was prepared from E. coli 
cultures using a QiaFilter Plasmid Maxi Kit (Qiagen). Plasmid DNA was linearized with Not 1 
(Fermentas) or fragmented (14 DNA fragments) with HaeIII  (Roche) restriction enzymes. 
Plasmid DNA was nicked using DNase I (Invitrogen). Linearized, nicked, and intact circular 
(supercoiled) plasmid forms were distinguished by agarose gel electrophoresis (see Fig 4 D 
inset). M13mp18 single stranded plasmid DNA was obtained from Bayou Biolabs. 
Oligonucleotide-derived substrates: The oligonucleotide 5’-(dG)40-(dA)30-3’ (ssDNA70) was 
annealed to oligonucleotide 5’-(dT)30-(dC)40-3’ to generate dsDNA70. Y-DNA70 and forkDNA70 
were generated as described previously (25). Oligonucleotides 5’-ggttgacgttctagtgtgaccgc 
aatacggataagggctgagcacgccgacgaacatac-3’ (HJ-strand 1), 5’-gtatgttcgtcggcgtgctcagcccttatccc 
agaatgcaccaacagttcctcaagatagagactc-3’ (HJ-strand 2), 5’-gagtctctatcttgaggaactgttggtgcattc 
tgggataagggcactatggctccactgatgtcgtaagcatcc-3’ (HJ-strand 3), and 5’-ggatgcttacgacatcagtggagc 
catagtgcccttatccgtattgcggtcacactagaacgtcaacc-3’ (HJ-strand 4) were annealed to form HJ-
DNA68 [134 bp] as previously described (45). HJ-strand 4 was annealed to HJ-strand 5: 5’-
ggttgacgttctagtgtgaccgcaatacggataagggcactatggctccactgatgtcgtaagcatcc-3’ to generate a linear 
dsDNA fragment (dsDNA68 [68 bp]) with sequence similarity to the Holliday junction. HJ-
DNA68 and dsDNA68 structures were labeled with γ-32P-ATP at the 5’ end of HJ-strands 3 and 
5, respectively and purified by electrophoresis through a non-denaturing 4% polyacrylamide 
gel. DNA structures were excised from the gel and eluted into 40 µl of EB buffer using the 
QIAEX gel extraction kit (Qiagen).  
Bead-DNA: Streptavidin-conjugated magnetic beads (Dynal, Inc.) coupled to biotinylated DNA 
structures were incubated for 35 min in egg extracts. The biotin group was attached to the 3'-
end of 5’-(dG)40-(dA)30-3’ (in ssDNA70, dsDNA70, Y-DNA70 and forkDNA70), the 3’-end of 
HJ-strand 3 (HJ-DNA68) or the 3’ end of HJ-strand 5 (dsDNA68). Following incubation, DNA-
coupled beads were washed five times with XB-buffer (46) by collection with a magnetic rack. 
Immunodepletion 
Immunodepletions were performed essentially as described previously (46). In brief, 200 µl of 
sepharose 4B beads (50% slurry, Amersham) were rotated overnight at 4ºC with 500 µl of PBS 
and 100 µl of anti-xFANCA, -xFANCD2, -xMre11, or -xATRIP affinity purified antisera, or 
the corresponding pre-immune sera. The beads were pelleted from solution and washed three 
times in XB buffer. For depletion, 100 µl of extract was added to the beads and the extract/bead 
mix was rotated for two rounds at 4ºC for 40 minutes.  
Immunoblotting   
Protein samples were separated on gradient gels (Invitrogen) and transferred to Immobilon P 
membranes (Millipore). After blocking in 5% milk for 1h, membranes were incubated with the 
following primary antibodies: anti-XFANCD2 (1: 1000), xFANCA (1: 1000), xATRIP (1: 
1000), and xMRE11 (1: 5000). Horseradish peroxidase (HRP)-conjugated rabbit secondary 
(Jackson labs) was used (1: 10,000). Protein bands were visualized using an ECL plus system 
(Amersham). 
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Ubiquitination assay 
The ubiquitination assay was conducted as previously described (51) using Ni-NTA Agarose 
beads (Qiagen). 
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The Fanconi anemia (FA)/breast cancer (BRCA)-associated DNA damage 
response pathway is proposed to be involved in maintaining genomic integrity 
and processing DNA interstrand crosslinks (ICLs), although the precise 
mechanism of the pathway is unknown. We designed a novel assay utilizing 
Xenopus laevis egg extracts to identify small molecules that modulate activation of 
the FA/BRCA pathway by monitoring the DNA substrate-stimulated formation 
of monoubiquitylated FANCD2 (FANCD2-L), a key indicator of the activity of 
the pathway. Known inhibitors of the pathway such as curcumin and 
wortmannin inhibited FANCD2-L formation in the Xenopus assay. DDN (2,3-
dichloro-5,8-dihydroxy-1,4-naphthoquinone), an analog of the antitumor agent 
menadione, was identified as an inhibitor in both egg extracts and human cells. 
This approach provides the first example of a cell-free assay for identifying 
compounds that modulate the FA/BRCA pathway and provides a new 
biochemical platform for mapping the functions of its various components with 
specific chemical inhibitors. 
 
INTRODUCTION 
DNA interstrand crosslink (ICL)-inducing agents such as cisplatin, melphalan and 
mitomycin C (MMC) remain a mainstay in the treatment of common cancers such as 
ovarian, testis, breast, bladder, and head and neck cancers [1-3]. However, many 
cancers become refractory to these drugs by multiple mechanisms during a course of 
chemotherapy, leading to treatment failure [4]. Therefore, the re-sensitization of tumor 
cells to these chemotherapeutic agents has great potential for treating a wide variety of 
cancers. One strategy for re-sensitization entails the discovery of small-molecule 
inhibitors of proteins that control the cellular response to DNA ICLs. Current evidence 
suggests that the Fanconi anemia (FA)/breast cancer (BRCA) DNA damage response 
pathway (which includes major breast cancer susceptibility gene products BRCA2, 
BRIP1/BACH1, and PALB2/FANCN) is involved in the repair of DNA ICLs. As a 
consequence, acquired ICL-resistance of cancer cells may be associated with re-
activation of the FA/BRCA pathway in tumors initially deficient in this pathway [2,4-
9]. Supporting this idea, one study found that epigenetic silencing of FANCF occurs in 
17%, 21% and 30% of breast, ovarian and cervical cancers, respectively [5]. 
 88 
 
Therefore, compounds that inhibit the FA/BRCA pathway would be expected to re-
sensitize cancer cells that rely on an intact pathway for resistance to chemotherapeutic 
drugs. Yet, a rational approach for discovery of candidate compounds is hampered by 
the complexity of the network and because the functions and interactions of its 
component proteins are not well understood. Moreover, because the FA/BRCA 
pathway is activated only conditionally (after certain DNA damage and in S phase) 
cell-based assays can be difficult to interpret. 
 
To circumvent some of the difficulties, we recently developed a cell-free system to 
evaluate the function of the FA/BRCA pathway proteins in the DNA damage response 
using Xenopus egg extracts [6, 7]. These egg extracts are naturally synchronized in S-
phase and are capable of supporting DNA replication and DNA damage responses 
under normal cell cycle control, including the monoubiquitylation of FANCD2 [8-11].  
In both human and Xenopus cells, the FA pathway is controlled by a ‘core complex’ 
composed of at least 10 proteins. This core complex acts as an E3 ubiquitin ligase that 
mediates DNA damage-triggered monoubiquitylation of the downstream FA protein, 
FANCD2 ([6] and reviewed in [12]). Monoubiquitylation of FANCD2 (FANCD2-L) 
during S-phase and following DNA damage is a hallmark of an intact FA pathway and 
predictive for normal cellular resistance to DNA crosslinking agents [13, 14]. Thus, 
formation of FANCD2-L can be used as a direct readout for the activity of the 
FA/BRCA pathway. This approach provides the first example of a rapid and 
inexpensive in vitro assay for screening compounds that modulate the FA/BRCA 
pathway, bridging the gap between biochemical and cell-based assays. Using this 
system, we identified the menadione analog DDN (2,3-dichloro-5, 8-dihydroxy-1,4-
naphthoquinone), a known antitumor agent, as a novel inhibitor of the FA/BRCA 
pathway. We propose that inhibition of FANCD2-L formation may underlie the known 
antitumor and chemosensitizing activities of this class of compounds. 
 
RESULTS  
The hallmark of an intact Fanconi anemia pathway is the formation of 
monoubiquitylated FANCD2 (FANCD2-L) during S-phase and following induction of 
ICLs or stalled replication forks [13, 14].  In vitro identification of small molecules 
that modulate FANCD2-L formation is currently not possible, because attempts to 
recapitulate the FANCD2 monoubiquitylation reaction with recombinant proteins in 
vitro have been unsuccessful.  In cells, the S-phase specific monoubiquitylation of 
FANCD2 is dependent on an E3 ubiquitin ligase complex composed of at least ten 
proteins (FANCA, B, C, E, F, G, L, M, FAAP100, FAAP24), the FANCD2 binding 
partner FANCI, and other unidentified proteins. Therefore a complete reconstitution of 
the pathway may be difficult to mimic with recombinant proteins in vitro.  To bypass 
these obstacles we explored a cell-free chemical screening approach using Xenopus 
egg extracts, a biochemical environment that is completely primed for carrying out 
replication of exogenous DNA. We found that FANCD2-L is rapidly induced in egg 
extracts following addition of several dsDNA substrates including circular double  
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Figure 1. dsDNA induces xFANCD2 monoubiquitylation and xMre11 phosphorylation in Xenopus 
egg extracts. (A) Egg extracts were incubated with increasing concentrations of plasmid DNA and 
analyzed for xFANCD2 (top panel) and xMre11 (bottom panel) size modification by immunoblot. (B) 
The percent ratio of long to short form of xFANCD2 and xMRE11, indicated below each immunoblot in 
(A), were plotted against DNA concentration. 
 
stranded plasmid DNA (Fig. 1, [11]). We previously showed that formation of 
FANCD2-L is replication- and checkpoint-independent and that quantitative 
immunodepletion of xFANCA, one of the FA core complex proteins, abrogates the 
DNA-stimulated formation of FANCD2-L in egg extracts, as predicted from 
observations in human cells where FANCD2-L formation is strictly dependent on the 
FA core complex [6, 7]. We infer thatinduction of ICLs or stalled replication forks [13, 
14].  In vitro identification of small molecules that modulate FANCD2-L formation is 
currently not possible, because attempts to recapitulate the FANCD2 
monoubiquitylation reaction with recombinant proteins in vitro have been 
unsuccessful.  In cells, the S-phase specific monoubiquitylation of FANCD2 is 
dependent on an E3 ubiquitin ligase complex composed of at least ten proteins 
(FANCA, B, C, E, F, G, L, M, FAAP100, FAAP24), the FANCD2 binding partner 
FANCI, and other unidentified proteins. Therefore a complete reconstitution of the 
pathway may be difficult to mimic with recombinant proteins in vitro.  To bypass 
these obstacles we explored a cell-free chemical screening approach using Xenopus 
egg extracts, a biochemical environment that is completely primed for carrying out 
replication of exogenous DNA. We found that FANCD2-L is rapidly induced in egg 
extracts following addition of several dsDNA substrates including circular double 
stranded plasmid DNA (Fig. 1, [11]). We previously showed that formation of 
FANCD2-L is replication- and checkpoint-independent and that quantitative  
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Figure 2. Screening strategy to identify modulators of the FA/BRCA and Mre11 pathways. Plasmid-
containing Xenopus egg extracts (A) are incubated with compounds from a chemical library (B). In this 
example, screening of compounds is performed in a 96-well plate set-up. Analysis of the induction status 
of xFANCD2 is performed by immunoblot using an xFANCD2-specific antibody (C). Comparison 
between xFANCD2 induction in plasmid-activated, untreated extracts (lane 2) and compound-treated 
extracts (lanes 3 – 9) reveals compounds that modulate xFANCD2 either by decreasing the long form 
(inhibiting compound, lane 4) or by increasing it (stimulatory compound, lane 7) (D). DNA-free, 
untreated extract is used as a negative control (lane 1).  
 
immunodepletion of xFANCA, one of the FA core complex proteins, abrogates the 
DNA-stimulated formation of FANCD2-L in egg extracts, as predicted from 
observations in human cells where FANCD2-L formation is strictly dependent on the 
FA core complex [6, 7]. We infer that the formation of FANCD2-L in response to the 
addition of dsDNA in egg extracts is also dependent on functional FA core complex 
proteins upstream of FANCD2.  
 
As an internal positive control for our in vitro system we measured the inducible 
hyperphosphorylation of Mre11 (termed Mre11-PPP).  As reported previously by 
Gautier and coworkers, hyperphosphorylation of Mre11 is stimulated by structures 
containing dsDNA breaks [15].  We found that high concentrations of circular plasmid 
DNA (150 ng/µl) also stimulated Mre11 phosphorylation, (Fig. 1) [7]. Thus, our in 
vitro system is capable of monitoring critical steps in at least two distinct DNA repair 
pathways.  
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Figure 3. Inhibition of FANCD2-L and xMre11-PPP by curcumin in egg extracts. (A) Egg extracts 
were incubated with increasing concentrations of curcumin  (lanes 3 – 6). DNA-free extracts and DNA-
containing, untreated extracts were used as negative and positive controls, respectively (lanes 1-2). The 
relative induction of xFANCD2-L and xMRE11-PPP are indicated below each immunoblot. For each 
experiment, the ratio of long to short form of FANCD2 and Mre11 in DNA-free (lane 1) and DNA-
containing, compound-free extract (lane 2) was set at 0 and 1.0, respectively. Induction in other lanes was 
calculated relative to these min/max values. (B) The values calculated in (A) were plotted to show the 
curcumin-induced inhibition of xFANCD2-L (top graph) and xMre11-PPP (bottom graph). IC50 values 
(boxed on the right of the graphs) were determined from fit curves calculated using IgorPro software. 
Lower panel: chemical structure of curcumin. 
 
Based on the robust DNA-inducible formation of xFANCD2-L we hypothesized that  
the induction of xFANCD2-L could be exploited as an endpoint in a Xenopus cell-free 
assay to screen for small molecules that modulate the FA/ BRCA pathway (Fig. 2).  
 
We tested this hypothesis by determining whether compounds that are known to 
inhibit DNA damage-induced FANCD2-L formation in human cells such as curcumin 
and wortmannin [2] could also inhibit plasmid DNA-induced FANCD2-L formation in 
Xenopus egg extracts. As shown in Fig. 3, curcumin blocked xFANCD2-L formation 
in egg extracts in a dose-dependent manner with an IC50 of 220 µM. In comparison, 
Chirnomas et al. reported an IC50 of 15 µM in HeLa cells [2]. A higher IC50 in egg 
extracts compared to cell-based assays appear to be a general trend (see below and 
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Figure 4. Inhibition of FANCD2-L and xMre11-PPP by wortmannin in egg extracts. (A) Immunoblot 
of egg extracts treated with wortmannin and probed with xFANCD2 and xMre11. Quantitative analysis 
was identical to the one performed in Fig. 3A.  (B) The values calculated in (A) were plotted to show the 
wortmannin-induced inhibition of xFANCD2-L (top graph) and xMre11-PPP (bottom graph). The 
analysis was performed as in fig. 3B. Lower panel: chemical structure of wortmannin. 
 
data not shown), possibly due to the very high concentration of soluble proteins in egg 
extracts. Interestingly, curcumin also inhibited the induction of xMre11-PPP (IC50 = 45 
µM) (Fig. 3), suggesting that curcumin may have an inhibitory effect on DNA repair 
pathways other than the FA/BRCA network. Next we tested the effect of wortmannin, 
previously shown in human cells to inhibit the FA/BRCA pathway through inhibition 
of the ATR kinase [16]. Wortmannin inhibited xFANCD2-L at higher concentrations 
than curcumin (IC50 = 900 µM) (Fig. 4). In comparison, Andreassen et al. reported that 
200 µM wortmannin significantly suppressed FANCD2-L formation following DNA 
damage in HeLa cells [16]. In ontrast with the effect on xFANCD2-L, wortmannin 
significantly inhibited xMre11-PPP at much lower concentrations (IC50 = 4 µM) (Fig. 
4).  Taken together, these data provide proof of principle that the Xenopus cell-free 
system is able to identify inhibitors of the FA/BRCA pathway that are active in cell-
based assays.  
 
To explore whether our in vitro system is capable of detecting novel inhibitors, we 
screened a small molecule library (Cancer Plate, MicroSource Discovery  
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Figure 5. Inhibition of FANCD2-L and Mre11-PPP by DDN in egg extracts. (A) Immunoblot of egg 
extracts treated with DDN (2,3-dichoro-5,8-dihydroxynaphthoquinone) and probed with FANCD2-L and 
Mre11-PPP. Quantitative analysis was identical to the one performed in Fig. 3A.  (B) The values 
calculated in (A) were plotted to show DDN-induced inhibition of xFANCD2-L (top graph) and xMre11-
PPP (bottom graph). Analysis was performed as in fig. 3B. Lower panel: chemical structure of DDN. 
 
Systems, Inc) composed of 80 compounds with known experimental or therapeutic 
anticancer activity. We identified DDN (2,3-dichloro-5,8-dihydroxy-1,4-
naphthoquinone), an analog of the vitamin K derivative menadione [17] as a potent 
inhibitor  of FANCD2-L. DDN inhibited the DNA-stimulated formation of 
xFANCD2-L in a dose-dependent manner (Fig. 5), with an IC50 of 25 µM. Like 
curcumin and wortmannin, DDN also affected xMre11-PPP formation (IC50: 42 µM, 
Fig. 5), but its more potent effect on FANCD2-L suggests that it is a more specific 
inhibitor of the FA/BRCA pathway. 
 
We next wanted to determine whether DDN has a similar effect on FANCD2-L in 
human cells. HeLa cells were treated with increasing concentrations of DDN in the 
presence of 2 mM hydroxyurea (HU), an inducer of stalled replication forks classically 
used to stimulate the FA/BRCA pathway in cells [13, 18]. Immunoblot analysis 
showed that DDN inhibited FANCD2-L in a dose-dependent manner with an IC50 of 5 
µM (Fig. 6A, B). To rule out cell death as a possible cause of inhibition of FANCD2 
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monoubiquitylation, a survival assay was done in the same conditions of DDN and HU 
treatment. Figure 6C shows that the concentration of DDN required to kill 50% of the 
cells (LD50) was 3 times higher than the IC50 for FANCD2-L formation (LD50: 16 µM 
vs. IC50: 5 µM). 
 
FANCD2 has been shown to form nuclear foci when exposed to DNA damaging 
agents in a functional FA/BRCA pathway context [13]. We therefore tested the effect 
of DDN on the formation of HU-induced FANCD2 foci in HeLa cells. In agreement 
with the inhibition of FANCD2-L induction observed by immunoblot, DDN also 
reduced FANCD2 foci formation in a dose-dependent manner with an IC50 of 7 µM 
(Fig. 6D). 
 
Next, we sought to investigate if DDN is a specific inhibitor of the FA pathway by 
comparing its effect on a FA/BRCA-deficient cell line and its complemented, wild-
type-like counterpart in the presence of MMC. If DDN specifically targets the 
FA/BRCA pathway, it should sensitize the complemented but not the FA/BRCA-
deficient cell line to MMC. We used a patient-derived FANCA-deficient cell line, 
HSC72OT, and its complemented counterpart HSC72OT+FANCA. As expected, 
HSC72OT+FANCA was resistant to MMC treatment compared to HSC72OT, with a 
LD50 of 15 ng/ml and 4 ng/ml, respectively (Fig. 7B and C, top curves). Addition of 
1.6 µM DDN (a concentration that did not affect the survival of either cell line, Fig. 
7A) slightly reduced the survival of the MMC-treated HSC72OT (LD50: 3.3 µM, Fig. 
7B) cell line. By contrast, the same combined treatment induced a dramatic decrease 
of cell survival in the FA/BRCA-competent cell line (LD50: 8 µM, Fig. 7C), suggesting 
that DDN sensitized HSC72OT+A cells to MMC by specifically inhibiting the 
FA/BRCA pathway. 
 
In summary, the data presented here collectively suggest that DDN is a potent and 
possibly specific inhibitor of the FA/BRCA pathway. 
 
DISCUSSION 
Cell-free screening strategies using Xenopus egg extracts have been used previously to 
identify small molecule inhibitors of the cell cycle machinery [19, 20].  Applying an 
analogous approach to identify modulators of the FA/BRCA pathway, as presented 
here, may be a significant improvement relative to cell-based screens, for several 
reasons. First, the system is cost-effective, simple to implement and rapid: egg extracts 
are readily available in large quantities, are easy to handle (e.g. they can be frozen for 
long periods before use), contain abundant and easily detectable FA/BRCA proteins 
and are robustly activated within minutes by the simple addition of plasmid DNA. 
Second, screening performed in egg extracts takes place in a fully soluble in vitro 
context, minimizing cell-based screening problems related to compound toxicity and 
bioavailability. Third, extracts are in a replication-competent state that mimics S 
phase, maximizing the sensitivity of detection of replication-associated DNA damage  
 95 
 
      
 
Figure 6. DDN reduces HU-induced FANCD2-L and FANCD2 foci in HeLa cells (A) DDN inhibits 
HU-induced FANCD2-L. Lysates of HeLa cells treated with HU and DDN were analyzed by immunoblot 
(top panel). Quantitative analysis was identical to the one performed in Fig. 3A. (B) Graph and IC50 
calculations were conducted as in Fig. 3B. (C) Survival of HeLa cells treated with HU and DDN. 
Percentage of viable HeLa cells treated in the same conditions as in (A) was monitored by MTS assay and 
plotted against DDN concentrations. LD50 was determined from the IgorPro fit curve. (D) DDN inhibits 
HU-induced FANCD2 foci. Immunofluorescence analysis of HeLa cells treated with HU and DDN was 
performed using an hFANCD2 antibody. The percentage of FANCD2 foci-positive cells is plotted for 
each treatment condition. The IC50 corresponds to 50% inhibition between the maximum value and the 
baseline level (dotted lines). 
 
 
response events such as FANCD2 ubiquitylation and Mre11 phosphorylation. Fourth, 
the simplicity of the system reduces the risks of non-specific, off-target effects of the 
compounds screened: as extracts support neither plasmid replication [21, 22]nor 
transcription [23], active compounds are more likely to target direct protagonists of the 
FA/BRCA pathway than upstream replication or transcription events. Fifth, 
monitoring the effect of candidate compounds on several DNA repair pathways (as 
shown here with Mre11) would give indications about its specificity toward the 
desired target. One can envision a systematic integrated approach in which each 
compound would be characterized by its effects on key proteins involved in different 
DNA repair pathways. Such multidimensional analysis would also be very helpful to  
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Figure 7. DDN sensitizes a FA-competent cell line  to MMC but not its FA-deficient counterpart. 
(A) DDN does not significantly affect HSC72OT and HSC72OT+FANCA survival at concentrations 
below 1.6 µM. Both cell lines were incubated with increasing concentrations of DDN and cell survival 
was monitored by MTS assay after 4 days. (B) DDN does not further sensitize the FANCA-deficient cell 
line to MMC. Survival of HSC72OT cells treated with 1.6 µM DDN and increasing concentrations of 
MMC was monitored and analyzed as in (A). (C) DDN sensitizes the FANCA-complemented cell line to 
MMC. HSC72OT +FANCA cells were treated and analyzed as in (B). 
 
 
determine the precise mechanism of action of the compound. Finally, the cell-free 
screen is easily amendable to high-throughput methods with ELISA orFRET-based 
detection. Taken together, the characteristics of this assay are particularly well suited 
for detection of chemical modulators of extended and functionally undefined protein 
networks that operate in S-phase, such as the FA/BRCA pathway.Initial experiments 
with curcumin and wortmannin confirmed that cellular inhibitors of the FA/BRCA 
pathway display similar activity in the Xenopus cell-free assay. Although required 
concentrations were higher in the cell-free assay, the most active compound in cells, 
curcumin (IC50: 15 mM versus 200 mM for wortmannin) was also more active in our 
assay (220 mM versus 900 mM). We were also able to partially assess the specificity 
of these compounds toward the FA/BRCA pathway using Mre11-PPP as a control. 
Both compounds were much more active for inhibition of Mre11-PPP (45 mM and 4 
mM, respectively) than FANCD2-L, suggesting that they have strong off-target 
activities. This result is not unexpected because both have been shown previously to 
have pleiotropic effects. Curcumin is a natural phenolic compound with anti-
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inflammatory, anti-oxidant and potent antineoplastic properties [24-26], alone or as a 
chemosensitizing agent. The cellular mechanisms are diverse, from apoptosis 
induction [27] to inhibition of enzymes involved in oxidative pathways, such as 
cyclooxygenase [28]. Curcumin is also a potent inhibitor of several kinases, including 
PKC, EGFR tyrosine kinase and IkB kinase [29-31]. Wortmannin is a potent inhibitor 
of various kinases including phosphoinositide 3-kinases (PI3Ks) such as ATM and 
ATR, PI3K-related enzymes (mTOR and DNA-PK) and polo-like kinases, suggesting 
that the low activity of wortmannin toward FANCD2 is the result of a rather non-
specific effect. 
 
By screening a chemical library composed of compounds with anticancer properties 
using the cell-free assay, we identified DDN as a novel inhibitor of the FA/BRCA 
pathway. DDN displayed a stronger inhibitory activity than curcumin and wortmannin 
toward FANCD2-L (IC50: 25 mM versus 220 mM and 900 mM, respectively). In 
addition, DDN inhibited Mre11-PPP at concentrations higher than FANCD2-L (IC50: 
42 mM), suggesting that DDN exerts a more specific effect toward the FA/BRCA 
pathway than curcumin and wortmannin. DDN displayed similar activity against 
FANCD2-L in HeLa cells as monitored by FANCD2-L induction and FANCD2 foci 
formation. DDN also sensitized FA/BRCA-competent cells to the ICL agent MMC 
without a significant effect on the FA/BRCA-deficient cell line counterpart, further 
strengthening the idea that DDN specifically targets the FA/BRCA pathway. 
 
The molecular mechanism of the FA pathway and its inhibition by DDN, however, 
remains to be determined. It may involve interference with proteins acting upstream of 
FANCD2, e.g. by destabilization the FA core complex, or direct inhibition of 
FANCD2 monoubiquitylation. DDN is a polar analog of menadione, a vitamin K 
derivative that induces growth arrest in G1 and apoptosis in various cancer cell lines. 
Known DDN targets include cdc25A phosphatase, Bcl-2 and Akt, none of which have 
been functionally connected to the FA/BRCA pathway. Interestingly, menadione has 
been tested in combination with MMC in phase II trials for treatment of lung and 
gastrointestinal cancers [32, 33]. The rationale was that elevated levels of intracellular 
pools of reduced glutathione in cancer cells correlate with resistance to alkylating 
agents such as MMC, whereas menadione lowers reduced glutathione levels. Our data 
further suggest that DDN could be developed as a chemosensitizer of ICL-inducing 
agents in FA/BRCA-competent tumor cells. 
 
To our knowledge, this is the first description of a cell-free screen for modulators of 
the FA/BRCA pathway.  This assay has the potential to identify not only negative, but 
also positive modulators of DNA repair pathways that might act to prevent de novo 
tumor formation. Other proteins in the FA pathway may be useful in small molecule 
inhibitor screens similar to those described here.  For example, FANCM is a member 
of the FA core complex that exhibits DNA-damage inducible phosphorylation, a 
modification that could be used as endpoint in a chemical screen. Another attractive 
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target is FANCI, the most recently identified member of the FA pathway that –like 
FANCD2— is activated by monoubiquitylation following DNA damage [34-36]. 
Future studies will determine if the same inhibitors target FANCI and FANCD2 or 
whether activation of FANCI can be suppressed independently of FANCD2. 
 
In addition to finding small molecules that might be used as chemosensitizers, the 
assay described here may be useful to elucidate functions of the FA/BRCA pathway 
proteins using well-defined target-specific inhibitors. 
 
MATERIALS AND METHODS 
Chemicals  
Wortmannin (Sigma), Curcumin (Sigma) and DDN (Calbiochem) were dissolved in DMSO. 
Hydroxyurea (Sigma), and MMC (Sigma) were dissolved in H20. 
Xenopus cell-free assay  
Low-speed extracts were prepared from Xenopus laevis eggs as described previously [6]. Ten 
µl extract were left untreated (negative control) or supplemented with 0.5 ul DNA (3.0 µg/µl) 
and 1 µl compound. Following incubation for 30 min at room temperature, 100 µl of 1X 
sample buffer (NuPage, Invitrogen) were added and the reaction incubated at 95oC for 5 min 10 
µl of each sample were analyzed by SDS-PAGE and immunoblotting. 
Antibodies 
The xFANCD2 and hFANCD2 rabbit polyclonal antibodies used in immunoblot experiments 
were described previously [6]. Antibodies against xMre11 (immunoblotting) and hFANCD2 
(immunofluorescence) were a kind gift of J. Gautier [15] and K.J. Patel [37], respectively.  
Preparation of plasmid DNA  
Circular supercoiled pBluescript plasmid DNA (pBSKS, 2961 bp) was prepared from E. coli 
cultures using a QiaFilter Plasmid Maxi Kit (Qiagen).  
Immunoblotting  
Protein samples were separated on 3-8% Tris-Acetate gels (Invitrogen) and transferred to 
Immobilon-P membranes (Millipore). After blocking in 5% milk for 30 min, membranes were 
incubated with anti-xFANCD2 (1:1000), anti-hFANCD2 (1:500), or anti-xMRE11 (1:5000) 
and subsequently with HRP-conjugated rabbit secondary antibody (1:10,000). Immunoblots 
were revealed with ECL plus system (Amersham). Protein band densitometry was performed 
using ImageJ software [38]. The graphing software used was IGOR Pro 6.01 
(www.wavemetrics.com). 
Library screening  
Each compound of the Cancer plate (MicroSource Discovery, Inc) was initially tested at 500 
µM final concentration in the Xenopus cell-free assay in a 96-well plates format. Immunoblots 
were probed with antibodies against xFANCD2 and xMre11. Positive compounds identified in 
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the initial screen were further tested by serial dilution to confirm the inhibitory effect and to 
establish the IC50. 
Cell lines and cell culture  
HeLa cells were grown in DMEM medium supplemented with 10% serum in humidified 5% 
CO2 atmosphere. The FANCA deficient cell line (HSC720T) and its FANCA-complemented 
counterpart (HSC72OT) [39] were grown in RPMI 1640 medium supplemented with 10% 
serum. 
Cell survival assay, FANCD2 ubiquitylation assay and immunofluorescence microscopy 
HeLa cells were incubated with 2 mM HU and various concentrations of DDN for 7 h. Survival 
assay was performed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay 
(Promega) following manufacturer’s recommendations. For monitoring FANCD2 
monoubiquitylation, cells were lysed in 50 mM Tris pH 7.7, 150 mM NaCl, 0.5% NP-40, 5 
mM EDTA and 1 mM PMSF. After Bradford quantification of the crude lysate, 15 ug total 
proteins were boiled in SDS-loading buffer for 30 min and analyzed by 3-8% SDS-Page and 
immunoblotting. For immunofluorescence microscopy, HeLa cells grown on chamber slides 
were washed with PBS, fixed with 3.7% paraformaldehyde, permeabilized with PBS 
containing 0.2% Triton X-100 and blocked with a solution of 7.5% BSA in PBS. Primary and 
secondary antibodies were diluted in PBS containing 1% BSA. Cells were incubated in primary 
antibody (1:300 anti-hFANCD2) for 1 h at 4°C, washed in PBS and incubated in secondary 
antibody (Alexa Fluor 594-conjugated goat anti-rabbit, 1/1000; Molecular Probes). Nuclei were 
counterstained with Hoechst 33342 dye (10 ng/ml, Molecular Probes). Cells were mounted 
with anti-fade mounting solution (Vectashield, Vector Laboratories). For quantification of 
FANCD2 nuclear foci, wide-field images containing up to 100 cells were taken using a Nikon 
TE800 microscope with an Optronics DEI750 camera. Each cell was scored for FANCD2 foci 
using ImageJ software, and cells displaying more than 5 foci were considered as “foci-
positive”. 200 cells were counted per experiment. 
MMC sensitization assay 
HSC72OT and HSC72OT+A cells were seeded at 6000 cells/well in 96-well plates and treated 
with various combinations of MMC and DDN concentrations. Cell viability was measured after 
4 days using the MTS-based CellTiter 96 assay (Promega). 
Calculation of IC50 values 
For all experiments, fit curves were determined from experimental data using IgorPro. The 
concentration of compound that induces 50% inhibition of the measured endpoint (i.e. 
FANCD2 ubiquitylation, FANCD2 foci, Mre11 phosphorylation and cell survival) was then 
plotted on the fit curve. 
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Fanconi anemia is associated with variable developmental abnormalities, bone 
marrow failure, and cancer susceptibility.  FANCG/XRCC9 is member of the FA 
core complex, a group of proteins that control the monoubiquitylation of 
FANCD2, an event that plays a critical role in maintaining genomic stability.  
Here we report the identification of the Xenopus laevis ortholog of human 
FANCG (xFANCG), its expression during development, and its molecular 
interactions with a partner protein, xFANCA.  The xFANCG protein sequence is 
47% similar to its human ortholog, with highest conservation in the two putative 
N-terminal leucine zippers and the tetratricopeptide repeat (TPR) motifs. 
xFANCG is maternally and zygotically transcribed. Prior to the midblastula 
stage, a single xFANCG transcript is observed but two additional alternatively 
spliced mRNAs are detected after the midblastula transition. One of the variants 
is predicted to encode a novel isoform of xFANCG lacking exon two. The mutual 
association between FANCG and FANCA required for their nuclear import is 
conserved in Xenopus egg extracts.  Our data demonstrate that interactions 
between FANCA and FANCG occur at the earliest stage of vertebrate 
development and raise the possibility that functionally different isoforms of 
xFANCG may play a role in early development.  
 
INTRODUCTION 
The hereditary syndrome Fanconi anemia (FA) belongs to the group of caretaker gene 
diseases that are characterized by genomic instability and increased susceptibility to 
cancer. The FA patient phenotype is highly variable featuring impaired growth, 
hypogonadism, and developmental abnormalities of the skeleton, kidney and heart. On 
a cellular level, the hallmark of FA is hypersensitivity to DNA interstrand cross-
linking agents, such as mitomycin C, suggesting a defect in the DNA damage response 
(Auerbach et al. 1997; Joenje & Patel 2001). This idea is further supported by the 
identification of a member of the FA pathway FANCD1 as BRCA2, a protein that is 
indispensable for DNA repair by homologous recombination (Howlett et al. 2002).  
Despite recent progress in FA research, the function of the majority of members of the 
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FA pathway has not been elucidated. Thirteen FA complementation groups have been 
identified, and all of the corresponding genes, except FANCI, have been cloned 
(FANCA, FANCB, FANCC, FANCD1 (BRCA2), FANCD2, FANCE, FANCF, FANCG, 
FANCI, FANCJ (BRIP1), FANCL, FANCM and FANCN) (reviewed in (Thompson 
2005)(Reid et al. 2007; Xia et al. 2007). The FANCA/B/C/E/F/G/L/M proteins 
interact in a nuclear multiprotein “core” complex, which is required for the 
monoubiquitylation of FANCD2 (Garcia-Higuera et al. 2001). FA proteins typically 
lack recognizable functional domains, except for FANCJ/BRIP1, which has a DEAH-
box helicase domain; FANCM, which contains a DNA helicase and endonuclease 
domain; FANCL, which contains a WD40 repeat, a PHD-finger, and a E3 ubiquitin 
ligase domain; FANCN which contains an N-terminal prefoldin like domain and two 
C-terminal WD40-like repeats; and FANCG which has at least seven tetratricopeptide 
repeat (TPR) motifs (Blom et al. 2004; Levitus et al. 2005; Levran et al. 2005; Meetei 
et al. 2003a; Meetei et al. 2005; Reid et al. 2007; Xia et al. 2007). 
TPR motifs are often found in multi-protein complexes such as the FA core complex; 
the tertiary structure forms superhelical structures that mediate protein-protein 
interactions. Human FANCG is believed to bind FANCA through TPR motifs 1, 2, 5 
and 6 (Blom et al. 2004). The FANCA-FANCG interaction is required for 
stabilization and entry of either protein into the nucleus and has been suggested to 
be an early event in the nuclear assembly of the FA core complex (de Winter et al. 
2000). Though the exact function of the FANCG protein is unknown, it has been 
shown to be required for the assembly of the FA core complex, and for the 
interaction between XRCC3 and FANCD1/BRCA2, proteins involved in homologous 
recombination (Garcia-Higuera et al. 2000; Hussain et al. 2006; Waisfisz et al. 1999). 
We recently described several orthologs of the Xenopus Fanconi anemia genes and 
showed that they are required for maintenance of genomic stability in Xenopus cell-
free extracts (Sobeck et al. 2006). In this paper, we extend the Xenopus model for FA 
with the identification and characterization of the Xenopus ortholog of 
FANCG/XRCC9 (xFANCG) (de Winter et al. 1998; Liu et al. 1997). We found three 
differently spliced transcripts of xFANCG in Xenopus, all of which were expressed 
after the midblastula transition during early vertebrate development. We show that 
xFANCG and the core complex protein xFANCA associate in egg extracts and that 
they are mutually dependent for nuclear import, as described previously for human 
cells (Garcia-Higuera et al. 2000; Waisfisz et al. 1999). Moreover, both proteins are 
required for the monoubiquitylation of Xenopus FANCD2 (xFANCD2). 
 
RESULTS 
Isolation of Xenopus laevis FANCG (xFANCG) cDNA.  
To isolate xFANCG cDNA we performed a TblastN search of a Xenopus tropicalis 
protein database (www.xenbase.org) with the amino acid (aa) sequence of human 
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Figure 1. Comparative sequence analysis of Xenopus and human FANCG.  
A ClustalW alignment of full-length Xenopus laevis FANCG (xFANCG) with full-length human FANCG 
(hFANCG). Dark grey shading indicates amino acid identity; light grey shading indicates amino acid 
similarity. The exons described in this paper are outlined with black boxes—labeled (on top) 1, 2, and 3. 
Asterisks indicate positions of serines shown to be important for hFANCG function (Mi et al. 2004; Qiao 
et al. 2004). Black arrows indicate the critical leucine residues of the previously described leucine zipper 
motifs. (Demuth et al. 2000) Grey boxes indicate TPR motifs—labeled (on bottom) 1-7 (Blom et al. 
2002). The black underlined sequence (amino acids 378-407) shares homology with the transcriptional 
co-repressor NAB1(van De Vrugt et al. 2002). 
 
FANCG. We found two X. tropicalis sequence fragments that aligned with the central 
region of human FANCG (hFANCG) (aa 120-308, and 396-487). Based on the 
corresponding nucleotide sequence of the X. tropicalis matches, we designed primers 
for reverse transcription-PCR (RT-PCR). The full-length Xenopus laevis FANCG 
cDNA sequence (xFANCG) was isolated from a X. laevis cDNA made from pooled 
stages 8 - 13 embryos (Nieuwkoop & Faber 1967) by PCR and 5’ and 3’ RACE-PCR. 
The full-length sequence was then confirmed by sequencing cDNA from the tadpole-
derived Xenopus XTC-2 cell line (Pudney et al. 1973) and submitted to NCBI 
(accession #EF107711). The primer sets described in materials and methods amplified 
the full-length xFANCG and a shorter version of xFANCG termed xFANCGshort. 
 
Comparison of the full-length xFANCG and hFANCG protein sequences revealed 
34% identity and 47% similarity overall (Fig 1 and Table 1). Although the overall 
homology between human and xFANCG is low, the amino acid similarity of the two 
N-terminal leucine zippers is 64%, and 72%, and TPR motifs 3, 4 and 5 are 68%, 74% 
and 68% respectively, suggesting that these domains could be critical for FANCG 
function (Fig 1 and Table 1).  
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Isolation of a xFANCG variant that 
skips exon 2 
Sequence analysis revealed that 
xFANCGshort was missing 92 bps 
beginning at nucleotide 63 (Fig 2A). 
Because this position corresponds to the 
junction of exon two of hFANCG, we 
hypothesized this sequence could be a 
splice variant that skips exon two. We 
sequenced X. laevis genomic DNA in 
this region and found that acceptor and 
donor sites were conserved between X. 
laevis and hFANCG for exon two 
(shown schematically in Fig 2B) 
confirming the position of exon two and 
suggesting that exon two was deleted in 
the variant xFANCGshort. Further 
analysis of the splice variant showed that 
the splicing event disrupted the open 
reading frame of exon one. However, we 
identified a potential downstream alternative start codon in exon one that is in-frame 
with exon three that could encode the xFANCGshort isoform shown in Fig 2C.  
 
To determine if and when the different splice isoforms of xFANCG are expressed 
during embryonic development, we examined xFANCG expression by RT-PCR using 
mRNA isolated from eggs or developmentally staged embryos ranging from blastula 
through tadpole stages (Nieukoop stages 1, 5, 8, 20, 24, 33, 39, and 41) (Nieuwkoop & 
Faber 1967). The different splice isoforms were amplified from cDNAs isolated from 
staged embryos using primers that directly flanked exon two.  
 
xFANCG mRNA of the expected size was expressed throughout development from 
stage 1-41 (Fig. 3A, panel 1: termed xFANCG-1). Two additional xFANCG mRNA 
transcripts were detected in stage 20 embryos (Fig. 3A, panel 1: termed xFANCG-2 
and xFANCG-3).  Sequencing analysis of the transcripts revealed that xFANCG-1 
corresponded to full-length xFANCG, whereas xFANCG-3 corresponded to 
xFANCGshort. The sequence of xFANCG-2 was not determined (shown in Fig 3A, 
panel 1). However, since the PCR to amplify xFANCG at different stages was 
performed with primers directly flanking exon two, we suspect xFANCG-2 is a splice 
variant of xFANCG that contains part of exon two. We also investigated whether 
mRNA transcripts of xFANCA, -D2, -F, and -L were expressed during development. 
As shown in Fig 3A, panels 2-5 respectively, transcripts of all xFA genes were 
detected at all embryonic stages 1-41; however, no variants were detected for these 
genes.  
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Figure 2. An mRNA splice variant of Xenopus FANCG, lacking exon 2 is present during embryo 
development. (A) A ClustalW alignment shows the nucleotide sequence of hFANCG cDNA compared 
with full length xFANCG and an xFANCG deletion variant that lacks exon 2 (xFANCGshort). The borders 
of exons 1, 2 and 3 are conserved between human and Xenopus as indicated by black arrows.  (B) A 
schematic of the alternative splice event that leads to skipping of exon 2 in xFANCGshort. Line 1: 5’ 
cDNA sequence of full-length xFANCG encompassing exons 1-3.  Line 2: Exon-intron structure of 
xFANCG on the genomic level. Introns are indicated as black lines. The boxed region represents the start 
codon (ATG) for full-length xFANCG.  Line 3: cDNA sequence of the alternative splice variant 
xFANCGshort, which is missing exon 2. A putative start codon is indicated by a boxed ATG located at 
the end of exon 1 which is in frame with exon 3 (+2 reading frame) but not with the original start codon at 
the beginning of exon 1. (C) A ClustalW alignment shows the translation product of exons 1-3 of 
hFANCG compared with that of full-length xFANCG and xFANCGshort. Black arrows indicate the 
borders of exons 1, 2 and 3. 
 
xFANCG protein is expressed maternally and throughout development 
To investigate the protein expression of xFANCG during development, we made a 
polyclonal antibody against xFANCG amino acids 354-374.  This sequence is 
common among full-length xFANCG and the variants we describe in this paper.  The 
antibody specifically recognized a band of the expected size (69 kDa) in egg extracts 
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Figure 3. xFA genes are expressed maternally and during embryonic development. (A) An agarose 
gel shows the RT-PCR products for xFANCG -A, -D2, -F, and -L from different developmental stages (as 
indicated at the top of panel 1) using the primers listed in materials and methods. Transcripts of all FA 
genes were expressed throughout development (panel 1-5). Three alternative transcripts were detected for 
xFANCG at stages 20, 24, 33, 39 and 41 (after the midblastula transition at stage 8, panel 1). (B) An 
immunoblot probed with anti-xFANCG, anti-xFANCA, and xFANCD2 indicated on the left of each 
panel, shows that xFANCG, xFANCA, and xFANCD2 are expressed throughout the developmental stages 
indicated (top). The right-most lane is a negative control (labeled “Pre”) consisting of a re-probe of the 
same immunoblots with the pre-immune antisera corresponding to the antibody listed at the left of each 
panel. 
 
 
by immunoblot. This band was confirmed as xFANCG by mass spectrometry analysis 
(data not shown).  
 
xFANCG was present in protein lysates prepared from whole embryos throughout 
development, from stage 0 (oocyte) to stage 31. As in egg extracts, only a single 
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protein product was detected for xFANCG (Fig. 3B, panel 1), Proteins predicted to be 
expressed by the shorter splice variants were not detectable by immunoblot.  Similar to 
xFANCG, xFANCA and xFANCD2 were detected throughout development from 
stage 0 through 31 (Fig. 3B, panel 2 and 3, respectively) consistent with the robust 
amounts of FANCA and FANCD2 in egg extracts as we described previously (Stone, 
Sobeck  et al. 2006). 
 
The interaction of xFANCG with xFANCA is conserved in Xenopus 
To determine if the interaction between FANCG and FANCA observed in human cells 
(Waisfisz et al. 1999) is conserved in Xenopus interphase egg extracts, we performed 
reciprocal co-immunoprecipitations of xFANCA with xFANCG (Fig 4A). We found 
that xFANCG co-immunoprecipitated xFANCA in the extracts (Fig 4A: panel 1, lane 
3), and the reciprocal immunoprecipitation by xFANCA co-immunoprecipitated 
xFANCG (Fig 4A: panel 2, lane 4). Immunoprecipitation of xFANCD2 did not 
detectably co-immunoprecipitate xFANCA or xFANCG, as expected from previous 
studies with human cell lysates (Fig. 4A: panel 3, lanes 3 and 4) (de Winter et al. 
2000). In addition, xFANCG and xFANCA co-migrated in predominantly one 
complex of approximately 900 kDa on a Superose-6 size exclusion column (Fig. 4B). 
These data demonstrated that the interaction between endogenous xFANCG and 
xFANCA was conserved in Xenopus egg extracts. 
 
Next we wanted to test if the absence of xFANCG affected nuclear import of 
xFANCA or the monoubiquitylation of xFANCD2 as described in human cells. 
(Garcia-Higuera et al. 2000) To analyze this, we used extracts prepared from Xenopus 
eggs as described by Murray (Murray 1991). Briefly, these extracts are arrested at the 
end of meiosis and contain only negligible amounts of DNA. Upon chemical 
activation, the extracts are released into interphase in tight synchrony. When sperm 
chromatin is added to these extracts, the DNA decondenses and a nuclear membrane 
forms around the DNA, followed by one round of semiconservative chromosomal 
replication. Following replication, we reisolated the nuclei that formed in the extract 
and examined the nuclear accumulation of xFANCA, and xFANCG, as well as the 
non- monoubiquitylated (short) and monoubiquitylated (long) form of xFANCD2 in 
depleted extracts (Sobeck et al. 2006). A quantitative depletion of xFANCG only 
partially co-depleted xFANCA but prevented the residual xFANCA protein remaining 
in the extract from entry into the nuclei (Fig. 4C, lane 2 and 5). Similarly, quantitative 
depletion of xFANCA prevented residual xFANCG from entering the nuclei (Fig. 4C, 
lanes 1 and 4). Moreover, depletion of either xFANCA or xFANCG prevented the 
shift of xFANCD2 from short to long form in the nuclei, a mobility shift that is 
concomitant with monoubiquitylation of FANCD2. In contrast a mock-depleted 
control was capable of supporting the shift of FANCD2 (Fig. 4C, compare lanes 4-6). 
It is important to note here that FANCG is sometimes observed as two or three 
isoforms (as is seen in Fig. 4C) in Xenopus extracts, in human cells, and in Chinese 
hamster ovary cells. (Qiao et al. 2001)(Tebbs et al. 2005). We believe the multiple  
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Figure 4. Interactions between human FANCA and FANCG are conserved in Xenopus egg extracts. 
(A) An immunoblot (antibodies used are indicated on left of each panel) shows that an 
immunoprecipitation (IP) with anti-xFANCG (lane 3, panel 2) co-immunoprecipitated (co-IPed) 
xFANCA (lane 3, panel 1) but not xFANCD2 (lane 3, panel 3). An IP with anti-xFANCA (lane 4, panel 
1) co-IPed xFANCG (lane 4, panel 2) but not xFANCD2 (lane 4, panel 3). An IP with anti-xFANCD2 
(lane 2, panel 3) did not co-IP xFANCA (lane 2, panel 1) or xFANCG (lane 2, panel 2). 1µl of egg extract 
was used as a positive control for all three proteins (lane 1, all panels). Lane 5 is a mock control IP with 
xFANCG pre-immune sera. (B) An immunoblot (antibodies used are indicated on left of each panel) 
shows the protein complex elution profile of egg extract from a Superose 6 gel filtration column. The 
majority of xFANCG and xFANCA proteins co-eluted similarly at approximately 900 kDa. (C) An 
immunoblot (antibodies used are indicated on left of each panel) shows that in Xenopus extracts (lanes 1-
3) depletion of xFANCA (lane 1, panel 2) partially co-depleted xFANCG (lane 1, panel 3) and a depletion 
of xFANCG (lane 2, panel 3) partially co-depleted xFANCA (lane 2, panel 2) when compared to an IgG 
control depletion (lane 3, panels 2 and 3). The bands indicated as xFANCG have been identified by mass 
spectrometry (unpublished, S. Stone). xFANCD2 was used as a loading control for the first three lanes 
(panel 1). After the formation of nuclei in the depleted extracts (lanes 4-6), there was no nuclear import of 
residual non-depleted xFANCA or xFANCG (lanes 4 and 5, panels 2 and 3) following the depletion of 
either protein. Whereas the IgG control depleted nuclei shows normal import of xFANCA and xFANCG 
(lane 6, panel 2 and 3). Although imported into the nuclei (panel 1, lanes 4-6), xFANCD2 was not 
monoubiquitylated in the absence of xFANCA or xFANCG (lane 4 and 5, panel 1) but was 
monoubiquitylated in the IgG control depleted nuclei (lane 6, panel 1). 
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bands are not the products of the alternative transcripts we describe since the extracts 
are derived from unfertilized eggs that contain only the full-length xFANCG 
transcript.  Future work will determine if these multiple bands are due to 
phosphorylation, degradation or other protein modification. 
 
DISCUSSION  
We identified the Xenopus laevis ortholog of human FANCG, examined its expression 
during embryonic development and its molecular interactions in egg extracts. Our 
results suggest that several FA Xenopus orthologs are coordinately expressed during 
early development and participate in protein complexes that are conserved in 
vertebrates from frog to man. 
 
Fanconi anemia patients have an increased incidence of cancer, bone marrow failure 
and a variety of developmental abnormalities.  Little is known about how the FA 
proteins participate in these processes.  Xenopus is an attractive model system for FA 
because extracts from the Xenopus eggs provide a biochemical platform to dissect the 
functions of the FA proteins in a cell-free and replication-competent context, and 
because Xenopus is an excellent model organism for primitive hematopoiesis.  Unlike 
other vertebrate models, the Xenopus embryo has been precisely fate-mapped, making 
it possible to misregulate the expression of proteins in single blastomeres within 
embryos so that the fate of specific tissues can be studied (Galloway & Zon 2003; 
Lane & Sheets 2005; Maeno 2003; Moore 2004).  We previously described Xenopus 
orthologs for xFANCD2, -A, -F, and -L, and established that FA proteins are required 
for maintenance of genomic stability during unperturbed replication in Xenopus cell 
free extracts (Sobeck et al. 2006).  The results described here further develop Xenopus 
as model organism for FA by cloning and characterizing xFANCG, by establishing the 
expression pattern of several FA genes during early development, and by establishing 
that the architecture of the FA core complex proteins is conserved in egg extracts with 
regard to another key feature; the FANCA-FANCG interaction. 
 
To date, FA gene expression has not been well characterized in the developing 
embryo.  Here we report that xFANCD2 and the core complex genes xFANCA, -L, -F 
and -G are expressed maternally and throughout early development.  Interestingly, by 
the neurula stage of development, two shorter xFANCG transcripts are expressed. The 
variants of xFANCG are present after the midblastula transition until the tadpole stage, 
while the majority of the maternal sequences were full-length xFANCG. Sequence 
analysis revealed that one of the shorter variants is an alternative version of xFANCG 
that lacks exon two, which encodes the beginning of one of the putative leucine 
zippers. 
 
Because FANCG and other core complex proteins functionally interact, expression of 
developmentally regulated alternative versions of FANCG may be important for early 
development in vertebrates.  Evolutionary conservation of exon-skipping events has 
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previously been shown to represent functional alternative splicing from mouse to 
human (reviewed in (Lareau et al. 2004)).  Although splice variants for FANCG have 
not been described in human or mouse, an alternative FANCG transcript, also 
involving exon two, has been reported in chicken DT40 cells (Yamamoto et al. 2003).  
Thus, alternative splicing events affecting exon two appear to be common between 
frog and chicken, reinforcing the idea that these variants may be functional.  The 
alternative FANCG transcript in chicken lacks the nucleotides encoding 11 amino 
acids in the 3’ region of exon two, and is predicted to encode a version of FANCG that 
is missing the beginning of the first of two putative N-terminal leucine zippers. 
Ectopic expression of this variant was not able to complement chicken FANCG-
deficient cells, suggesting that exon two-encoded sequences are required for FANCG 
function (Yamamoto et al. 2003).  In a survey of FANCG protein expression during 
development we did not observe protein corresponding to the multiple xFANCG 
isoforms expected from expression of the splice variants.  However, if the predicted 
variants are translated detection might be difficult.  First, the RT-PCR method we used 
was not quantitative so it may be that these transcripts and/or the encoded proteins are 
only weakly expressed.  The proteins may be quickly post-transcriptionally degraded 
(by a process termed “RUST” or “regulated unproductive splicing and translation” 
used to regulate gene expression (Lareau et al. 2004)).  The variant proteins might also 
be post-translationally modified and unable to be detected by our antibodies in the 
modified form. It’s also possible that the full-length and variant proteins, if they are 
expressed, were not separated by our methods.  Further studies will be required to 
resolve this issue. 
 
The Xenopus laevis ortholog of FANCG is 47% similar and 34% identical to human 
FANCG. The previously published TPR domains 3, 4 and 5 and leucine zippers 1 and 
2 are the most similar between human and Xenopus with 68%, 74%, 68%, 64%, and 
72% homology, respectively. Interestingly the serines known to be important for 
FANCG phosphorylation (serines 7, 383, 387) are not conserved in Xenopus (Mi et al. 
2004; Qiao et al. 2004). However both the full-length xFANCG and the splice variant 
have a threonine at position 7, raising the possibility that phosphorylation at these sites 
substitutes for the serine phosphorylation observed in the human FANCG protein. In 
addition, a glutamic acid residue is located in the Xenopus sequence at the human 
serine 387 position, which has been reported to mimic the addition of a phosphate 
moiety to a protein (Wagner et al. 2004).  
 
Co-immunoprecipitation of FANCA and FANCG was also conserved in Xenopus. In 
addition, we show that quantitative depletion of xFANCA in a Xenopus egg extract 
results in a partial co-depletion of xFANCG (approx. 50%) and vice versa, suggesting 
that xFANCA and xFANCG do not form a stoichiometric (1:1) complex in Xenopus 
extracts (Fig 4A&C). This was not a surprising result, since human FANCA has 
previously been shown to reside in at least three different complexes in 
unsynchronized HeLa nuclear extracts (Meetei et al. 2003b). Interestingly, analysis of 
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xFANCA and xFANCG complexes in the naturally synchronized Xenopus interphase 
extracts by Superose-6 size exclusion chromatography, revealed that both proteins 
eluted in a complex of approximately 900 kDa. Though this does not rule out the 
possibility that multiple xFANCA- or xFANCG-containing complexes might elute at 
900 kDa, the larger 1.5 to 2 MDa (BRAFT complex) and the smaller 500kDa FANCA 
complex, present in HeLa nuclear extracts, were not detected (Meetei et al. 2003b).  
One possible explanation is that the 900-kDa complex might be the predominant 
FANCA-containing complex in cell-cycle synchronous Xenopus interphase extracts. 
Further experiments are necessary to determine if BRAFT and other FA complexes 
exist in Xenopus extracts. 
 
Although approximately 50% of residual xFANCA and xFANCG protein remains in 
xFANCG and xFANCA immunodepleted extracts respectively, the residual xFANCA 
or xFANCG protein can no longer enter the nucleus. This observation supports the 
existing data that xFANCA and xFANCG depend on one another for nuclear entry. 
(Garcia-Higuera et al. 2000; Waisfisz et al. 1999) Thus, several hallmarks of the 
functional molecular interactions of these FA proteins are conserved in egg extracts, 
underscoring the idea that egg extracts faithfully reproduce critical molecular 
interactions in the FA protein network.  
 
Fanconi anemia research is still in the pathway-building stages with little known about 
the functions of the FA proteins, in particular the FA core complex proteins.  With the 
many advantages Xenopus offers for cell-free biochemical analysis and as a classical 
developmental model, further studies to develop the Xenopus model for FA should be 
a valuable part of the research effort to understand the role of these proteins in 
supporting primitive hematopoiesis, development of the early embryo, and cancer 
susceptibility in humans. 
 
 
MATERIALS AND METHODS 
Animals 
Xenopus laevis were purchased from NASCO and reared at the Animal Facility of Oregon 
Health & Science University (OHSU). Experimental procedures were preformed in compliance 
with federal regulation and OHSU institutional animal care and use committee (IACUC). 
RT-PCR from Xenopus laevis embryo RNAs 
Xenopus eggs were obtained, and embryos were cultured as described (Christian 1989). 
Embryos were staged according to Nieuwkoop and Faber (Nieuwkoop & Faber 1967). 
 
To make mixed developmental stage mRNA, total RNA was isolated from 60 embryos ranging 
from stage 8 to 13 (10 embryos from each stage). To make individual developmental stage 
mRNA, we isolated embryos of developmental stages ranging from one-cell stage to swimming 
tadpole (stage 1 to 41). For each mRNA preparation, 15 embryos of the same developmental 
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stage were homogenized in buffer containing 50 mM NaCl, 50 mM Tris-HCl, pH 7.5, 5 mM 
EDTA, 0.5% SDS and 200 µg/ml proteinase K. After incubation on ice for 1h, total nucleic 
acids were isolated by phenol-chloroform extraction and subsequent ethanol precipitation. 
RNA was selectively precipitated in 4 M LiCl. Total RNA samples were treated with RNase-
free DNase. The RT-PCR was done in a two-step reaction using the Ambion RETROscript™ 
kit (Ambion). Following the recommendations of the manufacturer.  Specific primers are listed 
in the table below. 
 
Gene 5’ to  3’ primer sets  
(forward and reverse) 
NCBI 
Accession 
xFANCA ACATGTTTCTTAAGGATG 
TTAAAAGACAGGCTCAAAGAA  
AY633664 
xFANCD2 GATGTCATTAAATCGTCTG  
CCAGGTAATCTAATATACCC 
AY633665 
 
xFANCF ATGACTGCCTCAGAAATGCTCTT  
TTAAATCCTTTTCACTTCAAGTA 
AY547288 
xFANCG ATGGCAGGAGACTGTCTGACG  
CACTCTCCATGCTTTCAGCAG  
EF107711 
xFANCL ACTGGAGTCATTGAAAGGTT 
AGGCTGCCCACAACGGGGGT 
AY633666 
 
All PCRs were performed using the proofreading polymerase, Elongase (Invitrogen) according 
to the manufacturers protocol. For sequencing, products separated by agarose gel were purified 
using the QIAquick kit (Qiagen) according to the manufacturers protocol.   
 
Isolation of full length Xenopus laevis FANCG cDNA 
An amino acid search (TblastN) of the Xenopus laevis NCBI database (www.ncbi.nlm.nih.gov) 
with the human FANCG protein sequence did not provide any relevant matches. A similar 
search of a species closely related to Xenopus laevis, Xenopus tropicalis, (www.xenbase.org) 
showed several sequence matches within amino acids 120-490 of human FANCG. Based on 
sequence similarity between human and X. tropicalis the following primer set was designed 
(5’F-GCACAGAGTGGCGGGCCTG-3’, 5’R-AGGTGGGCAGCCGATGCCC-3’) which 
amplified a 1000 bp PCR product from the Xenopus laevis stage 8-13 cDNA library.  
 
To determine the nucleotide sequence of the 5’ and 3’ regions of Xenopus laevis FANCG we 
generated a pool of adaptor-ligated double stranded cDNAs for RACE PCR, as previously 
described (Schaefer 1995). Briefly, Xenopus laevis stage 8-13 total RNA was treated with 
Tobacco Acid Pyrophosphatase (TAP) to remove the guanine cap from full-length mRNA 
leaving a 5’-monophosphate. A 45 base RNA adapter (5’-
GCUGAUGGCGAUGAAUGAACACUGCGUUUGCUGGCUUUGAUGAAA-3’) was 
ligated to the free 5’-monophosphate with T4 RNA ligase. The 3’ RACE cDNA was 
synthesized from mRNA after annealing a 3’ RACE adapter sequence. (5’-
GCGAGCACAGAATTAATACGACTCACTATAGGT12VN-3’) that binds to the poly A tail.  
 
Following the protocol of the manufacturer of FirstChoice® RLM-RACE Kit (Ambion), A 5’ 
RACE PCR was performed using outer and inner adapter binding primers (5'F-
GCTGATGGCGATGAATGAACACTG-3', 5'F-CGCGGATCCGAACACT 
GCGTTTGCTGGCTTTGATG-3') and outer and inner xFANCG-specific primers (5’R-
CTTATAGAGCAAGTTCAGCGCC-3’, 5’R-CACTCTCCATGCTTTCAGCAG-3’). It is 
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important to note here that the above primer sets amplified predominantly the 5’ truncated form 
of xFANCG missing exon 2 (termed xFANCGshort). After sequencing the product, an 
underlying second nucleotide sequence was identified and a new primer set was designed 
against this underlying sequence (5’F-GGAGGAGAATAACGTCATAGT-3’, 5’R-
CTTATAGAGCAAGTTCAG CGCC-3’). This amplified the second exon of the 5’ xFANCG 
sequence. The 3’ RACE PCR was performed using outer and inner adapter binding primers 
(5'R-GCGAGCACAGAATTAATACGACT-3', 5'R-CGCGGATCCGAATTAATA 
CGACTCACTATAGG-3') and outer and inner xFANCG-specific primers (5’F-
CTGCTGAAAGCATGGAGAGTG-3’, 5’F-GGCGCTGAACTT GCTCTATAAG-3’).  
Antibody Production 
A polyclonal rabbit antibody was raised against a synthetic xFANCG peptide ([H]-
CLENKRGEEAVEHYLDLLALL-[OH]) conjugated to Keyhole Limpet Hemocyanin (KLH) 
(Covance) corresponding to amino acids 354-374 of X. laevis FANCG. The antibody was 
affinity purified using the same (non-KLH-bound ) synthetic peptide immobilized on an 
AminoLink® Plus column (Pierce) according to the manufacturer's instructions. The xFANCA 
and xFANCD2 antibodies have been previously described (Sobeck et al. 2006). 
Preparation of egg extracts 
Extracts were prepared from Xenopus eggs according to the method of Murray (Murray 1991). In 
brief, eggs were dejellied in 2% cysteine, pH 7.8; washed three times in XB buffer (10 mM 
KCl, 1 mM MgCl2, 100 nM CaCl2, 10 mM HEPES, 5 mM EGTA, 1.75% [wt/vol] sucrose, 
pH 7.8); and washed three times in CSF-XB buffer (XB buffer containing 5 mM EGTA and 2 
mM MgCl2). Eggs were crushed by low-speed centrifugation (10,000 x g; 10 min), and the 
cytoplasmic fraction was cleared by centrifugation (16,000 x g; 20 min) after the addition of 
energy mix (15 mM creatine phosphate, 2 mM ATP, 2 mM MgCl2), cytochalasin B (10 
µg/ml), cycloheximide (100 µg/ml), and Pefabloc (100 µg/ml). To release extracts from M to S 
phase, CaCl2 was added to a final concentration of 0.4 mM, and the extracts were incubated for 
20 min at 23°C.  
Immunodepletion  
To immunodeplete FANCA, or FANCG from S-phase extracts, 100 µl of protein A beads 
(Amersham) were incubated overnight at 4°C with 500 µl of phosphate-buffered saline and 100 
µl of xFANCG, xFANCA affinity-purified antisera, or pre-immune sera. The beads were 
pelleted from solution by centrifugation at 2,500 X g for 10 min at 4°C and washed three times 
in XB buffer. A total of 100 µl of extract was added to the beads. The extract-bead mixture was 
rotated for two rounds at 4°C for 40 min.  
Preparation of nuclei 
50 µl of egg extract (after immunodepletion by xFANCA, xFANCG or preimmune sera) was 
incubated 1h, at 23°C with 1,000 pronuclei (sperm heads)/µl and then diluted in nuclear 
isolation buffer (40 mM HEPES, 100 mM KCl, 20 mM MgCl2) and purified through a 30% 
(wt/vol) sucrose cushion. Samples were centrifuged for 20 min at 6,000 x g; the nuclear pellets 
were analyzed by SDS-PAGE gel and immunoblot.  
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Xenopus extract fractionation  
16 mg of interphase Xenopus extract prepared as described previously (Sobeck et al. 2006) was 
centrifuged (20,000 X g) at 4°C for 15 minutes and directly applied to a Superose-6 column (HR 
16/50; Amersham) equilibrated with the column running buffer containing 20 mM HEPES (pH 
7.9), 200 mM NaCl, 1 mM DTT, 0.1 mM PMSF, and 10% glycerol. Fractions were collected 
(1.5 ml each) and analyzed by SDS-PAGE and immunoblot. 
Immunoprecipitation  
2 mg of egg extract was added to 1 ml of lysis buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1% 
NP40, 0.5% Deoxycholate, 1mM EDTA, 0.5 mg/ml Pefabloc, 1mM DTT). 10 µl of rabbit 
polyclonal antibody against xFANCD2 , xFANCA, or xFANCG, were added and samples were 
mixed by rotating overnight at 4°C. Then 100 µl of pre-swelled and washed (50% slurry in 
PBS) sepharose 4B beads (Amersham) were added and rotated for 30 minutes at 4 °C. The 
beads were pelleted from solution by centrifugation at 2500 rpm for 10 minutes at 4°C and 
washed three times with lysis buffer. 
Freon Extraction of proteins from Xenopus embryos 
10 embryos of the same developmental stage were euthanized and homogenized in 300 µL of 
buffer containing 15 mM Tris-HCl and 2 mM PMSF. 300 µL of freon (1, 1, 2-
trichlorotrifluoroethane) was added to the tubes and vortexed for 60 seconds. The solution was 
then centrifuged (13,000 X g) at 4°C for 10 minutes to separate the top aqueous phase from the 
freon phase. 1/3 volume of 4X sample buffer was added and the proteins were analyzed by SDS-
PAGE and immunoblot. 
Immunoblotting  
Protein samples were separated on 3 to 8% NuPAGE Tris-acetate gels or 8 to 16% Tris Glycine 
gels (Invitrogen) and transferred to Immobilon P membranes (Millipore). 
DNA sequencing and protein alignments 
Sequencing of all PCR products were performed by the sequencing facility at OHSU with a 
PE/ABI automated sequencer. Protein sequence alignments and homology scores were derived 
from the MacVector™ 7.2.3 Clustal W alignment program.  
Nucleotide sequence accession numbers 
The full-length and shorter transcript variants encoding the Xenopus laevis FANCG cDNA 
sequence has been deposited at NCBI under accession number EF107711 and EF519913, 
respectively.   
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Chapter 6 
Discussion 
 
Fifteen years after the cloning of FANCC, the first Fanconi anemia (FA) gene (15), the 
identification of 12 additional genes in a common FA pathway has created new 
opportunities to study the disease at the molecular level (reviewed in (198)). Eight of 
the FA gene products form a multiprotein complex (known as the FA core complex) 
thought to act as a E3 ubiquitin ligase, and five others function downstream, or 
independent of this complex: FANCD2, the FA core complex's monoubiquitylation 
substrate (79, 86), FANCI, an additional monoubiquitylation substrate of the FA core 
complex and paralog of its binding partner, FANCD2 (193, 201, 202), BRIP1/FANCJ, 
a DNA helicase that binds to BRCA1 (161-163), BRCA2/FANCD1 (95), and 
PALB2/FANCN, a binding partner of BRCA2 (186, 187). However, despite the 
identification of so many of the underlying FA gene products, a coherent picture of 
how this novel pathway functions to preserve genome integrity remains elusive. 
Moreover, little is known about how these molecular components relate to the 
phenotypic features of FA patients such as progressive bone marrow stem cell loss, 
abnormal development, and cancer risk. Therefore, considerable emphasis has been 
placed on finding remaining FA genes and developing model organisms to help fill the 
gaps in our knowledge of this pathway (reviewed in (200)). 
 
Model organisms are of great importance for the functional analysis of gene products. 
Evolutionarily conserved protein sequence domains often denote regions important for 
elucidating unknown protein function. Although no single model organism perfectly 
mimics a particular human disease, diverse data from the different models may 
together contribute to an understanding of the functional relationships within the FA 
protein network. However, as in human cells, mechanistic studies have proven difficult 
in all organisms used to model FA because of the novelty and complexity of the 
pathway, the influence of cell cycle, and the contribution of essential proteins such as 
ATR and BRCA2.  
 
This thesis proposes a new model organism for FA research: Xenopus laevis. Xenopus 
laevis egg extracts are a concentrated, cell-cycle synchronized, and DNA-free extract 
that is accessible to biochemical manipulation, including activation or inhibition of 
DNA replication, and is capable of recapitulating many of the cellular events that—
when defective—cause FA in humans.  An important advantage of using cell-free 
extracts is that the consequences of depleting essential proteins can be studied and that 
cell-cycle checkpoints can be manipulated (Chapter 1.3). 
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The FA pathway is conserved in Xenopus laevis. 
At the start of this thesis project, demonstrating evolutionary conservation of the 
structural and functional components of the FA pathway was necessary in order to 
establish Xenopus laevis as a model system for FA. Full-length Xenopus orthologs 
(referred to as xFANC-) are reported in this thesis for xFANCD2, xFANCG, xFANCA, 
xFANCF (132), and xFANCL. In addition, at least partial sequences have been 
identified in Xenopus by database searches for all other reported human FA proteins, 
indicating that all known FA genes are conserved. mRNA and protein expression 
profiles have shown at least some of the xFA genes to be transcribed and translated 
throughout Xenopus embryonic development (Chapter 5).  
 
The identification of xFA protein sequences allowed development of antibodies 
capable of specifically detecting the xFA gene products by immunoblotting. 
Coimmunoprecipitation of the xFANCA, xFANCM, and xFANCG proteins was 
demonstrated, confirming that protein interactions of the FA core complex are 
conserved in Xenopus. Moreover, quantitative immunodepletion of core complex 
components eliminated the capacity of extracts to support the shift of xFANCD2-S to 
xFANCD2-L, a phenotype common to all human FA core complex patient cell lines. 
As predicted, immunodepletion of xFANCA from egg extracts completely abrogated 
the ability of the egg extract to modify xFANCD2-S to the xFANCD2-L form which 
was determined, like its human counterpart, to be monoubiquitylated xFANCD2 
(Chapter 3).  
 
These observations confirmed that the structural and functional hallmarks of the FA 
pathway are conserved in Xenopus laevis egg extracts, underscoring the idea that egg 
extracts faithfully reproduce critical molecular interactions in the FA protein network. 
 
Do FA proteins process specific DNA defects? 
The fact that FA patient cells display spontaneous chromosome breakage suggests a 
role for FA proteins in resolving DNA damage from endogenous sources. With the use 
of egg extracts, this thesis provides evidence that xFA proteins play a role in 
preventing DNA breaks during unperturbed replication, at least in vitro. Analysis of 
the chromatin binding behavior of xFA proteins during replication shows that both 
xFA core complex proteins and xFANCD2-L are recruited to chromatin during 
unperturbed replication (Fig 1). This recruitment of the xFA proteins to chromatin is 
potentiated in the presence of the DNA interstrand crosslinking (ICL) agent mitomycin 
C (MMC). However, the potentiated recruitment can be brought back to basal 
(unpotentiated) levels by the addition of caffeine, an inhibitor of phosphatidylinositol 
(PI) kinases, such as ATM and ATR. Therefore the recruitment of xFA proteins to 
chromatin in response to exogenous ICLs and the binding of the xFA proteins during 
unperturbed replication are not controlled by same mechanism. This suggests that 
there may be two differently regulated responses of the FA proteins to DNA damage, a 
 122 
 
response to damage that occurs during normal replication and a response that occurs as 
a result of exogenous ICLs. 
 
What is the DNA insult that triggers the recruitment of the FA proteins during normal 
replication? It may be ICLs, though it is not known if ICLs occur endogenously, as 
ICLs and other lesions created during replication are difficult to detect (116). 
However, ICLs have been predicted to occur because endogenously generated DNA 
crosslinkers such as malondialdehyde are produced by autoxidation of unsaturated 
fatty acids, a process that may take place under normal conditions (116).  In addition 
excision repair-deficient mammalian cells have demonstrated a means for dealing with 
up to 40 ICLs (with cell death being the ultimate endpoint) (32), whereas a single ICL 
can kill excision repair-deficient bacteria and yeast (8).  It is possible that the 
differences in ICL sensitivity reflect the fact that FA proteins exist in mammalian cells 
but do not appear to be in bacteria. Taken together it is reasonable to hypothesize that 
FA proteins have evolved, in vertebrates, to deal with the presence of endogenous 
ICLs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. (A) Accumulation of xFANCA protein on chromatin throughout replication. The solid line represents 
accumulation in the presence of DNA damage (MMC) and a fully functional intra-S-phase checkpoint. The 
dashed line represents accumulation in the presence of DNA damage (MMC) and caffeine, an inhibitor of PI 
kinase activity. The dotted line represents accumulation during unperturbed replication. (Note: under the same 
conditions xFANCD2 and xFANCF had accumulation patterns similar to xFANCA). (B) Incorporation of α-32P 
labeled nucleotides into replicating DNA (0-90 minutes) in the presence of MMC (solid line), MMC + caffeine 
(dashed line), and without any additions (dotted line).  
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Whether ICLs occur endogenously or exogenously, they would most likely be 
processed by the same mechanism within the cell. Additional recruitment of the xFA 
proteins to chromatin in the presence of ICLs (induced by MMC) by PI kinases might 
be an ICL-specific response. But why should there be a base-line level of 
recruitment—independent of PI kinases—during normal replication? We hypothesize 
that the recruitment of the xFA proteins during unperturbed replication might be due to 
a specific intermediate state of the replication fork itself (63). 
  
To test this hypothesis, we assayed FANCD2 activation in response to various DNA 
structures including specific replication intermediates. The data presented in Chapter 3 
show binding of xFANCD2-L to structures that mimic a replication fork. We propose 
that the binding of xFANCD2-L to irregular fork-like structures would need to be 
strictly controlled during replication to prevent the binding of xFANCD2-L to normal 
replication structures. This regulation of xFANCD2-L is evident by its chromatin 
binding behavior because it continues to accumulate when other replication-associated 
proteins are decreasing and when replicative DNA synthesis has dropped below 
detection (Chapter 2). This may suggest that xFANCD2-L is recruited to chromatin 
when the remaining replication forks would most likely be the result of a stalling 
event. Indeed, xFANCD2 chromatin recruitment increases after the addition of 
aphidicolin, which stalls replication forks by inhibiting replicative polymerases. Taken 
together, these results suggest that the FA proteins function—not only to handle 
ICLs—but also to bind and/or stabilize stalled replication forks, which arise during 
normal replication as a result of various types of DNA lesions (Fig 2). In a similar 
study, by mimicking DNA damage intermediates, MacDougall and coworkers defined 
the minimal DNA requirement for ATR checkpoint activation as primed single 
stranded DNA (ssDNA). They also determined the quantity of primer-template 
junctions required to activate the ATR/ATRIP pathway at 10-30 per somatic cell 
nucleus. This suggests that the multiple primed ssDNA junctions that exist during 
unperturbed replication may fall below the threshold for checkpoint activation, making 
the primed ssDNA formed during DNA damage the trigger for ATR/ATRIP activation 
(197). Further study of the FA proteins and other DNA structures and proteins at 
stressed replication forks or sites of DNA repair will provide a more comprehensive 
understanding of the role of FA proteins in the DNA damage response.  
 
Xenopus as a developmental model  
In addition to using Xenopus extracts as a model system, the Xenopus embryo has long 
served as a major model for the study of embryonic development. Its external 
development, large size, identifiable blastomeres, and its ability to withstand extensive 
surgical intervention and culture in vitro enable investigation of the earliest embryonic 
patterning events. The Xenopus embryo is also an excellent model organism for 
primitive hematopoiesis.  Unlike other vertebrate models, the Xenopus embryo has 
been precisely fate-mapped, making it possible to misregulate the expression of 
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proteins in single blastomeres within embryos so that the fate of specific tissues can be 
studied (107, 138, 160). This may be of great importance for studying the mechanisms 
underlying the developmental defects in hematopoiesis observed in FA patients.  
 
To date, FA gene expression has not been well characterized in the developing 
embryo.  In Chapter 5 it is reported that xFANCD2 and the core complex genes 
xFANCA, -L, -F and -G are expressed in the egg and throughout early development.  
Interestingly, by the neurula stage of development, two shorter xFANCG transcripts 
are expressed. Evolutionary conservation of exon-skipping events has previously been 
shown to represent functional alternative splicing from mouse to human (reviewed in 
(131)).  Although splice variants for FANCG have not been described in human or 
mouse, an alternative FANCG transcript, involving the same exon, has been reported 
in chicken DT40 cells (122). Reinforcing the idea that these variants may be 
functional. Further production of antibody reagents will aid in determining the protein 
expression, and the functional relevance of the alternative xFANCG transcripts. 
 
Fanconi anemia research is still in the pathway-building stages with little known about 
the functions of the FA proteins. With the many advantages Xenopus offers for cell-
free biochemical analysis and as a classical developmental model, further studies to 
develop the Xenopus model for FA will be a valuable part of the research effort to 
unravel the role of these proteins in supporting hematopoiesis, development of the 
early embryo, and cancer susceptibility in humans. 
  
 
 
Fig 2. (Following page) A simplified model for the response of FA proteins to DNA replication forks 
that have become stalled as a result of endogenous (left pathway) or exogenous (right pathway) 
DNA damage. When a replication fork encounters a stalling lesion, the helicase may uncouple from the 
polymerase, creating long stretches of single stranded DNA that results in DNA damage. The FA proteins 
function to prevent DNA damage during normal replication (left pathway). Endogenous DNA damage 
typically stays below the threshold of ATR/ATM checkpoint activation (left pathway) however the FA 
proteins bind chromatin, independent of ATR/ATM, late during unperturbed replication when the 
replication forks that remain would most likely be due to a stalling event. The FA proteins play a role in 
the processing of these stalled forks by unknown mechanisms to maintain genomic stability.  If the 
amount of damage created by stalled forks in response to exogenous DNA damage is sufficient to induce 
the ATR/ATM checkpoints there is an additional recruitment of FA proteins, or an ATR/ATM dependent 
recruitment, to sites of DNA damage (right pathway).  
 
 126 
Chapter 7 
Summary 
 
Fanconi anemia (FA) is a rare autosomal and X-linked recessive disorder in which 
patients develop life-threatening bone marrow failure, myelodysplasia, and acute 
nonlymphocytic leukemia. Patients that survive to adulthood typically develop early 
onset epithelial cancers. Because of diverse phenotypes, FA patients are often 
definitively diagnosed based on their unique cytogenetic sensitivity to DNA 
interstrand crosslinking agents such as mitomycin C. Classical clinical features of this 
disease vary but often include: slowed growth, small head size, café-au-lait spots, and 
radial ray defects. FA is caused by a defect in any one out of at least 13 genes that 
encode proteins, which interact in a common pathway termed the “FA pathway.” The 
FA pathway of proteins function by largely unknown mechanisms, to protect against 
chromosomal instability and are required for error-free DNA replication. 
 
In Chapter 1.1 of this thesis, we provide a brief overview of the human syndromes that 
are associated with genomic instability and cancer predisposition.  
 
Chapter 1.2 briefly summarizes what is currently known about the focus of this thesis, 
the genomic instability syndrome FA.  
 
In Chapter 1.3 we introduce and describe the various methodologies of Xenopus laevis 
cell-free egg extracts and how such extracts may be used for the study of FA.  
 
In Chapter 2 we provide evidence that chromatin recruitment of the FA proteins is 
dependent on replication and their recruitment increases when moving replication 
forks encounter certain DNA lesions, thus making FA proteins crucial to prevent 
chromosomal DNA breaks during normal replication.  
 
In Chapter 3 we investigated the specific DNA lesions that activate the FA pathway. In 
a replication-free context, we found that the substrate specificity of the activated form 
of FANCD2 is rather broad including both single- and double-strand, linear or 
branched DNA lesions—but not simple DNA double strand breaks. The data in this 
Chapter suggests a model in which FANCD2 activation occurs during DNA 
replication when double stranded DNA is exposed at the replication fork due to either 
stalling or damage.  
 
In Chapter 4 we introduce a novel cell-free assay using Xenopus extracts as an 
approach to identify small molecules that suppress the activation of the FA pathway, 
by monitoring the DNA substrate stimulated monoubiquitylation of FANCD2. We 
also present a novel inhibitor of FANCD2 monoubiquitylation. This Chapter further 
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discusses the use of the cell-free assay to re-sensitize non-FA tumor cells that have 
become resistant to chemotherapeutic DNA interstrand crosslinking agents such as 
cisplatin and melphalan. 
 
In Chapter 5 we introduce Xenopus laevis as a developmental model for FA and show 
for the first time, the protein expression of the FA proteins during embryonic 
development. In addition we present evidence that FANCG is zygotically regulated 
during embryonic development. 
 
In a general discussion we provide evidence for a biphasic recruitment of FA proteins 
to chromatin. During normal replication FA proteins are recruited in the absence of 
any exogenous damage and without checkpoint activation. After DNA damage, there 
is an increased recruitment of FA proteins that is ATR dependent and may be in 
response to specific DNA lesions. 
 
In conclusion, the research presented in this thesis introduces a new system for 
dissecting the function of the FA proteins within the network of other proteins that 
collaborate to ensure genomic stability in vertebrates.  
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Samenvatting 
 
 
Xenopus Laevis als modelsysteem voor het bepalen van de functie van 
Fanconi anemie eiwitten 
 
Fanconi anemia (FA) is een zeldzame, recessief overervende, genetische aandoening 
gekarakteriseerd door levensbedreigende symptomen zoals beenmergfalen, 
myelodysplasie en acute myeloïde leukemie. Patiënten die overleven tot de volwassen 
leeftijd ontwikkelen vaak plaveiselcelcarcinomen. Het klinisch fenotype is divers, 
maar de uiteindelijke diagnose ‘FA’ wordt uitsluitend bepaald door een positieve 
uitslag van een chromosoombreuktest, waarbij lymfocyten van de patiënt worden 
blootgesteld aan een zgn. ‘DNA cross-linkend agens’, zoals mitomycine C; in deze test 
vertonen lymfocyten van een FA patiënt veel meer chromosomale breuken dan cellen 
van een gezonde controle. Het klinisch beeld van de ziekte wordt tevens gekenmerkt 
door groei achterstand en afwijkingen van het skelet en pigmentatie van de huid.  
FA wordt veroorzaakt door mutaties in één van de inmiddels bekende 13 FA genen. 
Deze genen coderen voor eiwitten, die samen verantwoordelijk zijn voor het correct 
verlopen van een biochemisch proces, het zogenoemde “FA pad”.  Dit pad is 
verantwoordelijk voor het handhaven van de integriteit van de chromosomen en is 
essentieel voor het foutloos kopiëren van het DNA bij de celdeling. 
 
In hoofdstuk 1 van dit proefschrift wordt een overzicht gegeven van de humane 
syndromen die gekenmerkt worden door chromosomale instabiliteit en predispositie 
voor kanker, met name FA. Verder wordt een inleiding gegeven over de verschillende 
technieken, die gebruikt worden om celvrije ei-extracten van de Zuid-Afrikaanse 
klauwpad Xenopus laevis aan te wenden om de functie van cellulaire eiwitten te 
bestuderen en hoe deze methoden kunnen worden ingezet voor het onderzoek naar de 
functie van FA eiwitten. 
  
In hoofdstuk 2 wordt experimentele evidentie aangevoerd, die er op wijst dat het 
aantrekken van FA eiwitten door chromatine afhankelijk is van replicatie en dat dit 
proces wordt gestimuleerd door de aanwezigheid van DNA laesies, die de 
replicatievork blokkeren. De aanwezigheid van FA eiwitten blijkt essentieel voor het 
voorkómen van dubbelstrengs DNA breuken tijdens het normale proces van DNA 
replicatie.  
 
In hoofdstuk 3 hebben we onderzocht welke DNA structuren het FA pad kunnen 
activeren, zoals afgeleid uit de mono-ubiquitinering van het FA eiwit, FANCD2. 
Diverse structuren bleken hiertoe in staat, zoals enkel- en dubbelstrengs DNA, zowel 
lineair als vertakt, maar niet dubbelstrengsbreuken in het DNA. De gegevens 
suggereren dat FANCD2 activering (door mono-ubiquitinering) optreedt tijdens het 
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proces van DNA replicatie, waarbij dubbelstrengs DNA in de directe nabijheid van de 
replicatievork wordt blootgesteld als gevolg van het geblokkeerd raken van de vork 
door aanwezige DNA schade.  
 
In hoofdstuk 4 wordt een nieuwe methode geïntroduceerd om verbindingen (‘small 
molecules’) te vinden, die het FA pad kunnen blokkeren. Bij deze methode, die 
gebaseerd is op celvrije extracten van X. laevis eieren, wordt de mono-ubiquitinering 
van FANCD2 als indicatie voor een functionerend FA pad gebruikt. Als resultaat van 
een eerste screening werd een nieuwe verbinding geïdentificeerd, die in staat blijkt het 
FA pad te kunnen remmen. In dit hoofdstuk wordt verder besproken op welke wijze 
dergelijke remmers ingezet zouden kunnen worden voor het gevoelig maken voor 
chemotherapie van kankercellen, die resistent zijn geworden voor cytostatica zoals 
cisplatin. 
  
In hoofdstuk 5 wordt de embryonale ontwikkeling van Xenopus laevis gebruikt als een 
model om FA eiwitten te bestuderen bij dit proces. Hier laten we voor het eerst zien 
hoe de expressie van bepaalde FA eiwitten verloopt tijdens de embryogenese en dat 
het FANCG gen ‘zygotisch’ gereguleerd wordt tijdens dit proces. 
 
In de algemene discussie (hoofdstuk 6) wordt besproken dat het aantrekken 
(‘recruitment’) van FA eiwitten door chromatine waarschijnlijk in twee fasen 
geschiedt. Tijdens normale replicatie, zonder activering van een celcyclus checkpoint, 
wordt een basaal niveau van recruitment gerealiseerd, terwijl er bij DNA beschadiging 
extra FA eiwitten worden ‘gerecruteerd’.  Deze extra recrutering is afhankelijk van het 
kinase ATR, dat waarschijnlijk door de aanwezige DNA beschadiging wordt 
geactiveerd. 
 
Het onderzoek samengevat in dit proefschrift introduceert een nieuw modelsysteem 
voor het bepalen van de functie van FA eiwitten, als deel van het netwerk van eiwitten 
die tesamen de stabiliteit van het genoom moeten bewaken.  
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